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A successful coronavirus infection is characterized by the release of infectious 
progeny particles which entails the replication of the viral genome and its packaging 
into infectious particles by its structural proteins. These two processes are dependent 
upon its ability to synthesize both the positive-sense genomic mRNA and a set of 
positive-sense subgenomic mRNAs for genome replication and viral proteins 
expression respectively. 
The cleavage products from the coronavirus replicase gene, also known as the non-
structural proteins (nsps), are believed to make up the major components of the viral 
replication/transcription complex. Although viral RNA synthesis is thought to be one 
of the most important parts of the virus life cycle, it is still not fully understood with 
respect to how the complex functions as a whole, or the degree of cellular protein 
involvement. Till date, only a number of enzymatic functions have been assigned to 
several nsps and a handful of host proteins have been identified so far to play a role in 
coronavirus RNA synthesis.   
Zinc finger CCHC-type and RNA binding motif 1 (ZCRB1 alias MADP1) has been 
identified as a possible host protein involved in RNA synthesis of coronaviruses. The 
protein has found to interact with the positive-sense 5’untranslated region (UTR) of 
infectious bronchitis virus (IBV) but weakly with that of severe acute respiratory 
syndrome coronavirus (SARS-CoV) and human coronavirus OC43 (HCoV-OC43). 
Further characterization of this interaction confirmed it to be specific and the 
interacting domains have been subsequently mapped to the RNA recognition motif 
domain of MADP1 and stem-loop I of the positive-sense IBV 5’-UTR. It was 
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observed that upon virus infection, MADP1 translocated to the cytoplasm, a deviation 
from its regular nuclear localization pattern, an indication of possible involvement in 
the virus life cycle.  
Functional analyses using small interfering RNA to silence the gene has elucidated 
the function of MADP1, a determinant of efficient negative-sense RNA synthesis. A 
confirmation of the role of MADP1 in virus infection was obtained when it was 
shown that the expression of MADP1 resistant to the silencing effects of the hairpin 
RNA targeting MADP1 enhanced virus infection in stable MADP1 knock-down cells. 
While progress has been made on host involvement in coronavirus RNA synthesis, 
the role of viral proteins has not been forgotten. Several nsps encoded by IBV were 
screened for RNA-binding activity and interaction with its RNA-dependent RNA 
polymerase, nsp12. Four non-structural proteins, nsp2, nsp8, nsp9 and nsp10 were 
found to bind to either of the UTRs assessed and nsp8 was confirmed to interact with 
nsp12. Nsp8 had been reported to form a complex with nsp7 which was functionally 
assigned as the primase synthesizing RNA primers for nsp12. 
Further characterization of the interaction between nsp8 and nsp12 revealed that the 
interaction is independent of the presence of RNA was subsequently shown that nsp8 
interacts with both the N- and C-termini of nsp12. These results have prompted a 
proposal of how the nsp7-nsp8 complex could possibly function in tandem with 
nsp12, forming a highly efficient complex which could synthesize both the RNA 
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1.1 Overview of Coronaviruses 
1.1.1 Taxonomy, genomic and physical properties of Coronaviruses 
Coronaviruses are a group of enveloped RNA viruses whose genome is in the form of 
a positive-sense single stranded RNA molecule. They are classified under the order of 
Nidovirales, family of coronaviridae and subfamily of coronavirinae. Within this 
subfamily, the coronaviruses are divided into three genera, the alpha-, beta- and 
gammacoronavirus, based on their antigenic and genetic properties.  
The outermost layer of the coronavirus particle, as depicted in the Figure 1.1 is a 
double-membrane envelope, embedded with the virus structural proteins spike (S), 
membrane (M) and envelope (E). Some betacoronaviruses are able to encode an 
additional structural protein, the haemagglutinin-estarase (HE), which is also 
represented on the double-membrane envelope. Encompassed within the virus 









Figure 1.1: Schematic diagram of a coronavirus particle. 
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mRNA genome and the structural protein, nucleocapsid (N). The N protein packages 
and compact the fairly large viral genomic RNA into the relatively small sized virus 
particle through RNA-protein interactions. 
The coronavirus genome is a 5’-capped, single-stranded positive-sense mRNA, which 
is the largest known of its kind, ranging from 27 to 32 kb in length (1). The mRNA is 
flanked by two untranslated regions, the 5’-UTR, which ranges from 209 – 528 
nucleotides (nt) in length, contains the leader sequence (65 – 98 nt) and the 3’-UTR 
(288 – 506 nt), contains an octameric sequence of GGAAGAGC (beginning at residue 
73 – 81) upstream of the poly(A) tail. As shown in Figure 1.2, coronaviruses have an 
extremely large gene 1 (ORF 1), spanning about two-thirds of the entire genome, 
which encodes for the non-structural proteins involved in viral RNA transcription. 
Figure 1.2: Genome Organization of selected coronaviruses. Replicase and structural 
genes and ribosomal frameshift site (RFS) are indicated. Internal ORF within N gene 




ORF 1 is translated into two poly proteins, pp1a and pp1ab via a pseudoknot-induced 
frameshifting event upstream at the ORF1a/1b junction. 
The structural genes are encoded in the order of S, E, M, N, 5’ – 3’, within the 3’ one-
third of the genome. Interspersed between these structural genes is a variable number 
of ORFs encoding accessory proteins including HE. Some of these accessory genes, 
like ORF 4, 5a (2,3), have been proven to be dispensable for virus replication in 
cultured cells or even in their natural host (4). 
The most prominent feature of the virus particle, and that which gives the coronavirus 
its name, is the S protein, a large (≈180 kDa) class I virus fusion protein (5) embedded 
in the virus envelope. S is cleaved post-translationally into two fragments by cellular 
proteases (6,7), S1 (receptor binding domain) and S2 (transmembrane domain) that 
interacts with each other through non-convalent bonding (8). S1 is responsible for 
receptor recognition, defining cell tropism (9), whereas S2 mediates the fusion 
between viral and cellular membranes through the fusion peptide sequence.  
In betacoronavirus, phylocluster A, an additional protein is present on the viral 
envelope, the HE protein. The ability to express the HE protein is lost in many 
laboratory strains of the murine coronavirus (MHV) (10), including the widely studied 
MHV-A59 (11), but is however retained in other laboratory strains like MHV-S, -
JHM and –DVIM (10,12,13) as well as field strains. The coronavirus HE protein has 
been shown to exhibit both sialic acid binding and receptor-destroying enzymatic 
activity (RDE) (14,15). The significance of sialic acid binding activity of HE varies 
between coronaviruses, in bovine coronavirus (BCoV) and human coronavirus 
(HCoV) OC43, HEs appear to play only a modest role in viral attachment to sialic 
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acids (16,17). On the otherhand, hemagglutination activity of MHV-DVIM appears to 
depend upon the availability of HE.  
The coronavirus N protein is a RNA chaperone (18) which is essential for the 
formation of the helical ribonucleoprotein (RNP) core with viral genomic RNA that 
which is also its primary function. The coronavirus N is composed of about 400 
amino acid residues, contains two structural domains, the N-terminal RNA-binding 
domain and the C-terminal dimerization domain joined by a linker region (19). The 
coronavirus N has been shown to be capable of self-association, forming dimers or 
oligomers of higher orders through its C-terminal dimerization domain (20,21) in a 
concentration dependent manner (22). The ability of N to self-associate and its 
subsequent formation of oligomers is vital for the encapsidation of coronaviral 
genomic mRNA (23). It has also been reported that the dimerization domain exhibits 
strong RNA-binding activity (24) and its association with nucleic acids can promote 
the formation of higher-order oligomers (25) which may have been the mechanism for 
the long RNP formation.  
Embedded within the viral envelope is another structural protein of the coronavirus, 
the integral membrane glycoprotein, M. In terms of its structure, the M protein has a 
short ectodomain in its N-terminus, followed by three transmembrane regions and a 
long endodomain at its C-terminus and functions in dimers. The main function of M is 
in the adaptation of regions in the intracellular membranes, at the endoplasmic 
reticulum-golgi intermediate compartment (ERGIC) (26), for virus assembly by 
capturing other structural proteins at the budding site through protein-protein 
interactions with other structural proteins, S and N (27) as well as the viral gRNA 
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(28). Its ability to self-associate (29,30) also allows it to form a network which may 
have excluded some host proteins from the viral envelope. 
A small integral membrane protein, the coronavirus envelope protein, E, is the 
smallest structural protein encoded by the virus. The E protein plays an important role 
in the formation of virus particles, including budding and morphogenesis (31-34). Its 
importance is heightened by the observation of it being able to form virus-like 
particles alone, in the absence of M, when it is over-expressed in cells (31,35). 
Mutations of the E protein also results in the formation of virions with aberrant 
morphologies (36) which implied the importance of E in viral morphogenesis. 
1.1.2 Coronaviruses and diseases 
Coronaviruses have identified in a variety of domesticated animals, rodents as well as 
humans. As coronaviruses infect livestock, viral infections in farms have resulted in 
large scale economic losses in farming nations, and hence are of exceptional 
veterinary research value. Coronaviruses in fowls, exemplified by the highly 
contagious infectious bronchitis virus (IBV) in chickens, can be highly lethal to young 
chicks and are mainly associated with upper respiratory tract infections in adults, and 
to a lesser extent, nephrogenic infections. In larger livestock like pigs and cattle on the 
otherhand, coronaviruses typically establish enteric infections. In both cases, an 
infection or outbreak can cause severe economic losses from death of young, lifelong 
impact on the yield of animal produce (eggs and milk), weight losses and the general 
health of the population. With respect to their significance to the economy, vaccines 
have been developed for many coronaviruses in a bid to prevent localized infections 
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from progressing into serious outbreaks. This has however proved to be a hard battle 
as the vaccines are unable to provide complete cross-protection between the various 
serotypes of each coronavirus and have to be updated regularly to target emerging 
strains. 
Murine coronaviruses, exemplified by MHV, can cause high mortality epidemic 
illness, which particularly impacts laboratory mice colonies which are kept in close 
proximity. As the murine coronavirus infections complicate research, it has been 
promptly picked up by researchers in order to exclude this disease from laboratories 
worldwide, and was the most extensively studied coronavirus before 2002. 
Human coronaviruses have, in the recent years, been placed in the limelight with the 
emergence of severe acute respiratory virus (SARS-CoV) in late 2002, infecting more 
than 8000 people with a mortality rate of roughly 10%. Prior to the outbreak, human 
coronaviruses, being the etiologic agent responsible for 10-15% of common cold, 
have received little attention due to the mild display of symptoms although they may 
result in fatalities, especially in in weaker individuals complicated by other diseases. 
After the SARS-CoV epidemic, 2 new human coronaviruses have also been isolated, 





1.2 The Coronavirus Life Cycle  
There are multiple stages in the coronavirus life cycle and the very first step would be 
its attachment to a suitable host cell via cellular receptors followed by the entry of the 
virus particle into the cytosol where the helical virus genome is released from the N 
protein it was packaged with. The virus genome is a 5’-methyl capped positive sense 
mRNA which mimics the eukaryotic mRNAs and hence is able to make use of the 
existing ribosomes to translate its genome. Only the ORF on the 5’ most of the 
mRNA, the replicase gene, is translated, producing two polyproteins, pp1a and pp1ab 
via a (-1) ribosomal frame shift event. These two polyproteins are auto-proteolytically 
cleaved into the non-structural proteins co-translationally. The non-structural proteins 
make up the bulk of the replication/transcription complex (RTC) which is anchored 
onto double membrane vesicles (DMVs), the site where virus transcription/replication 
takes place (37-39).  
The products of the RTCs is a nested set of mRNAs that are co-terminal at both their 
5’- and 3’- ends and the longest being mRNA1, the genomic-sized mRNA (gRNA) 
and the sub-genome sized mRNAs (sgRNAs) which are destined to be packaged into 
progeny virus particles and used for viral structural and accessory gene expression 
respectively. Translation of the structural genes produces the viral S, E, M and N 
proteins which are assembled at the endoplasmic reticulum-golgi intermediate 
compartment (ERGIC) together with the gRNA into progeny viruses which are 
eventually exported out of the host cell via exocytosis.  
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Figure 1.3 is a diagrammatic representation of the key events in the coronavirus life 
cycle, a slightly modified version of that published by Stadler et al. (2003) (40). 
Figure 1.3: Life cycle of a coronavirus. Virus particle attached onto the host cell 
via cellular receptors on the surface and enters. Entry is followed by the uncoating 
of the ribonucleocapsid to expose the positive-sense genomic RNA which is 
translated by the host ribosomes to yield the viral replication complex. Viral 
transcription and replication of genome is achieved by the viral replication 
complex, yielding a nested set of positive-sense sub-genomic sized mRNAs as 
well as the full length virus genome. Sub-genomic sized mRNAs are translated by 
host ribosomes into viral structural (S, E, M, N) and accessory proteins. The N 
protein packages the positive-sense genomic RNA into a ribonucleocapsid and is 
assembled into the virus particles. The newly formed virus particles undergo 
maturation by passaging through the Golgi and exit the host cell via exocytosis. 
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1.2.1 Attachment and entry 
Entry of the virus can take place either through direct entry when the viral envelope 
fuses with the cell membrane directly, or through the endosomal pathway where the 
virion enters by endocytosis and fusion occurs between the viral envelope and the 
endosomal membrane in an acidic pH environment (41,42). Most coronaviruses are 
able to utilize the endosomal pathway and some are able to engage in pH independent 
direct entry like most MHVs (43,44). The very first step of virus entry is the 
attachment of the virus particle onto host cells via their attachment protein, S, the 
receptor binding protein. S protein has two functional domains, the receptor binding 
domain, which defines the tropism of the virus as well as a membrane fusion domain, 
which mediates the fusion event between viral envelope and cell membrane during 
virus entry.  
Many host cell proteins have been identified as receptors for the different 
coronaviruses including the angiotensin converting enzyme 2 (ACE2) for HCoV-
NL63 and SARS-CoV (45-47), carcinoembryonic antigen-cell adhesion molecules 
(CEACAMs) for the MHV, aminopeptidase N for most alphacoronaviruses eg. feline 
infectious peritonitis virus (FIPV) and transmissible gastroenteritis virus (TGEV). 
Some betacoronaviruses, eg. BCoV and HCoV-OC43, employ a similar strategy to 
influenza viruses by using the N-acetyl-9-O-acetyl neuraminic acid as a receptor and 
encodes an additional non-structural protein, the HE, which possess receptor 
destroying activity, preventing the formation of virus aggregates as well as facilitating 
virus release.  
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On the otherhand, the receptor for some coronaviruses, in particular, that of 
gammacoronavirus IBV, has not been identified. The presence of α2, 3-linked sialic 
acids serves as a receptor determinant of IBV in primary attachment as it has been 
shown that neuraminidase treatment rendered the previously permissible host cells 
resistant to IBV infection (48). This however does not establish the identity of the 
receptor employed by IBV for virus entry as α2, 3-linked sialic acid has a broad 
distribution pattern in different tissues and varies between species, in contrast to the 
narrow host tropism exhibited by the virus. This implied the existence of another 
receptor in addition to the α2, 3-linked sialic acid (9), required for successful entry of 
the IBV particle into the host cell and primary attachment to sialic acid may have 
enhanced the probability of the virus S protein coming into close proximity of the 
actual receptor.  
After the receptor-binding ectodomain of S protein on the surface of the viral 
envelope attaches onto the receptor presented on the host cell surface, a conformation 
change takes place to expose the protease cleavage site, which prepares for the second 
step in virus entry, membrane fusion. Whether the virus uses the direct entry pathway 
or the endosomal pathway, cellular proteases are required to cleave the virus S protein 
into two parts the S1 (receptor binding domain) and the S2 (membrane fusion 
domain). This in turn induces a conformation change in the S2 domain to expose the 
membrane fusion peptide (heptad repeat regions) which initiates the formation of a 
six-helix bundle, bringing viral and cellular membranes into close proximity, thereby 
facilitating membrane fusion.  
12 
 
From studies in the human coronavirus, SARS-CoV, several cellular proteases have 
been found to serve as fusion activators, including  endosomal protease, cathepsin L 
(49), soluble proteases elastase, trypsin, thermolysin (50), factor Xa (51), furin (52) 
and transmembrane protease/serine subfamily member 11a (TMPRSS11a) (53). Some 
of these proteases have also been found to play a role in facilitating virus entry in 
other coronaviruses like trypsin and cathepsin L in MHV (54) and furin in IBV (55). 
Although soluble proteases have been identified to be fusion activators, the 
mechanism behind which these proteases may catalyze the proteolytic cleavage on the 
cell surface has not been established. It was however speculated that they can either 
function in the early endosome or are anchored near the receptors after being released 
onto the cell surface. 
1.2.2 Translation and auto-proteolytic processing 
Upon successful membrane fusion either at the cell surface or the endosomal 
membrane, the ribonucleocapsid is released into the cytosol and rapidly uncoats, 
releasing the viral genomic mRNA. The virus genomic mRNA is 5’-methylated 
capped and has a poly(A) tail which appears very similar to the host mRNA. This 
strategy allows the virus to make use of the host translation machinery directly for the 
translation of the replicase gene, the first ORF on the mRNA.  
The replicase gene, which spans the 5’-two-thirds of the mRNA, is translated by the 
host ribosomes into two large polyproteins, pp1a and pp1ab via a (-1) frameshift event 
(56-58). Figure Figure 1.4 illustrates the domain organization of the two polyproteins. 
The polyproteins are auto-proteolytically processed into 15 or 16 non-structural 
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proteins (59) by means of the virus encoded proteases, the papain-like protease (PLpro) 
nsp3 and the 3C-like protease or main protease (Mpro) nsp5 (60,61). The use of 
protease inhibitors specific to cysteine proteases, the class of protease nsp3 and nsp5 
belongs to, blocks their protease activity and inhibits viral RNA synthesis, 
highlighting the importance of these two proteins (62). As the name suggests, the 
main protease (Mpro) or 3C-like protease, nsp5, is the major protease which is required 
for the processing of most non-structural proteins, except at the 3 cleavage sites at the 
N-terminal (or 2 sites for IBV) which is performed by nsp3. A relatively well 
conserved and fairly large protein, nsp3 ranges between 180 to 210 kDa and contains 
a pair of paralogous papain-like protease (PLpro)domains, PLP1 and PLP2, the former 
non-functional in IBV (63). 
Mature nsps as well as some processing intermediates (64-66) are incorporated into 
the replicase complex which is assembled on double membrane vesicles (DMVs) (37-
39), the site of viral RNA synthesis. 
Figure 1.4: Domain organization of the replicase polyproteins pp1a and pp1ab (pp1a 
joined with pp1b). Major conserved domains of pp1a include: papain-like protease 
(PLP1 and PLP2), Y domain (Y), 3C-like protease (3CL) and transmembrane 
domains (TM1, TM2, TM3). Major conserved domains of pp1b include: RNA-
dependent RNA polymerase (RdRP), RNA-helicase (HEL), exonuclease  (ExoN), 
uridylate-specific endoribonuclease  or NendoU (N) and methyltransferase (MT). 
Numbers indicate name of non-structural proteins (nsps) after complete protease 
cleavage. Note: IBV does not contain nsp1. 
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1.2.3 Transcription and replication 
The purpose of coronavirus transcription is the generation of mRNAs for viral protein 
expression downstream of the replicase gene. The sub-genome sized mRNAs encode 
for viral structural (S, E, M, N) and other accessory genes. Genome replication is 
achieved through the synthesis of mRNA1 or the gRNA which serves the primary 
purpose of genome duplication, producing new copies of the viral genome to be 
packaged into progeny virus particles, but may also serve as the mRNA for the 
replicase gene (pp1a and pp1ab). Central to the transcription and replication of the 
virus genome is the virus-encoded replicase complex made up of the non-structural 
proteins, auto-proteolytic products of the polyproteins 1a and 1ab in every 
coronavirus.  
The final product of coronavirus transcription is a nested set of sgRNAs, which varies 
between 6 for IBV, shown in Figure 1.5, to 9 for SARS-CoV including newly 



































Figure 1.5: The transcription of gammacoronavirus IBV produces a nested set of 6 
positive-sense mRNAs that are 5'- and 3'- co-terminal. (+) gRNA is mRNA1 and 
mRNAs 2 to 6 are (+) sgRNAs which become templates for translation of structural 




contain in their 5’-end a terminal leader sequence fused to distant RNA coding 
sequences, which is likely achieved through discontinuous transcription during 
negative strand synthesis (67-70).  
With regards to transcription initiation, it was proposed that both the 5’- and 3’-UTR 
interact either directly or indirectly through RNA-protein and protein-protein 
interactions (71) to form the promoter for negative-strand synthesis, analogous to the 
picornavirus replication-transcription model (72). This model supports the 
observation that only genome length RNA is able to serve as a template in the process 
as the sgRNAs do not contain the entire 5’-UTR and the requirement of certain cis-
acting sequences in the 5’-UTR in negative-strand transcription. The two ends of the 
genome, including some internal sequences in certain coronaviruses, contain multiple 
cis-acting sequences which have been shown to be important for the replication of 
defective interfering (DI) RNA. 
The coronavirus 5’-UTR is predicted to fold into several stem loop structures. The 
extreme 5’-end of the coronavirus 5’-UTR is the leader sequence which is predicted 
to fold into two stem-loops, stem-loops I and II and the leader transcription regulatory 
sequence (TRS-L) is situated at the 3’ end of the leader sequence. The first secondary 
structure, the thermodynamically unstable stem-loop I, is characterized by the 
presence of bulges and/or non-canonical base-pairing, and is especially unstable at its 
base (73). This characteristic instability of stem-loop I appear to be conserved in the 
absence of primary sequence conservation among the key members of the three 
genera (74). Also, the structural lability has been shown in MHV to be important, its 
function in both positive and negative-strand transcription, which is likely mediated 
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through an interaction with the viral 3’-UTR, at a site very close to the poly(A) tail 
(75). In contrast to stem-loop I, the coronavirus stem-loop II is predicted to fold into a 
highly conserved short U-turn motif but has also been experimentally shown to be 
important for viral sgRNA synthesis (both positive and negative-strand) but not in 
gRNA synthesis. In addition to its function in viral transcription, coronavirus stem-
loop II appears to play a role in viral translation (74,76).  
Downstream of the coronavirus 5’-leader lie a short ORF, which likely encodes a 
short peptide between 3 to 11 amino acid residues. This region has been 
experimentally shown in BCoV to fold into stem-loop III harbouring the AUG start 
codon of the ORF within its left stem. Using a defective interfering (DI) RNA system, 
the importance of structural integrity in stem-loop III as well as the presence of the 
short ORF in DI RNA replication had been highlighted (77). The same group also 
found another RNA structure, designated stem-loop IV in the publication (78), also 
known as stem-loop VII (74), to be required for the replication of BCoV DI RNA in 
its positive strand, as well as interacting with several unidentified cellular proteins. 
The structure was reported to be conserved in both in sequence and structure within 
betacoronaviruses (78). It is not known if the structure is present in alpha- and 
gammacoronaviruses.  
Cis-acting signals at the 3’-UTR of the coronavirus genome, the start site of negative 
sense RNA synthesis, have been mapped for betacoronaviruses to a 5’-proximal 
segment corresponding to the mutually exclusive bulged stem loop structure and 
pseudoknot (stem-loops 1 and 2) as well as the last 29 nt of the 3’-UTR which base-
pairs with loop 1 and sequences downstream of stem 2 (79). These structures are 
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highly conserved in betacoronaviruses and substitution within the genus produces no 
discernible defect, despite primary sequence heterogeneity (79-81). Hence, it is likely 
that alpha- and gammacoronaviruses possess similar secondary structures although 
evidence supporting the presence of the bulged stem loop and pseudoknot has been 
elusive for alphacoronaviruses (82) and gammacoronaviruses (83,84) respectively. 
Although it has been previously discovered in a promoter mapping experiment that 
only the poly-A tail as well as the last 55 nt at the 3’ UTR are necessary for the 
initiation of negative strand synthesis (85) of DI RNA, it was unclear if the upstream 
sequences had been supplied in trans by the helper virus genome (79). 
An important feature of coronavirus discontinuous transcription is the TRS, 
comprising of a highly conserved core sequence (CS), which varies between 
coronaviruses. The CS is flanked by relatively variable sequences (5’-TRS and 3’-
TRS) which are regulatory factors for transcription (86,87). The TRSs are found at the 
3’-end of the 5’-leader sequence (TRS-L) and immediately upstream of each gene or 
ORF, the body TRSs (TRS-Bs), as shown for IBV in Figure 1.6, and they share an 
identical CS. This similarity between the CS of TRS-L and TRS-B (CS-L and CS-B 
respectively) allows for complementary base pairing between the nascent negative 
sense CS-B (cCS-B) and the template CS-L, a key event which mediates 
discontinuous transcription (88-91). It is believed that the TRS is important for 
discontinuous transcription and not genome replication as its absence was found to 
impair template switching but not continuous transcription of the genome (92). 
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In a model of discontinuous transcription, the TRS-B is proposed to act as both an 
attenuation and dissociation signal for the transcription complex, the viral replicase 
complex. Template switching follows the pausing of the viral RdRP, upon 
transcribing CS-B, and the replicase complex, together with the nascent negative 
strand, containing the cCS-B, dissociates from TRS-B and associates with the TRS-L 
which is in close proximity. In the sequence context, TRS-L and TRS-B are distal 
sequences, and their induced proximity should most probably have been achieved 
through RNA-protein and protein-protein interactions. A diagrammatic representation 
of the key features in discontinuous transcription in coronaviruses presented by 






































Figure 1.6: Discontinuous transcription in negative-strand synthesis of 
gammacoronavirus IBV. TRS is present in the 5’-leader (TRS-L) and upstream of 
each designated ORF (TRS-B) of the IBV genome. Each time a TRS-B is being 
transcribed by the replicase complex, the replicase complex may exchange its 
template for TRS-L, located at the 5’-end of the genome and transcribe the leader 
sequence or it may retain its template and continue transcribing from the 3’-end of 
the genome. This results in the generation of a set of negative-sense mRNAs bearing 
an identical 5’-terminus as well as an anti-leader at their 3’-end. 
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The relative abundance of the different sgRNA species is most probably influenced by 
the relative position of their TRS-B from the 3’ end of the genome. The further the 
TRS-B is located from the 3’ end, the more attenuation signals need to be passed over 
by the replicase before reaching it, resulting in a lower probability of that particular 
TRS-B being encountered, ie. longer sgRNAs are less abundant. That is however not 
the only contributing factor as a linear correlation could not be established between 
Figure 1.7: A model of discontinuous transcription in coronaviruses in three steps. 
(I) Initiation begins with genome circularization facilitated by RNA-binding 
proteins (ellipsoids) interacting with the 5’- and 3’-UTR respectively. (II) The 
replicase complex (hexagon) transcribes the genome from the 3’-UTR up to the first 
CS-B (grey block), synthesizing the cCS-B (white block). Complementarity 
between cCS-B and CS-L stalls the replicase and the replicase may either (III) read 
through the transcribed CS-B and continue transcription or it may (III’) switch its 
template to CS-L and transcribe the leader sequence. 
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3’-end proximity and mRNA abundance in all coronaviruses. The context in which 
the CS is situated, 5’- and 3’- TRS, is also an important factor as it determines the 
extent of complementarity between TRS-B and TRS-L and hence the likelihood that a 
template switching event occurs (86). The importance of these flanking sequences is 
highlighted through reports that sequences flanking the CS-L can act as acceptor sites 
for template switch, even in the absence of a canonical CS in the TRS-L (94,95) 
although it is still the preferred site.  
In TGEV, the TRS-L was found to fold into a bulged stem-loop, presenting the CS-L 
in an apical heptaloop and both its low stability and secondary structure are essential 
for replication and transcription (96). This finding coincides well with the proposed 
mechanism for template switching as it promotes CS-L for complementary base-
pairing with cCS-B. However, this hairpin structure of TRS-L is predicted not to be 
conserved and may have been unstructured or part of the stem of another stem-loop 
structure in other coronaviruses (73,74). This could have been due to the low thermal 
stability characteristic associated with the secondary structure resulting in a negative 
structure prediction and would require experimental confirmation. 
1.2.4 The viral replication/transcription complex 
It was proposed that the polyprotein intermediates (partially cleaved nsps) function in 
negative-strand synthesis while the fully processed nsps form the RTCs responsible 
for positive strand synthesis due to the instant ceasure of negative-strand synthesis 
upon cycloheximide treatment while positive strand synthesis is able to continue for a 
longer period of time (97).  
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Presumably central to the function of the RTC is the main enzyme, RNA-dependent 
RNA polymerase (RdRP) nsp12 (98) and the RNA helicase (99,100). Nsp12 is a 
primer dependent, RdRP (101), generates new gRNA for replication as well as 
sgRNAs to be used in translation to produce virus structural and other accessory 
proteins while nsp13 has been shown to be crucial for the function of nsp12 (102). A 
second RNA-dependent RNA polymerase, nsp8, has been proposed to be the primase 
(103) which produces primers required by nsp12. Nsp8 forms a channel-like 
hexadecameric complex with nsp7, has a positively charged cylindrical channel, 
presumably to facilitate interaction with the negatively charged phosphate backbone. 
Its capability to encircle RNA (both single and double stranded) coincides with its 
proposed role as a primase (104). The allowance of incomplete cleavage between 
nsp7-nsp8, nsp8-nsp9 and nsp9-nsp10 (65) is indicative that these proteins may 
function closely or even as a polyprotein (66). Indeed, both nsp9 and nsp10 have been 
reported to colocalize with nsp8 at the RTCs (105).  
Individually, nsp9 has been reported to possess non-specific binding to single 
stranded RNA (ssRNA) and double stranded DNA (106-108). The structure of nsp10 
reveals that it has two highly conserved zinc finger motifs and is able to bind both 
single- and double- stranded DNA and RNA non-specifically (109). It was also 
reported that through self-association, nsp10 forms a dodecameric structure with 
positive electrostatic potential on both its inner and outer surface (110). It has also 
been reported to be essential for coronavirus RNA synthesis (111). 
The coronavirus genome is of an unprecedented scale among non-segmented single-
stranded RNA viruses, hence, its highly sophisticated replicase complex does not just 
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possess the ability to synthesize RNA but also a number of RNA-modifying 
enzymatic activities. Nsp14 and 15 have been reported to possess 3’- to 5’- 
exonuclease (ExoN) and endoribonuclease (NendoU) respectively while nsp16 is 
reported to be a S-adenosyl methionine-dependent ribose 2’-O-methyltransferase. 
Universally conserved across Nidovirales (112), nsp15 represents a genetic marker of 
nidoviruses (113) critically involved in viral RNA synthesis, as illustrated by blocked 
viral RNA synthesis upon disruption of its endonucleolytic activity (113). 
Exonuclease activity of nsp14 was shown to be important in ensuring a high fidelity 
in viral genome replication, and hence a role in ensuring the stability of the large 
coronavirus genome (114,115).  
Cap formation is yet another important post-transcriptional process in coronavirus 
RNA synthesis as it ensures that the viral RNAs can be translated by host ribosomes 
as well as being differentiated from the host mRNAs. Nsp13, the viral RNA helicase 
possesses NTPase activity which implies an additional role in capping viral RNAs 
(116). Nsp14 on the otherhand has been revealed to possess N7 methyltransferase 
activity, thereby producing a N7-methylated guanine cap (cap-0) (117). This could 
have been followed up by 2’-O-methyltransferase (nsp16), together with its activator 
nsp10 (118-120) catalyzing the conversion of the cap-0 structure to a cap-1 structure 
(121) of viral RNAs. Another RNA processing activity associated with the viral 
replicase rests upon the ADP-ribose-1” monophosphatase (ADRP) domain (122) of 
nsp3. The ADRP domain is assigned based on structural evidence (123) but binding 
of the protein to its canonical substrate, ADP-ribose, was found to be relatively weak 
(124) if not undetectable, in the case of IBV (122). Hence it is unclear whether the 
ADRP domain plays a major role in viral transcription. 
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The anchorage of the complex onto the membrane of DMVs is likely achieved by the 
transmembrane domains of nsp3, nsp4 and nsp6 (38,125-129) and that of nsp3 has 
been shown to be important for its protease function (130,131). Although they appear 
to be critical for coronavirus replication (132), no function has been assigned to nsp4 
and nsp6 apart from anchoring the replicase complex to the membrane through their 
hydrophobic regions and likely interaction with other viral proteins (128,133). 
Apart from the replicase gene products, viral structural protein, the nucleocapsid, has 
also been shown to be associated with the viral replication-transcription complexes 
(134). The presence of the N gene was found to be required for efficient replication 
coronavirus HCoV-229E vector RNAs which would otherwise only be able to 
complete transcription (135). In addition, it has also been reported to function as a 
chaperone protein, facilitating template-switching during discontinuous transcription 
(136), and therefore, is required for efficient transcription to take place. 
1.2.5 Translation and cotranslational modification of structural proteins, viral 
assembly and release  
The products of sgRNA transcription, positive-stranded mRNAs are translated in the 
cytosol by host ribosomes and only the 5’-proximal ORF is being translated from 
each mRNA. This produces the four virus structural proteins, S, E, M and N as well as 
a number of accessory proteins, which varies between coronaviruses. While the 
structural proteins are to be packaged into the progeny virus together with the viral 
gRNA, they have other functions in the pathogenesis of the virus. The accessory 
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proteins, on the otherhand, are believed to be dispensable for in vitro virus infections 
and function only in establishing infections in their natural hosts. 
The viral S protein is cotranslationally modified via glycosylation and palmitoylation 
(137-139) and subsequently trimmed in the Golgi (140). A subset of the modified 
trimeric S protein gets transported to the plasma membrane directly (141,142) and 
engages in membrane fusion with adjacent cells, resulting in the spread of virus 
infection and eventually, the appearance of large fusion cells, the syncytia (143).  
The key players in the budding of virus particles from the endoplasmic reticulum-
golgi intermediate compartment (ERGIC), are the M and E proteins. As such, the 
coronavirus M protein is the most abundant protein in the viral envelope and together 
with the E protein in much smaller amounts, are the only viral proteins required to 
drive the efficient formation virus-like particles (VLPs) (32,33). To form an infectious 
virus particle, the other structural proteins, as well as the viral genome has to be 
packaged as well. E protein, is palmitoylated (144-146) post-translationally, 
accumulates in throughout the Golgi (31) when expressed alone exogeneously and 
carries in its C-terminal tail as well as the N-terminal hydrophobic domain, Golgi-
targeting signals (144,147). M protein, on the otherhand, is glycosylated and localizes 
to the Golgi when expressed alone (26,148,149) by virtue of a Golgi-targeting signal 
in the first transmembrane domain for (150) IBV or C-terminal cytoplasmic tail for 
(151) MHV.  
In virus-infected cells, N forms ribonucleoprotein complexes with all viral mRNAs 
(28,152) however only those comprised of the viral gRNA or mRNA 1 can be 
packaged into virions efficiently (153-159). An encapsidation signal that lies within 
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gene 1 (160-165), is unique to the viral gRNA, and is the prime factor in the specific 
incorporation of genome length mRNAs into the virions. The mechanism by which 
this is achieved is likely through specific interaction between M and the encapsidation 
signal (166), as well as the interaction of M with N in the presence of RNA (the 
nucleocapsid) (28). M has also been shown to interact with S (167) and non-structural 
protein HE (27), thereby incorporating these two membrane-spanning proteins into 
the budding virion. Although it has also been shown that IBV E protein interacts with 
(168), and retains M in the ERGIC (169), the general observation that the key players 
in viral assembly are not localized to the budding site by themselves point to the need 
of cooperative interaction between viral proteins and possibly unknown host proteins 
in this process. 
Apart from its role in virion assembly at the budding site, the E has been 
demonstrated to be essential for virion maturation and release in TGEV (170). In 
addition, the coronavirus E protein has been shown to oligomerize through its 
hydrophobic domain (171), forming cation-selective channels (172), whose function 
is essential for the efficient production of progeny virus particles as demonstrated by 
the use of ion channel inhibitor hexamethylene amiloride (173). The same 
hydrophobic domain has been shown to be responsible for the disassembly of the 
Golgi apparatus, altering the host secretory pathway and promoting virion trafficking 
towards the plasma membrane for release (174). Although it is not known if the 
mutation introduced for the study disrupted E oligomerization, it has been proposed 
that the presence E protein ion channels may disrupt the luminal pH and homeostasis 
of the Golgi apparatus (175) resulting in its disassembly, thereby protecting the 
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virions from damage by Golgi proteases as well as altering the secretory pathway to 
promote virion release. 
 
1.3 Virus-host interactions 
In a coronavirus infection, the virus replicates in the host cytosol, amid a myriad of 
host signaling pathways and systems, interaction between the virus and the host 
systems is inevitable. This is especially true when coronaviruses are severely gene-
poor in comparison to its mammalian hosts. Virus-host interplay occurs at multiple 
points during the virus replication cycle, from entry to exit. The nature of such 
interactions can range from a simple usage of existing machinery to destructive 
interactions that modulate the host environment to the advantage of the virus while 
inhibiting host activities. One of the most important interactions between virus and 
host is the modulation of host cell environment, converting it into one which the virus 
can replicate in safety. The significance of host components being used to supplement 
the gene-poor virus in various processes cannot be dismissed although they usually 
serve as enhancers, as they could become major pathogenicity factors. 
1.3.1 Innate immune system 
Upon infection by viruses, host cells could sense the invading pathogen through the 
recognition of pathogen-associated molecular patterns (PAMPs), present in viral 
genomes, by host pattern recognition receptors (PRRs) (176,177). Depending on host 
cell type and the invading pathogen, Toll-like receptors (TLR3, 7, 8 and 9) (178,179) 
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in endosomal compartments as well as cellular cytoplasmic helicases retinoic acid-
inducible gene-I (RIG-I) and melanoma differentiation-associated gene 5 (Mda5) may 
be activated (180-182). Detection of PAMPs triggers signaling cascades via adaptor 
proteins TIR-domain containing adapter-inducing interferon β (TRIF), myeloid 
differentiation primary response gene 88 (MyD88) or virus-induced signaling adapter 
(VISA) (178-181) leading to the activation of non-canonical inhibitor of NF-κB (IκB) 
kinase homologues (IKK), IKKε (183) and TANK-binding kinase 1 (TBK1) 
(184,185). This activates interferon regulatory factor 3 (IRF3) (186), IRF7 (187) and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (188-191) 
which translocate to the nucleus and activates transcription of type I interferons (IFNα 
and IFNβ) and inflammatory cytokines. The release of IFNs lead to the 
phosphorylation of Janus kinases (JAK) as well as signal transducers and activators of 
transcription (STAT) proteins which results in the transcription of anti-viral related 
genes (192,193). The viruses on the otherhand, have evolved multiple strategies to 
avoid elimination from the host which range from prevention of detection to 
inhibition of antiviral responses mounted by the host immune system. All these 
activities involve viral-host interactions at different levels. 
The first step to defending itself against viruses is the detection of viral material. The 
exact nature of PAMPs recognized by RIG-I and Mda5 has not been firmly 
established but it has been reported that RIG-I recognizes 5’-triphosphate single 
stranded RNAs (ssRNAs) (ie. uncapped RNAs) (194,195) and short double stranded 
RNAs (dsRNAs) (196,197), Mda5 can specifically bind 
polyriboinosinic:polyribocytidylic acid or poly(I:C) (198) and long dsRNAs (196). 
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TLR3, 7 and 9 have established to recognize dsRNA, ssRNA and CpG DNA 
respectively. 
A strategy coronaviruses have adopted to avoid detection of its newly synthesized 
mRNAs in the cytoplasm is to encode a 2’-O-methylase (nsp16), creating a 5’-cap 
structure analogous to the cellular mRNAs on their mRNAs, thereby escaping 
detection by Mda5 (199). However, during the course of viral transcription and 
replication, uncapped double-stranded RNA intermediates are generated and these 
may have served as ligands for the RIG-I and/or Mda5. Both RIG-I and Mda5 have 
been implicated in the detection of MHV infection (200) but conflicting evidence has 
been presented as well, especially when it is not understood how the cellular helicases 
could bind to viral replicative/transcriptive intermediates which should have been 
isolated by the DMVs (201).  
Detection by the PRRs would activate signaling cascades leading to the production of 
type I IFNs, resulting in the establishment of an antiviral state. Thus, coronaviruses do 
not just avoid detection by the host immune system, which appears to be the main 
strategy of ensuring successful replication (202), but some also encode proteins that 
function to disrupt the downstream signaling cascades at various points, preventing 
the establishment of an effective antiviral state when detection of the viral PAMPs has 
occurred. Indeed, the N protein has also been shown to interfere with the 2’, 5’-
oligoadenylate synthetase/RNaseL activation, downstream of IFN induction, 
inhibiting global translation shutdown (203). This activity is in addition to its 




Another structural protein, the SARS-CoV M, has been reported to interact with 
multiple components of the IFN induction pathway, namely IKKβ, IKKε, TBK1, 
TNF-receptor associated factor 3 (TRAF3) and RIG-I, resulting in a suppression of 
NF-κB activity and IRF3/7 activation, thereby impairing type I IFN production 
(205,206). 
In addition to processing the polyproteins, PLP2 domain of the nsp3 has been shown 
to possess deubiquitinating activity (207-209). PLP2 of nsp3 deubiquitinates both 
TBK1, the activating kinase for IRF3 and IRF3 itself, then sequesters the hypo-
phosphorylated TBK1-IRF3 complex in the cytoplasm. This prevents IRF3 nuclear 
translocation (210,211), thereby inhibiting the transcription of type I interferons (212). 
The ADRP domain of nsp3 in also appears to confer resistance against the antiviral 
effect of IFNα (213) through an unknown mechanism.  
Nsp1 is a highly divergent protein across sub-family Coronavirinae and absent in 
gammacoronaviruses. It has no known direct function in viral transcription, but 
SARS-CoV nsp1 was reported to cause a general suppression of  host gene expression 
most likely by promoting host mRNA degradation (214-217) and in particular the 
inhibition of IRF3/7 activation, activities of NF-κB and IFN promoters as well as 
STAT1 phosphorylation (218). Similarly, nsp2, possesses highly divergent sequences 
across coronaviruses and has been reported to act as a weak protein kinase RNA-
activated (PKR) antagonist, suppressing the phosphorylation of eukaryotic initiation 
factor 2 alpha (e-IF2α), which in turn blocks host translation while allowing viral 
translation to take place (219). There have been reports that both nsp1 and nsp2 are 
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dispensable for virus replication/transcription in vitro and mainly function as 
pathogenicity factors (215) and in other parts of the virus life cycle (220,221).  
Accessory protein SARS-CoV ORF 3b and 6 have also been implicated as an IFN 
antagonist (222) by which the latter works by interacting and subsequently 
sequestering the nuclear import factor, karyopherin alpha 2 (KPNA2) in the ER/Golgi 
region, preventing the nuclear translocation of STAT1 (223). SARS-CoV ORF 3b on 
the otherhand appears to stimulate activator protein 1 (AP-1) dependent synthesis of 
proinflammatory cytokines by activating both c-Jun N terminal kinase (JNK) and 
extracellular signal-regulated kinase (ERK) pathways (224). SARS-CoV 3a targets 
IFNα receptor subunit 1 (IFNAR1) for ubiquitination and subsequent lysosomal 
degradation as a consequence of PKR-like ER kinase (PERK) activation (225). MHV 
ORF 5a was also reported to be an IFN antagonist but the mechanism of action has 
not been established (226). Gene 7 is only present in a subset of alphacoronaviruses, 
and that of TGEV has been shown to interact with protein phosphatase 1 catalytic 
subunit c (PP1c) and the interaction is vital for eIF2α dephosphorylation. The innate 
immune response which can be triggered and subsequently countered by the 




Figure 1.8: Virus-host interaction in innate immune response. The activation of toll-
like receptors 3 and/or 7 as well as cytoplasmic helicases RIG-I and/or MDA-5 
triggers signaling pathways resulting in the synthesis of type I interferons (IFNs), 
inflammatory cytokines and interferon-stimulated genes (ISGs) which acts in concert 
to establish an antiviral state. Activation of 2’-5’ oligoadenylate synthesase (2’-5’ 
OAS) and PKR results in global degradation of cellular RNA and inhibition of 
translation which can inhibit viral propagation. Coronaviruses encode many proteins 
that target multiple steps in the innate immune response mounted by the host cells, 
ensuring its successful replication in the host. 
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1.3.2 Cell cycle arrest, ER stress and apoptosis 
Infections with viruses often result in cell cycle arrests, the activation of unfolded 
protein response (UPR) due to ER stress, both of which can be accompanied by the 
parallel activation of apoptosis in the infected cells. In this aspect, coronaviruses are 
no exception and Figure 1.9 summarizes how some coronavirus-encoded proteins 
interfere with the host cell cycle.  
Infection with MHV causes cell cycle arrest at G0/G1 phase (227) and IBV at S and 
G2/M phases (228,229). It has been observed that the N protein of several 
coronaviruses can localize in the nucleolus where it may have perturbed cell cycle 
activities of the host cell to benefit viral mRNA synthesis (230-233). SARS-CoV N 
Figure 1.9: Coronavirus-encoded proteins interfere with the cell cycle. Cell cycle 
progression is mediated through the temporal expression levels of different cyclins 
and CDKs. Different coronavirus arrest the cell cycle at different stages. MHV and 
IBV have been confirmed to cause cell cycle arrest at G0/G1 and G2/M phases 
respectively. This arrest is mediated through the nucleocapsid protein (N) as well as 
other virus-encoded non-structural (replicase) and accessory proteins. The proposed 
point of interaction for some proteins has not been confirmed (as indicated by (?) 
although they have been linked to cell-cycle arrest. 
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has been shown to interact with both cyclin D-CDK4 and cyclin A-CDK2 complexes, 
inhibiting their activities resulting in a block in S phase progression (234), despite 
being reported to localize to the nucleolus inefficiently (232,235,236). IBV N on the 
otherhand appears to target CDK2, cyclins A and D1 for proteasome-mediated 
degradation (229,237) and cause the accumulation of hypophosphorylated 
retinoblastoma (pRB), resulting in the downregulation of CDK1, cyclins E and B1 
(229). 
N is not the only viral-encoded protein implicated in causing cell cycle arrest in 
infected cells. MHV p28 (nsp1) over-expression was also linked to a reduction of pRb 
hyper-phosphorylation resulting in a G0/G1 cell cycle arrest (238). Over-expression 
of SARS CoV accessory proteins 3a, 3b and 7a has also been shown to lead to G0/G1 
phase arrest (239-241) likely through the modulation of cyclin D3 expression level 
and pRB phosphorylation.  
During virus replication, the newly translated viral proteins accumulating in the ER 
causes stress and activation of the UPR. The S protein of both MHV and SARS-CoV 
has been shown to be able to activate the UPR, albeit with differences in activation 
targets as MHV activates all three UPR transducers inositol-requiring enzyme 1 
(IRE1), activating transcription factor 6 (ATF6) and PERK (242) while SARS-CoV 
selectively activates PERK signaling (243). In particular, activation of PERK leads to 
the activation of p38 mitogen-activated protein (MAP) kinase (244), which stimulates 
virus replication (245,246). Although MHV S protein activates UPR by all three 
transducers, other MHV encoded proteins negatively modulate the downstream 
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effectors as demonstrated by the lack of spliced X-box binding protein 1 (XBP-1) 
accumulation and decline in activated/cleaved ATF6α (242). 
Coronavirus proteins tend to be multi-function in order to make up for their deficit in 
the number of genes the genome can contain. As such, the ER-localized SARS-CoV 
3a has also been reported as an inducer of apoptosis (247) and ER stress (225) by 
activating the extrinsic and intrinsic apoptotic pathways as well as the p38 MAP 
kinase (245). The latter which is also activated by SARS S, can also promote 
apoptosis by increasing p53 levels leading to increased Bax oligomerization, releasing 
cytochrome c from the mitochondria (248).  
SARS-CoV accessory proteins, 6 and 7a have been shown to induce apoptosis as well 
as UPR (249,250). SARS 7a has been shown to be able to interact and exhibit partial 
colocalization with anti-apoptotic protein Bcl-XL to the mitochondria compartment, in 
addition to its interaction with other anti-apoptotic proteins of the Bcl-2 family (251). 
It was also reported to activate the p38 MAP kinase through an unknown mechanism 
which may have contributed to the induction of apoptosis (252). Interaction between 
SARS-CoV 7a and the human asymmetrical diadenosine tetraphosphate hydrolase 
(Ap4A-hydrolase) (253), a signaling molecule that is proposed to function in multiple 
pathways including cell proliferation, RNA processing, apoptosis and DNA repair 
(254-259), has also been documented. This provides further evidence supporting the 
role of SARS-CoV 7a in modulating various signaling pathways in the infected cell. 
Like 7a, SARS-CoV 6 is also localized in the ER/Golgi compartment and has been 
shown to activate effector caspase 3 and induce ER-stress, triggering JNK-dependent 
apoptosis and UPR by unknown mechanisms (260). SARS-CoV 8a and 3b have also 
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been shown to induce apoptosis in host cells (241,261) and the latter may induce 
necrosis as well (262).  
SARS-CoV E is also an inducer of apoptosis and has been shown to interact with anti-
apoptotic protein Bcl-XL (263). Similarly, MHV infections can also induce apoptosis 
(264-267) which can be blocked by Bcl-XL over-expression (268) and the E protein is 
likely to be responsible for this activity (269). In IBV however, E protein was not 
shown to be an inducer of apoptosis, instead, nsp14 appears to trigger caspase-
dependent apoptosis in over-expressing cells (270). Other coronaviruses TGEV, 
canine coronavirus (CCoV) and equine coronavirus (ECoV) have also been reported 
to induce apoptosis (271-273) but the mechanisms have not been established. Figure 





Figure 1.10: The activation of apoptosis by coronavirus-encoded proteins. Extrinsic 
signals from receptors (eg. Fas) culminate in the activation of caspase 8 which 
activates the effector caspase 3 while intrinsic signaling requires the participation of 
the mitochondria in releasing cytochrome c (shown as circles labeled “C”) to activate 
caspase 9 in order to activate caspase 3. Key proteins in the intrinsic apoptosis 
signaling pathway are p53, both pro-apoptotic (eg. Bax, Bak) and anti-apoptotic 
proteins (eg. Bcl-2, Bcl-XL) from the Bcl-2 family. Both extrinsic and intrinsic 
apoptosis signaling pathways are targeted by coronavirus proteins and viral proteins 
act at multiple points along the different signaling pathways, enhancing the pro-
apoptotic effect brought upon by virus infection. Anti-apoptotic proteins (black oval) 
listed are key anti-apoptotic members from the Bcl-2 family of proteins. Other 
pathways triggered by coronavirus infections ie. ER stress and DNA damage 
response, also trigger apoptotic signaling. 
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1.3.3 Ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) plays a major role in regulating cellular 
protein levels (274,275). Viruses exploit and manipulate host metabolism to benefit 
their replication in permissive hosts, it is unsurprising that this system has been 
implicated in the replication of several other viruses (276-280), including 
coronaviruses. During a coronavirus infection, virus particles have been internalized 
through the endosomal pathway need to be transferred to the cytosol for viral 
replication to begin. This step as demonstrated in MHV, appears to require a 
functional proteasome as the application of proteasome inhibitors resulted in an 
accumulation of internalized particles in the lysosomes, lowering the progeny virus 
titre (281). This has been subsequently shown to be independent of ubiquitination 
activity (282). A later discovery that SARS-CoV N protein interacts colocalizes with 
the p42 subunit of the 26S proteasome in cultured cells affirms the significance of the 
UPS in coronavirus replication cycle (283).  
Not only is the UPS implicated in the transfer of virus particles from the endosome 
into the cytosol, ubiquitination has also been shown to be important for viral RNA 
synthesis (282). The mechanism by which ubiquitination affects viral RNA synthesis 
could not be determined and considering that the UPS plays a central role in cellular 
protein homeostasis, it is likely that the disruption of ubiquitination may perturb 




1.3.4 DMV biogenesis 
Coronavirus infection induces the formation of DMVs in host cells, creating a 
protected environment for viral replication and transcription to take place (285). It is 
widely believed that the DMV membranes originate from the endoplasmic reticulum 
(ER) (37,129,286) but the mechanism by which they are derived remained elusive. 
Although the early secretory pathway has been shown to be linked to DMV 
biogenesis (287,288), the absence of marker proteins casts doubt on the extent of its 
involvement (288). On the otherhand, autophagy has also been reported to be likely 
involved in DMV biogenesis. However, in addition to the discovery that an essential 
component of the autophagy machinery is dispensable for MHV replication (289), 
contradictory findings have been presented with regards to the presence (289,290) or 
absence (37,291) of autophagosome marker microtubule-associated protein 1 light 
chain 3 (LC3) on the DMVs. A recent discovery that DMVs are coated with non-
lipidated LC3-I, not autophagosome-associated LC3-II, has demystified the 
mechanism by which these virus-induces structures are derived from the ER (292). 
This study has elucidated the involvement of ER-derived vesicles exporting short-
lived ER-associated degradation regulators (EDEMosomes) in DMV biogenesis and 
viral replication. 
1.3.5 Viral RNA synthesis and translation 
In virus RNA synthesis, the replicase complex is indispensable but not an exclusive 
participant, as cytoplasmic factors had to be supplied in trans for purified RTCs to 
function efficiently (293). One of the most obvious ways that host proteins can take 
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part in viral RNA synthesis would be sustaining interactions with cis-acting 
regulatory signals on the virus 5’- and 3’-UTRs. The ability of host proteins to form 
ribonucleoprotein complexes with genomic RNA of coronaviruses have long been 
reported (294,295), and their significance in the regulation of coronavirus RNA 
synthesis documented (296). However, despite their noteworthy participation in this 
vital part of the coronavirus replication cycle, only a handful of such cellular proteins 
have been identified. 
The most well-studied host protein that interacts with the coronavirus genome is none 
other than heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), a nuclear 
protein, whose biological function is to regulate alternative splicing of cellular RNAs 
(297,298). In the first report, hnRNP A1 was shown to bind to both negative-sense 
leader sequence and negative-sense intergenic (IG) sequence of the MHV (299). 
Subsequently, the formation of a RNP complex between hnRNP A1, negative-sense 
leader and IG sequences has been demonstrated (300) and that the participation of 
hnRNP A1 is vital (301). In addition to its ability to interact with the coronavirus 
RNA, hnRNP A1 was also found to interact and colocalize with N protein (302,303), 
an important player in coronavirus RNA synthesis (91,136). It has also been 
highlighted that hnRNP A1 may be required to recruit other cellular proteins to the 
replicase complex (304). Information that diminishes the importance of hnRNP A1 
were also presented (305) but that could have been explained by the subsequent 
discovery that other members of the hnRNP A/B family are able to substitute for 
hnRNP A1 in viral RNA synthesis (306).  
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In addition, it has also been reported that hnRNP A1 binds positive sense MHV 3’-
UTR and the two binding sites overlap with that of another nuclear protein, 
polypyrimidine tract-binding protein (PTB), on the negative strand (307). In the same 
study, hnRNP A1 was also found to interact with PTB via protein-protein interactions 
and together form a RNP with the 5’- and 3’- ends of the MHV RNA.  
PTB has been demonstrated to interact with both the positive-sense leader RNA 
(308,309) and negative-sense 3’-UTR (310) of MHV RNA and that the RNA-binding 
activity is required for viral RNA transcription. PTB was found to be interacting with 
the MHV N protein, as mentioned earlier, is required for coronavirus RNA synthesis  
(311). The role played by PTB is however, controversial, as it was found that excess 
PTB had an inhibitory effect on viral RNA synthesis (311). Further evidence had been 
presented using TGEV supporting the finding that PTB exerts a negative impact on 
coronavirus RNA synthesis and may sequester viral RNAs in cytoplasmic stress 
granules during infections (309,312).  
Another protein belonging to the cellular splicing machinery, hnRNP Q, was also 
reported to exert a positive effect on coronavirus RNA synthesis, most likely through 
its interaction with the both positive and negative sense MHV 5’-UTR (313) as well 
as the 3’ UTR (309). Poly(A)-binding protein (PABP) was also found to interact with 
the coronavirus extreme 3’-UTR including the poly(A)-tail (309,314). This finding 
establishes the importance of the poly(A)-tail as a cis-acting signal and the possibility 
of genome circularization during coronavirus RNA synthesis. 
The MHV extreme 3’-UTR was reported in a separate study to form 
ribonucleoprotein complexes with at least four cellular proteins, one of which was 
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determined to be mitochondrial aconitase (m-aconitase) (315). The cytoplasmic 
counterpart of m-aconitase, iron-regulatory protein (IRP), functions as a translation 
regulator and binds to iron-responsive elements (IREs) on ferritin and transferrin 
mRNAs (316,317). Hence, although it was the first report of the RNA-binding 
capacity of m-aconitase, it is not surprising for the protein to possess such activity. 
Also, this work has demonstrated the partial colocalization of m-aconitase with viral 
RTCs, a crucial supporting evidence for the probability of a mitochondrial protein 
interacting with viral RNAs which are located at viral-induced DMVs. 
Interactions with viral RNA is not the only way by which cellular proteins can take 
part in viral RNA synthesis, protein-protein interactions with the viral replicase 
complex can modulate this process as well. ATP-dependent RNA helicase 1 (DDX1), 
a cellular RNA helicase (318), was reported to be an interacting partner of the viral 
exonuclease, nsp14 from both IBV and SARS-CoV, and in addition, shown to 
relocate to the viral RTCs in the cytoplasm in the presence of nsp14, deviating from 
its regular, nuclear localization pattern (319). 
1.3.6 Viral assembly and release 
Late in the virus replication cycle, the secretory pathway is hijacked by the virus for 
the budding of virus particles and the exocytosis of vesicles containing the virus 
particles. The principle requirement for efficient virion assembly is the accumulation 
of viral structural proteins, as well as viral gRNA in the assembly or budding site, 
which in the case for coronaviruses, is the ERGIC (26). The coronavirus S, when 
expressed alone exogeneously, do not accumulate at the ERGIC and is found further 
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downstream along the secretory pathway as well as the plasma membrane 
(141,320,321). However, in a virus infection, most of it accumulates in the ERGIC 
and ER. The discovery of an ER retention signal in its C-terminus which could 
interact with coatomer complex I (COPI) (322-325) sheds light upon the mechanism 
by which S could be assembled into the virus particles at the ERGIC. COPI is a 
cytosolic coat protein involved in the retrograde transport of vesicles from the Golgi 
back to the ER (326,327). Therefore, an interaction between coronavirus S and COPI, 
and that the signal is required for ER/ERGIC localization of S protein (323), point to a 
role for retrograde transport in virion assembly. 
On the otherhand, M protein has been reported to interact with actin, a cytoskeleton 
protein, and that the interaction is crucial for the budding or release of virus particles 
from the infected cells (328). It has however not been established which part of the 
process from virion assembly to exocytosis actin participates in. The observation that 
S protein interacts with M protein (167) as well as the involvement of actin 
microfilaments in retrograde transport of COPI coated vesicles from the Golgi (329-
331) to the ER may imply a role for actin in facilitating virion assembly. 
 
1.4 Objectives 
As described in the preceding sections of the chapter, both cellular proteins and virus-
encoded proteins, in particular, the nsps are important in ensuring the efficient 
production of the virus progeny. Also, one of the early steps of the coronavirus 
replication cycle is the synthesis of mRNAs, the efficiency of which can influence the 
outcome of the infection. Despite its significance, coronavirus RNA synthesis is still 
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poorly understood. Hence, this work has been dedicated to the identification of a 
cellular protein, zinc finger CCHC-type and RNA binding motif 1 (ZCRB1 alias 
MADP1), that could participate in coronavirus RNA synthesis through its interaction 
with the coronavirus UTRs and an investigation of the nsps in close contact to RNA 
or the RdRP (nsp12).  
The main objectives can be summarized as follows: 
• Identification of cellular proteins that could interact with the UTRs of SARS-CoV 
• Characterization of the interaction between MADP1, a candidate protein identified 
from the screen with IBV 5’-UTR (+) 
• Elucidation of the functional role played by MADP1 in coronavirus infection 
• Investigation of the RNA-binding activity of nsps 















2.1 Chemicals and Reagents 
2.1.1 Chemicals  
Diethyl pyrocarbonate (DEPC), polysorbate 20 (Tween® 20), sodium dodecyl 
sulphate (SDS), 4-morpholinepropanesulfonic acid (MOPS), sterile dimethyl 
sulfoxide (DMSO), actinomycin D and 5-bromouridine 5’-triphosphate (BrUTP) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). IGEPAL CA-630 (Nonidet P-
40 substitute) was purchased from US Biological (Marblehead, MA, USA). 
Formaldehyde (37% minimum), formamide and chloroform were purchased from 
Merck (Darmstadt, Germany) TRIzol® Reagent, UltraPureTM 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v), UltraPureTM Agarose was 
purchased from Invitrogen (Carlsbad, CA, USA). Ethidium Bromide (10 mg/ml) and 
acrylamide/bis (29:1) solution were purchased from Bio-Rad (Hercules, CA, USA). 
PCR digoxigenin (DIG) labeling mix, biotin RNA labeling mix, Protector RNase 
inhibitor were purchased from Roche Applied Science (Penzberg, Upper Bavaria, 
Germany). 
2.1.2 Culture medium and reagents 
Mammalian Cell Culture 
Roswell Park Memorial Institute (RPMI) 1640 medium with 2 mM L-glutamine and 
Dulbecco’s Modified Eagle Medium (DMEM) containing 4500 mg/L D-glucose, both 
containing 2 mM L-glutamine and phenol red indicator were purchased from 
Invitrogen (Carlsbad, CA, USA). Fetal Bovine Serum (FBS), US Origin, was 
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purchased from Thermo Scientific HyClone (Waltham, MA, USA). Penicillin-
streptomycin solution (PS), containing 10000 units (U) and 10000 µg of penicillin and 
streptomycin respectively was purchased from Invitrogen Gibco (Carlsbad, CA, 
USA). 0.25% Trypsin-EDTA solution containing phenol red was purchased from 
Invitrogen Gibco (Carlsbad, CA, USA). G418 disulphate salt solution (50 mg/ml) and 
carboxymethyl cellulose (CMC) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  
Yeast and Bacteria Culture 
BactoTM-peptone, BactoTM-yeast extract, BactoTM-tryptone, BactoTM-agar and 
DifcoTM nitrogen base without amino acids were purchased from Becton, Dickinson 
and Company (Franklin Lakes, NJ, USA). Drop-out media supplements were 
purchased from Clontech (Mountain View, CA, USA). 5-fluoroorotic acid (5-FOA) 
was purchased from US Biological (Marblehead, MA, USA). Antibiotics ampicillin, 
kanamycin, amino acid leucine and bovine serum albumin (BSA) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 
2.1.3 Antibodies, enzymes and other reagents 
Polyclonal rabbit antibody to MADP1 (serum) was produced by BioGenes (Berlin, 
Germany) using a peptide sequence in its N-terminus as the antigen. Antibodies to 
actin, histone H1 and HIS-probe were purchased from Santa Cruz (Santa Cruz, CA, 
USA). Antibodies to β-tubulin, FLAG and HA tags were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Antibody to bromodeoxyuridine (BrdU) was 
purchased from Roche Applied Science (Penzberg, Upper Bavaria, Germany) and 
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antibody to green fluorescent protein (GFP) was purchased from Clontech (Mountain 
View, CA, USA). All horseradish peroxidase (HRP) conjugated secondary antibodies 
were purchased from Dako (Glostrup, Denmark) and Alexa Fluor® conjugated 
secondary antibodies were purchased from Invitrogen Molecular Probes® (Eugene, 
OR, USA). Zymolase was purchased from Zymo Research (Irvine, CA, USA) and 
lysozyme was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
All restriction enzymes and calf intestinal phosphatase (CIP) were purchased from 
New England Biolabs (Ipswich, MA, USA). T4 DNA ligase and ribonucleotide 
triphosphates (NTPs) were purchased from Promega (Fitchburg, WI, USA). T7 RNA 
polymerase, Expand Reverse Transcriptase (RT), PCR DIG Labeling Mix, DIG RNA 
Labeling Mix and Biotin RNA Labeling Mix were purchased from Roche Applied 
Science (Penzberg, Upper Bavaria, Germany). Taq polymerase was purchased from 
KAPA Biosystems (Cambridge, MA, USA). KOD Hot Start DNA Polymerase was 
purchased from Merck (Darmstadt, Germany). Deoxyribonucleotide triphosphates 
(dNTPs) were purchased from Thermo Scientific Fermentas (Vilnius, Lithuania).  
All primers (100 µM) and siRNAs (100µM) were synthesized by Proligo, Sigma-
Aldrich (St. Louis, MO, USA) or purchased from Thermo Scientific Dharmacon 
(Lafayette, CO, USA). Acid-washed glass beads of particle size between 425 to 600 
µm, anti-FLAG® M2 affinity gel, 3X FLAG® peptide were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Fluorescence Mounting Medium was purchased from 
Dako (Glostrup, Denmark). 
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2.1.4 Molecular weight references 
BenchMarkTM Prestained Protein Ladder used as a molecular weight standard for 
most SDS-PAGE gels was purchased from Invitrogen (Carlsbad, CA, USA). 
Precision Plus Protein® Kaleidoscope Prestained ladder used in some SDS-PAGE gels 
was purchased from Bio-Rad (Hercules, CA, USA). 2-log, 1 kb and 100 bp DNA 
ladders used in all native agarose gels were purchased from New England Biolabs 
(Ipswich, MA, USA). DIG-labeled RNA Molecular Weight Marker I used in all 
denaturing agarose gels was purchased from Roche Applied Science (Penzberg, 
Upper Bavaria, Germany). 
2.1.5 Buffers 
Phosphate buffered saline (PBS) used in all experiments contained 8 mM Na2HPO4, 2 
mM KH2PO4, 150 mM NaCl, 3 mM KCl and pH was adjusted to 7.4. Lysis buffer 
used in all experiments contained 140 mM NaCl, 10 mM Tris (pH 8.0), 1% IGEPAL 
CA-630 unless otherwise stated. DEPC-treated water was prepared with 0.1% DEPC 
(v/v) deactivated by auto-claving. 
2.1.6 Membranes 
Nitrocellulose membrane, Hybond-C Extra, and nylon membrane, Hybond-N+, were 
purchased from Amersham (Amersham, United Kingdom). Polyvinylidene fluoride 
(PVDF) membrane was purchased from Bio-Rad (Hercules, CA, USA).  
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2.2 Yeast three-hybrid Screening 
2.1.1  Basis of the three-hybrid system 
The three-hybrid system was a gift from  Marvin Wickens (University Of Wisconsin-
Madison, USA), the corresponding author of the original publication (332) and 
employed as the strategy to detect RNA-protein interactions between SARS CoV 
UTRs and human proteins. As depicted in Figure 1 above, hybrid I is a fusion protein, 
Figure 2.1: An overview of the yeast three-hybrid system. The system is based on 
the successful interaction between three hybrids (labeled I, II and III) resulting in 
the transcriptional activation of a reporter gene (HIS3). Hybrid I is a fusion 
protein of LexA DNA-binding domain and the coat protein of bacteriophage 
MS2. Hybrid II is a fusion RNA of the MS2 coat binding sequence and any other 
protein binding sequence. Hybrid III is a fusion protein of a RNA-binding protein 
and the Gal4 transcriptional activation domain. Interactions between the three 
components bring the activation domain in close proximity to the promoter and 
activate the transcription of the reporter gene under its control. 
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which comprised of the LexA DNA-binding domain, tethers the bacteriophage MS2 
coat protein to the promoter. Hybrid III is fusion protein comprised of a RNA-binding 
domain and the Gal4 transcription activation domain. Hybrid II on the otherhand is a 
fusion RNA and the MS2 coat binding sequence on it binds to the MS2 coat protein 
with high affinity, therefore anchoring hybrid II to the promoter region. Thus, an 
interaction between hybrid II and the RNA-binding domain on hybrid III would result 
in the Gal4 transactivation domain being brought into close proximity to the 
promoter, resulting in reporter gene HIS3 or LacZ expression. The variable 
components of the system are designated to be the RNA-binding domain on hybrid III 
and hybrid II RNA sequence (apart from MS2 coat binding sites). The three hybrids 
required for the assay are supplied by the yeast strain (hybrid I) and plasmids (hybrids 
II and III). 
2.2.2 Yeast plasmids 
To create the fusion RNA hybrid II, the vector pIIIA/MS2-2 which was enclosed as 
part of the three-hybrid system obtained was used to express the SARS 5’- and 3’-
UTR  in yeast cells. The vector is a yeast/Escherichia coli (E. coli)  shuttle vector 
which contains a polymerase III promoter that can direct the transcription of a RNA 
containing two MS2 coat binding sequences in tandem and selection markers URA3 
for yeast and ampicillin for E. coli. Unique restriction sites Sma1 used was 5’ to the 
MS2 coat binding sequences (MS2s) which allowed for the expression of hybrid 
RNAs of the SARS UTR-MS2s-MS2s, 5’ to 3’.  
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Hybrid III for the screening was provided by a human cDNA library extracted from 
HeLa cells and cloned into the vector pGADT7. The library cloning was pre-prepared 
by another lab member. The pGADT7 vector carried the yeast genetic marker LEU2 
which conferred leucine autotrophy, and fuses the GAL4 activation domain as well as 
a HA-epitope tag to the human cDNA fragment. 
2.2.3 Yeast strain 
The yeast (Saccharomyces cerevisiae) strain L40-coat which was supplied with the 
system was constructed by the authors who integrated a plasmid encoding hybrid I 
(LexA-MS2coat) into the genome of yeast strain L40-ura (MATa, ura3-52, leu2-3, 
112, his3Δ200, trp1Δ1, ade2, LYS2::(lexAop)-HIS3, ura3::(lexAop)-LacZ). The 
resultant L40-coat is an auxotrophic strain for uracil, leucine, histidine, tryptophan 
and lysine, containing reporter genes HIS3 and LacZ under the control of LexA 
promoter and expressing hybrid I fusion protein (LexA-MS2coat). 
2.2.4 Yeast culture 
Yeast strain L40-coat was cultured in yeast peptone dextrose (YPD) medium 
composed of 20 grams per litre (g/L) BactoTM-peptone, 10 g/L BactoTM-yeast extract 
and 2% (w/v) glucose. SD media for culturing yeast transformants was composed of 
6.7 g nitrogen base without amino acids, 1X DO supplement, 2% (w/v) galactose, 1% 





2.2.5 Screening process 
The bait plasmid which carried the positive sense SARS 5’ untranslated region 
sequence (5’-UTR), MS2 coat binding site and marker gene URA3 was first 
transformed into yeast strain L40-coat. The transformants were selected for uracil 
prototrophy using SD/-ura plates. One single colony was selected for use in library 
transformation and the clone was expanded. This was followed by the transformation 
of the HeLa cell cDNA library which bears the marker gene LEU2 into the selected 
Figure 2.2: Screening process using the yeast three-hybrid system 
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clone. The transformants were selected for prototrophy of leucine and uracil first 
using SD/-leu/-ura agar plates and incubated for 7 days when the colonies have grown 
to substantial size. The colonies were transferred from the agar plates with 1 µl 
disposable inoculating loops, to 75 µl of freezing media and dispersed evenly in the 
solution by vortexing to create a liquid stock. 2 µl of each colony stock was dotted on 
SD/-his/-leu/-ura agar to screen for reporter gene, HIS3 activation. To verify that the 
activation of reporter gene HIS3 was accompanied by the expression of URA3 gene 
from the bait plasmid, 5-FOA, a negative selector for URA3 gene expression, was 
required. Hence, 2 µl of each colony stock was dotted on SD/-his/-leu/-ura/5-FOA 
agar as well. An additional selection criterion was imposed to confirm URA3 gene 
expression in leucine prototrophs, and 2 µl of each colony stock was dotted on SD/-
leu/5-FOA plates as well. The remaining colony stocks were frozen at -80°C and the 
plates were incubated until colonies on SD/-his/-leu/-ura have grown to a minimum of 
2 millimeters (mm). Colonies which appeared on SD/-his/-leu/-ura but not on SD/-
his/-leu/-ura/5-FOA were sequenced and the insert identified by alignment with the 
human transcript library using basic local alignment search tool (BLAST) from 
National Center for Biotechnology Information(NCBI). The key procedures of the 
screen had been summarized in Figure 2.2. 
2.1.6 Yeast transformations 
For the initial transformations of bait plasmids, 1 ml of YPD medium was inoculated 
with L40-coat strain of S. cerevisiae and vortexed to eliminate clumping. The 
resuspended yeast was transferred into a conical flask containing 25 ml of YPD 
medium and incubated at 30°C with shaking at 250 revolutions per minute (rpm) for 
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16 hours. 100 ml of YPD medium was inoculated with the overnight culture such that 
the optical density at 600 nm (OD600) fell between 0.2 and 0.3. The culture was 
incubated at 30°C with shaking at 230 rpm until its OD600 fell between 0.5 and 0.6. 
The cell suspension was then transferred into 50 ml polypropylene centrifuge and 
centrifuged at 1000 g for 5 minutes at room temperature with a table-top centrifuge. 
The pellet was resuspended with 30 millilitres (ml) of 1X TE buffer (10 milimolar 
(mM) Tris (pH 7.5), 1 mM ethylenediaminetetraacetic acid (EDTA)) then centrifuged 
at 1000 g for 5 minutes. The pellet was then resuspended in 1.5 ml of sterile 1X 
TE/Lithium acetate (LiAc) (1X TE, 0.1 molar (M) LiAc) solution to yield 
transformation-competent yeast cells.  
In a 1.5 ml polypropylene snap-cap tube, 0.1 micrograms (µg) of the bait plasmid and 
0.1 milligram (mg) of salmon testes carrier deoxyribonucleic acid (DNA) (Millipore; 
Billerica, MA, USA) was mixed with 0.1 ml of competent yeast cells vigorously. 0.6 
ml of PEG/LiAc solution (40% PEG, 1X TE, 0.1 M LiAc) was added and the mixture 
was mixed thoroughly then incubated at 30°C for 30 minutes with shaking at 200 
rpm. After which, 70 µl of DMSO  was mixed in by gentle inversion. 
To perform heat shock, the tube was placed in a 42°C water bath for 15 minutes then 
chilled on ice for 2 minutes and centrifuged at 14000 rpm for 5 seconds at room 
temperature using a table-top microcentrifuge. The supernatant was removed carefully 
and the cells were resuspended in 0.5 ml of 1X TE buffer, of which, 0.1 ml was plated 
on a SD/-ura agar plate and incubated at 30°C for 16 hours. 
For the transformation of the cDNA library, a 150 ml overnight culture of each 
confirmed transformant bearing the bait plasmid was prepared. 1 L of SD/-ura 
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medium was inoculated with the overnight culture and once the OD600 fell between 
0.5 and 0.6 the cells were pelleted. It was then washed with 500 ml of 1X TE buffer 
and resuspended in 8 ml of TE/LiAc solution. 0.5 mg of the HeLa cell cDNA library 
(pre-constructed by another lab member using pGADT7 vector), 20 mg of salmon 
testes carrier DNA and 8 ml of competent cells were mixed in a 50 ml polypropylene 
centrifuge tube. Half of the mixture was transferred to a new tube and 30 ml of 
PEG/LiAc solution was added to each tube then incubated at 30°C with shaking at 
200 rpm for 30 minutes. 3.5 ml of DMSO was then added to each tube and mixed 
gently. Heat shock was performed by incubating both tubes in a 42°C water bath for 
15 minutes with occasional swirling then chilled on ice for 2 minutes. The cells were 
then pelleted, resuspended in 10 ml of 1X TE buffer, and plated on SD/-leu/-ura agar 
plates. The plates were incubated at 30°C for 5 to 7 days until colonies appear. 
2.1.7 Yeast colony PCR  
A matchhead amount of yeast cells from each selected colony was washed with 500 
µl of de-ionized water in a 1.5 ml snap-cap eppendorf tube and pelleted by 
centrifugation at 5000 rpm for 1 minute using a microcentrifuge. The pellet was 
resuspended in 100 µl of water containing 6 U of zymolyase. 25 µl of glass beads was 
added to each sample and the tube was incubated at 37°C using a heating block for 30 
minutes. The samples were vortexed vigorously for 1 minute and incubated at 95°C 
on a heating block for 10 minutes then chilled immediately on ice for 5 minutes. The 
cell debris and glass beads were pelleted by centrifugation at 5000 rpm for 1 minute 
and the supernatant was transferred to a clean 1.5 ml snap-cap eppendorf tube. 10 µl 
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of supernatant for each sample was used in a 50 µl PCR reaction for amplification of 
the insert with the following primers:  
AD_5’ (5’-CTATTCGATGATGAAGATACCCCACCAAACCC-3’);  
AD_3’ (5’-GTGAACTTGCGGGGTTTTTCAGTATCTACGAT-3’) 
The PCR product of each sample was then purified and sequenced using the AD_3’ 
primer. 
 
2.3 Mammalian Cell Culture 
2.3.1 Cell lines 
Human lung cancer epithelial cell line, H1299, was cultured in RPMI-1640 medium 
supplemented with 5% FBS, 100 units (U) of penicillin and 100 µg of streptomycin. 
African green monkey kidney epithelial cell line, Vero, was cultured in DMEM 
supplemented with 5% FBS, 100 U of penicillin and 100 µg of streptomycin. Human 
liver cancer epithelial-like cell line, HuH-7, was also cultured in DMEM 
supplemented with 5% FBS, 100 U of penicillin and 100 µg of streptomycin. 
All cell lines were cultured at 37°C with an atmosphere of 5% carbon dioxide (CO2) 
and 95% air using an incubator. 
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2.3.2 Sub-culturing of adherent cell lines 
All adherent cell lines were maintained in flasks and sub-cultured once they have 
reached a minimum of 95% confluency. Culture medium was first removed and the 
cells were rinsed with sterile PBS once to remove traces of the culture medium. 
Trypsin-EDTA solution was then used to rinse the cells and excess was removed. The 
flask was allowed to sit at room temperature or incubated at 37°C in the incubator to 
allow trypsin to dissociate the cells from the flask surface. Once the cells had started 
to dissociate from the surface, fresh culture medium was added to resuspend the cells 
evenly. The cell suspension was then redistributed to new flasks, culture dishes or 
well-plates and topped up with fresh medium. 
2.3.3 Sub-culturing of suspension cell lines 
Suspension cell lines were maintained in culture dishes and sub-cultured when 
required. Culture medium and the suspended cells were centrifuged at 600 rpm using 
table-top centrifuge (Sorvall Legend RT Plus) for 5 minutes. The supernatant was 
removed and the pellet was resuspended in fresh culture medium and redistributed to 





2.4 Virology Methods 
2.4.1 Creating virus stocks 
IBV virus stock 
Monolayer Vero cells grown to a confluency of 100% in 180 cm2 culture flasks were 
washed twice with serum-free medium and inoculated with wild-type IBV at a 
multiplicity of infection (MOI) of approximately 1 in serum-free medium. The cells 
were incubated at 37°C with 5% CO2 for 16 hours until all cells exhibit cytopathic 
effects (CPE). The infected cells with the culture medium were then frozen at -80°C 
and thawed at room temperature for three cycles. The medium containing released 
virus particles was clarified by centrifugation at 1000 rpm at 4°C for 5 minutes with a 
table-top centrifuge. Clarified virus medium was divided into 1 ml aliquots and stored 
at -80°C. 
Vaccinia/T7 virus stock 
Monolayer Vero cells grown to a confluency of 100% in 180 cm2 culture flasks were 
washed twice with serum-free medium and inoculated with 1 ml of Vaccinia/T7 
recombinant virus in 20 ml of serum-free medium. The cells were incubated at 37°C 
with 5% CO2 for 16 hours and subjected to three freeze-thaw cycles. The virus-
containing medium was clarified by centrifugation at 1000 rpm at 4°C for 5 minutes 
with a table-top centrifuge. Clarified virus medium was divided into 1 ml aliquots and 




Mock virus stock 
Monolayer Vero cells grown to a confluency of 100% in 180 cm2 culture flasks were 
washed twice with serum-free medium and incubated with 20 ml of fresh serum-free 
medium at 37°C with 5% CO2 for 16 hours then subjected to three freeze-thaw cycles. 
The medium was clarified by centrifugation at 1000 rpm at 4°C for 5 minutes with a 
table-top centrifuge then stored at -80°C in 1 ml aliquots. 
2.4.2 Virus infections 
IBV and IBV-Luc recombinant virus infections 
A monolayer of cells grown to a confluency of 100% was washed with serum-free 
medium twice and inoculated with the virus at a MOI of approximately 1, unless 
specified. The cells were incubated at 37°C with 5% CO2 until it was ready to be 
harvested. For time-course experiments, 0h samples were harvested after the cells 
were incubated for 5 minutes.  
IBV infection using suspension cells 
Cells were collected in a sterile centrifuge tube by centrifugation at 600 rpm for 5 
minutes with a table-top centrifuge. The cells were resuspended in fresh serum-free 
medium and approximately 2.5 x 106 cells were seeded into a new 60 mm culture 
dish. The culture medium was inoculated with the virus at a MOI of approximately 1. 





A monolayer of H1299 cells grown to a confluency of 100% was washed with serum-
free medium twice and inoculated with 120 µl of virus in 3 ml of serum-free medium 
or 250 µl of virus in 8 ml of serum-free medium in a 60 mm or 100 mm dish 
respectively. The cells were incubated at 37°C with 5% CO2 for 90 minutes before the 
virus-inoculated medium was removed and replaced with fresh serum-free medium. 
2.4.3 Virus titration 
Plaque assay 
Viruses to be titrated were serially ten-fold diluted with serum-free medium up to a 
dilution factor of 1:10000X. Monolayers of Vero cells grown in 6-well plates to a 
confluency of 100% were washed twice with serum-free medium and the medium 
completely removed after the second wash. 200 µl of neat virus or diluted virus was 
added into each well and incubated at 37°C with 5% CO2 for 1 hour with regular 
agitation to make sure the cells were covered with the virus medium. The virus 
medium was then removed completely, washed once with serum-free medium gently 
and overlaid with serum-free medium containing 0.6% CMC was added. The plates 
were incubated at 37°C with 5% CO2 for 72 hours when plaques became visible.  
For easy visualization, the medium was removed and the cells were carefully washed 
twice with PBS then fixed with 4% formaldehyde for 15 minutes at room temperature. 
The cells were then washed three times with PBS and stained with 0.1% toluidine 
blue solution. Assays were performed in triplicates and results were averaged. 
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End-point dilution assay: 50% tissue culture infectious dose (TCID50) 
Viruses to be titrated were serially ten-fold diluted with serum-free medium up to a 
dilution factor of 1:100000X. Monolayers of Vero cells were grown in 96-well plates 
to a confluency of 100% using serum-free medium. The medium was removed and 
100 µl of each diluted virus was added to each of 5 wells of cells. The cells were 
incubated at 37°C with 5% CO2 for 5 days and the number of wells exhibiting CPE 
out of 5 for each dilution of each virus was recorded. Calculation of TCID50 was 
performed using Reed-Muench calculation method.  
The percentage (%) of wells infected at each dilution of each virus sample were 
tabulated and used to calculate an index using the formula as shown in Figure 2.3, 
panel A. For each sample, the calculated index was applied to the dilution factor at 
which the percentage (%) of infected wells was immediately above 50% as shown in 
Figure 2.3, panel B, to obtain the TCID50 of the virus sample. The reciprocal of 
TCID50 was taken to be the amount of virus present in 0.1 ml of the virus.  
Figure 2.3: TCID50 calculation by Reed-Muench method. (A) Calculation for index or 
proportionate distance from the closest dilution factor above that which 50% of the 






2.5 Polymerase Chain Reaction (PCR) 
2.5.1 Regular PCR 
PCR was used for the amplification of DNA for use in cloning as well as the detection 
of specific mRNAs when used in combination with reverse transcription (RT-PCR). 
Amplification of DNA not exceeding 2000 base pairs (bp) was achieved using either 
KAPA Taq DNA polymerase (Kapa Biosystems Inc, USA) or Fermentas Taq DNA 
polymerase (recombinant) (Thermo Scientific, USA). For amplification of DNA from 
plasmids using Fermentas Taq DNA polymerase, 150 ng of plasmid was mixed with 2 
picomoles (pmol) of each specific primer, 2 nanomoles (nmol) of each 
deoxyribonucleotide triphosphate (dATP, dTTP, dCTP, dGTP) (Fermentas, USA), 2 
mM MgCl2 and 5 U of polymerase in 1X reaction buffer. 
2.5.2 Site-directed mutagenesis 
Primers for mutagenesis were designed to be complementary to each other, 
harbouring the desired mutations in the middle of the base-pairing region. In a 50 µl 
reaction, 150 ng of template DNA was mixed with 1.5 pmol of each primer, 2 nmol of 
each dexoyribonucleotide triphosphate, 1 mM MgSO4 and 1.5 U of KOD Hot Start 
DNA polymerase in 1X PCR buffer. 18 to 20 thermal cycles was used for 
amplification and each product was kit purified, digested with DpnI to remove 




2.6 Nucleic Acid Manipulation Techniques 
2.6.1 Restriction digestion 
To perform restriction digestion on plasmid vectors, 3 µg of plasmid DNA was 
incubated in a 50 µl reaction with 15 units (U) of restriction enzyme, its supplied 
buffer, 100 µg/ml bovine serum albumin (BSA) (if required) for 2 hours at 37°C on a 
heating block. 20 U of calf intestinal phosphatase (CIP) (New England Biolabs, USA) 
was added into the reaction mixture and incubated for 1 hour at 37°C. Digestion 
products were purified with a kit. 
For the preparation of cloning insert from existing plasmids, 5 µg of plasmid DNA 
was incubated with 20 U of restriction enzyme in a similar manner as stated above. 
The insert fragment was purified from the rest of the DNA using gel extraction. 
For the preparation of PCR amplified fragments bearing flanking restriction sites as 
cloning insert, the PCR product was purified  and 2 µg of purified DNA was 
incubated with 20 U of each required restriction enzyme, including DpnI (to remove 
the template DNA used in the PCR reaction). Digestion products were purified with a 
kit. 
CIP was omitted if digestion was performed to generate insert DNA. Kit purifications 
were performed using QiaQuick PCR Purification Kit and DNA concentrations were 
determined using NanoDrop 1000. 
For digestion with SmaI restriction enzyme, the reaction was left on the bench-top for 
2 hours instead of incubating at 37°C. Multiple enzyme digestion was performed 
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either simultaneously when a common buffer was available for all restriction 
enzymes, or sequentially, if no common buffer was available. In a sequential 
digestion, the reaction mixture was purified before it was digested with the next 
enzyme. 
2.6.2 Nucleic acid purification 
Kit purifications were performed using QIAquick PCR Purificaation Kit from Qiagen 
(Hilden, Germany). 5 volumes of buffer PB was added to 1 volume of nucleic acid 
and applied onto the column. The column was washed with buffer PE and the nucleic 
acid was eluted with nuclease-free water. The concentration of the nucleic acid was 
determined using a spectrophotometer. 
Nucleic acid purifications were also performed using UltraPureTM 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1 v/v). The reagent was mixed vigorously 
with the nucleic acid at a 1:1 ratio (v/v) and centrifuged at 12000 rpm for 10 minutes 
at 4°C. The aqueous phase was transferred to a new tube and mixed vigorously with 
chloroform at a 1:1 ratio (v/v). The emulsion was centrifuged and the aqueous phase 
was transferred to a new tube. Sodium acetate (0.3 M final concentration) was added 
to the aqueous phase and mixed well. Isopropanol was added to the mixture at a ratio 
of 2:1 (v/v) and mixed by gentle inversion. Nucleic acid precipitation was allowed to 
proceed for up to one hour at -20°C and pelleted by centrifugation. The pellet was 




2.6.3 Gel extraction 
The digested DNA was resolved by agarose gel electrophoresis with an agarose gel of 
an appropriate concentration between 1 to 1.5%, which contained ethidium bromide 
for visualization. The resolved DNA was visualized under ultraviolet illumination 
(UV) and the band corresponding to the desired fragment was excised with a clean 
scapel blade. The mass of the excised gel fragment was determined using a weighing 
scale. Nucleic acid extraction was performed using QIAquick Gel Extraction Kit from 
Qiagen (Hilden, Germany). Buffer QG was added into the tube containing the excised 
gel fragment and incubated at 50°C for 10 minutes or until the agarose dissolved 
completely. The dissolved gel was applied onto the column, washed with buffer PE 
and eluted with nuclease-free water. The nucleic acid concentration was determined 
using a spectrophotometer. 
2.6.4 Agarose gel electrophopresis 
Agarose gels were prepared by dissolving UltraPureTM agarose in 1X Tris-acetate-
EDTA (TAE) buffer (40 mM Tris, 1 mM EDTA (pH 8.0), 20 mM glacial acetic acid) 
by boiling. Ethidium bromide was added for visualization of the resolved nucleic 
acids. Nucleic acid was mixed with at a volume ratio of 5:1 with 6X gel loading dye 
(0.25% bromophenol blue, 0.25% xylene cyanol, 30% glycerol) and loaded onto the 
agarose gel. Electrophoresis was performed using 1X TAE as the running buffer.  
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2.6.5 DNA ligation 
50 µg of linearized vector and insert DNA were mixed at a molar ratio of 1:3 with 1 U 
of T4 DNA ligase and 10X ligase buffer supplied with the enzyme. Minimum volume 
of reaction was 10 µl and the maximum was 20 µl. Ligation reactions were performed 
at 16°C in a water-bath for 16 to 18 hours and stored at 4°C or -20°C thereafter before 
they were transformed into bacteria. 
2.6.6 Crude plasmid DNA extraction from E. Coli 
200 µl of overnight bacteria culture was pelleted by centrifugation at 14000 rpm for 1 
minute in a microcentrifuge. The pellet was resuspended in 4 µl of nuclease-free 
water and 8 µl of sodium chloride-Tris-EDTA-Triton-X (STET) buffer (0.1 mM 
NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, 5% (v/v) Trixon X-100). The resuspended 
cells were incubated at 100°C for 5 minutes and centrifuged at 14000 rpm for 2 
minutes. The supernatant was transferred to a new tube and used for restriction 
digestion in the presence of RNase A. Plasmid DNA prepared by this method was 
only used in restriction enzyme screening of clones. 
2.6.7 RNA extraction from mammalian cells  
Adherent cells were lysed in the culture vessel with 1 ml of TRIzol® (more reagent 
was added if complete lysis was not possible) for 15 minutes at room temperature 
with shaking. The lysed cells were transferred into 1.5 ml polypropylene snap-cap 
tubes and 200 µl of chloroform was added into the lysate and mixed vigorously and 
left to stand for 15 minutes at room temperature. The tube was centrifuged at 11000 
67 
 
rpm, 4°C for 10 minutes for phase separation and the aqueous layer was transferred to 
a clean tube (interphase and organic phase were saved for protein extraction). 500 µl 
of isopropanol was added to the aqueous layer and incubated for 8 minutes at room 
temperature to precipitate the RNA. The precipitated RNA was pelleted by 
centrifugation at 9000 rpm, 4°C for 10 minutes. The pellet was washed with 70% 
ethanol and air-dried. The dried pellet was incubated with DEPC-treated water at 
55°C, using a heating block, up to 20 minutes for solubilization. All RNAs were 
stored at -80°. 
 
2.7 Molecular Cloning Techniques Involving E. coli 
2.7.1 Preparation of chemically-competent E. coli 
Both DH5 alpha and BL-21 strains of E. coli were prepared with the same method. 3 
ml of Luria-Bertani (LB) broth was inoculated with 5 µl of thawed competent cells 
and incubated 37°C for 16 hours with shaking (200 rpm). 100 ml of LB broth was 
inoculated with 1ml of the overnight culture each and incubated at 37°C with shaking 
(200 rpm) until OD660 fell between 0.65 and 0.75. The culture was transferred into 50 
ml conical centrifuge tubes and incubated on ice for 30 minutes. The tubes were then 
centrifuged at 5000 rpm at 4°C for 15 minutes. The pellet in each tube was 
resuspended with 20 ml of ice-cold wash buffer (0.1 M CaCl2). The resuspended cells 
were incubated on ice for 40 minutes then centrifuged again. Each pellet was 
resuspended with 1 ml of freezing buffer and aliquoted into 50 µl (DH5 alpha) or 100 
µl (BL-21) fractions with pre-chilled 0.5 ml polypropylene snap-cap tubes. The tubes 
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were rapidly frozen with liquid nitrogen (LN2) and transferred to the -80°C freezer for 
permanent storage. 
2.7.2 Transformation of DNA into chemically-competent E. coli 
For plasmid amplification transformations, 50 ng of plasmid DNA was mixed with 50 
µl of competent DH5 alpha cells and for transformations involving E. coli strain BL-
21, for bacterial protein expression, 100 ng of plasmid DNA was mixed with 100 µl 
of chemically-competent BL-21 cells. Each transformation mix was incubated on ice 
for 30 minutes in a 1.5ml tube before heat-shock. To perform heat-shock, the tube 
was incubated at 42°C for 1 minute followed by 2 minutes incubation on ice. The 
cells were then spread onto a LB agar plate containing the required antibiotic for 
selection. If the required antibiotic was kanamycin, the cells were recovered before 
plating. To perform recovery, 500 µl of SOC media (2% w/v BactoTM-tryptone, 0.5% 
BactoTM-yeast extract, 10 mM NaCl, 2.5 mM KCl, 20 mM glucose) was added to the 
tube and the mixture incubated at 37°C for 1 hour with shaking at 200 rpm. After 
which, it was centrifuged at 5000 rpm for 5 minutes at room temperature using a 
microcentrifuge and the pellet resuspended in 50 µl of SOC media. The cells were 
then spread onto a LB agar plate with antibiotics (100 µg/ml for ampicillin, 50 µg/ml 
for kanamycin) for selection. 
For ligation mix transformations, 50 µl of chemically-competent DH5 alpha E. coli 
was mixed with 10 µl of ligation mixture. Heat-shock was performed as described 
above and the cells were recovered before plating. All agar plates were incubated at 
37°C for 16 hours. 
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2.8 Construction of Clones 
2.8.1 Yeast three-hybrid screening 
SARS 5’-UTR and 3’-UTR were amplified by polymerase chain reaction (PCR) using 
the primer pairs SARS5’UTR_Fwd/SARS5’UTR_Rev and 
SARS3’UTR_Fwd/SARS3’UTR_Rev from pKT-SARSA1 (5’-most segment) and 
pKT-SARSN (3’-most segment from N gene) plasmids respectively (Primer sequence 
listed in Table 2.1). Both PCR products were ligated with vector pIIIA/MS2-2 and 
screened for clones in either orientation. Clones pIIIA/MS2-2-SARS5’UTR(+), 
pIIIA/MS2-2-SARS5’UTR(-) and pIIIA/MS2-2-SARS3’UTR(-) were obtained. 
Table 2.1: List primers used to amplify SARS 5'- and 3'- untranslated regions. 
Restriction sites were underlined. 






2.8.2 Cloning of full-length, wild-type MADP1 into Gateway® vectors 
Total RNA was extracted from HeLa cells using Trizol® and 5 µg was used for 
reverse transcription (RT) with primer Madp1_RT (Table 2.3). The primers 
5’Madp1attB and 3’Madp1attB (Table 2.2) were used to amplify MADP1 from the 
cDNA and the PCR product was inserted into pDONRTM221 vector in a 
recombination reaction using BP ClonaseTM enzyme mix from Invitrogen () to obtain 
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the clone pDONR-Madp1. MADP1 was subsequently inserted into pDEST15 vector 
in a recombination reaction using LR ClonaseTM enzyme mix from Invitrogen. 
Table 2.2: Primers used to amplify MADP1 from HeLa cDNA for cloning into 
pDONRTM221 vector. 
Primer 










2.8.3 Cloning of full-length, wild-type MADP1  
Primers used for the construction of all full-length wild-type MADP1 clones were 
tabulated in Table 2.3. Total RNA was extracted from HeLa cells using Trizol® and 5 
µg was used for reverse transcription (RT) with primer Madp1_RT. The RT product 
was used to perform a PCR with primers 5’Madp1_Sma1 and 3’Madp1_Sma1 and the 
PCR product was ligated with pGEM-T Easy vector to construct the plasmid pGEM-
Madp1. 
For bacterial expression of MADP1, pGEX-Madp1 and pET-Madp1 were constructed 
to express N-terminal glutathione S-transferase tagged (GST-MADP1) and 
6Xhistidine (HIS-MADP1) MADP1. The primers Madp1_EcoRIF and Madp1_Not1R 
were used to amplify MADP1 from pGEM-Madp1 and the fragment was cloned into 
vector pGEX-5X-1 to construct pGEX-Madp1. Primers Madp1_NdeIF and 
Madp1_NdeIR were used to generate the fragment from pGEM-Madp1 to be inserted 
into vector pET-16b to construct pET-Madp1. 
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Table 2.3: List of primer sequences used in the cloning of all full-length and truncated 
MADP1 constructs. Restriction sites were underlined. 

















For the expression of MADP1 in mammalian cell systems, pXJ40-Madp1 and 
pXJ40Flag-Madp1 were constructed to either express untagged MADP1 or N-
terminal FLAG-tagged MADP1 (FLAG-MADP1). The primers Madp1_HindIIIF and 
Madp1_BglIIR were used to amplify MADP1 from pGEM-Madp1. The fragment was 
cloned into the vectors pXJ40 and pXJ40Flag to generate the respective clones. 
2.8.4 Cloning of MADP1 truncation mutants 
All truncation mutants of MADP1 were generated by amplification of segments of 
MADP1 with primers listed in Table 2.3 from the plasmid pGEM-Madp1. The 
plasmids pXJ40Flag-Madp1n, pXJ40Flag-Madp1m and pXJ40Flag-Madp1c were 
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constructed to express FLAG-Madp1n, FLAG-Madp1m and FLAG-Madp1c 
respectively. The primer pairs used to amplify the inserts were Madp1_HindIIIF / 
Madp1_258-236BglIIR, Madp1_178-199HindIIIF / Madp1_529-497BglIIR and 
Madp1_430-451HindIIIF / Madp1_BglIIR respectively.  
Plasmids pXJ40Flag-Madp1x, pXJ40Flag-Madp1y and pXJ40Flag-Madp1z were 
constructed to express FLAG-Madp1x, FLAG-Madp1y and FLAG-Madp1z 
respectively. The primer pairs used to amplify the inserts were Madp1_HindIIIF / 
Madp1_300-280BglIIR, Madp1_121-144HindIIIF / Madp1_300-280BglIIR and 
Madp1_HindIIIF / Madp1_352-332BglIIR respectively. All inserts were cloned into 
the mammalian expression vector pXJ40Flag. 
2.8.5 Site-directed mutagenesis of MADP1 
To create a vector which could express wild-type FLAG-MADP1 and not be sensitive 
to the silencing effects of the siRNA, siMadp1b, three site-directed mutagenesis PCRs 
were performed sequentially with the primers listed in Table 2.4. The first mutant 
construct, pXJ40Flag-Madp1mutA, was generated with the primers 
Madp1_TTG76CTT_F and Madp1_TTG76CTT_R using pXJ40Flag-Madp1 plasmid 
as the template. The mutant was screened in E. coli and confirmed by sequencing. 
The second mutant, pXJ40Flag-Madp1mutAB, was generated with the primers 
Madp1_T72C_F and Madp1_T72C_R using pXJ40Flag-Madp1mutA as the template. 
The mutant was again screened in E. coli and confirmed by sequencing. Then the final 
mutant, pXJ40Flag-Madp1mutABC, was generated with the primers Madp1_A87CF 
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and Madp1_A87CR using pXJ40Flag-Madp1mutAB as the template. Likewise, it was 
screened in E. coli and confirmed by sequencing. 
Table 2.4: List of all primer sequences used in the generation of mutants of 
pXJ40Flag-MADP1. 












Several plasmids which could express point mutants of FLAG-MADP1 were also 
created using the primers listed in Table 2.4. Mutants FLAG-MADP1mutY, FLAG-
MADP1mutVF and FLAG-MADP1mutYVF were expressed by the plasmids 
pXJ40Flag-Madp1mutY13A, pXJ40Flag-Madp1mutV53F55A and pXJ40Flag-
Madp1mutY13V53Y55A respectively. The plasmid pXJ40Flag-Madp1 was subjected 
to site-directed mutagenesis PCRs with the primer pairs Madp1mutY13A_F / 
Madp1mutY13A_R and Madp1mutV53F55A / Madp1mutV53F55A to generate the 
mutant plasmids pXJ40Flag-Madp1mutY13A and pXJ40Flag-Madp1mutV53F55A 
respectively. The third mutant plasmid was generated via mutagenesis PCR using 
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pXJ40Flag-Madp1mutV53F55A as a template with primer pair Madp1mutY13A_F / 
Madp1mutY13A_R. 
2.8.6 Site-directed mutagenesis of IBV stem-loop I 
The mutant construct pKT-IBVA_SL1dsmut was created to serve as the template to 
generate the RNA probe 5’-UTRΔ2M1, a transcript of the IBV 5’-UTR which with a 
disrupted stem loop I. The primer pair i1-29_SL1dsmutF/i1-29_SL1dsmutR (Table 
2.5) and template pKT-IBVA were used for this mutagenesis PCR.  
Table 2.5: List of primers used in the generation of stem loop I mutant plasmids. 






Mutant construct pKT-IBVA_SL1rsmut was created to be used as the template to 
generate RNA probe 5’-UTRΔ2M2, a transcript of the IBV 5’-UTR which contained 
a mutation in 5’-UTRΔ2M1 which restored the structure of stem loop I. The primer 
pair i9_39SL1rsmutF/i39-9_SL1rsmutR (Table 2.5) and template pKT-
IBVA_SL1dsmut were used for the mutagenesis PCR. 
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2.8.7 Cloning of HCoV-OC43 5’-UTR 
The 5’-UTR of the coronavirus was amplified by PCR from a cDNA sample using the 
primers T7_oc1-20 and pT_oc210-192 (Table 2.6). The PCR product was ligated with 
pGEM-T Easy vector to generate the plasmid pGEM-oc5UTR. 
Table 2.6: Primers used to clone HCoV-OC43 5'-UTR. 




2.8.8 Cloning of Hairpin siRNA into pSilencerTM 2.1 U6-Neo 
Table 2.7: Oligonucleotide sequence used for generating hairpin siRNA insert. 
Oligonucleotide 











Two oligonucleotides Table 2.7 were designed based on the target sequence 5'-
CAAUGACUUGUACCGGAUA-3' (same as siMadp1b) according to the instructions 
supplied with the kit. Both oligonucleotides were diluted in TE buffer to a 
concentration of 1 µg/µl. In a 50 µl mixture, 2 µl of each oligonucleotide was mixed 
with 1X DNA annealing Solution (supplied in kit) in a clean 1.5 ml tube. The tube 
was heated at 90°C for 3 minutes then incubated at 37°C for 1 hour. The annealed 
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oligonucleotides (hairpin siRNA) were diluted at a factor of 1:10 with nuclease-free 
water and 1 µl was ligated with 1 µl of pSilencerTM U6-neo vector. 
2.8.9 Cloning of IBV nsp12 truncation mutants 
All nsp12 truncation mutants were created by amplification of the desired fragment 
from pXL-IBVC (obtained from another lab member), which contained a fragment of 
the IBV genome from nucleotide to, with the primers listed in Table 2.8. The 
fragments amplified by the primer pairs i12339-12360BamHIF / 
i13538_13516_XhoIR, i13296-13316_BamHIF / i14498-14474_XhoIF and i13926-
13948_BamHIF / i15128-15106_XhoIR were cloned into the vector pXJ40Myc 
generating plasmids that could express N-terminally tagged proteins Myc-iNsp12n, 
Myc-iNsp12m, Myc-iNsp12c.  
 
Table 2.8: List of primers used in the cloning of IBV nsp 12 truncation mutants. 
Restriction sites were underlined. 













2.9 Generation Of Template DNA For In vitro Transcription Labeling of RNA 
Probes 
2.9.1 DIG-labeled probes for north-western blots 
All probes were transcribed from PCR products amplified using the primers listed in 
Table 2.9. IBV 5’-UTR (+) probe was transcribed from the PCR product amplified 
from plasmid pKT-IBVA with the primers T7_i1-27 and pT_i507-528R. The template 
for SARS-CoV 5’-UTR(+) probe was amplified from the plasmid pKT-SARSA1 with 
the primers T7proF and pT_s325-342R. 
2.9.2 Biotin-labeled probes used in biotin pull-down assay 
All probes were transcribed with the PCR products from the respective PCRs 
performed with the primers listed in Table 2.9. EGFP (-) was transcribed from the 
PCR product of plasmid pEGFP-N1 amplified by the primers pT-EGFP_F and T7-
EGFP_510-528R. The PCR template for SARS-CoV 5’-UTR (+) probe was amplified 
from the plasmid pKT-SARSA1 with the primers T7proF and pT_s325-342R. The 
IBV 5’-UTR (+) and IBV 5’-UTR (-) probes were generated from PCR fragments 
amplified from the plasmid pKT-IBVA with the primer pairs T7_i1-27/pT_i507-528R 
and pT_i1-29/T7_i528-506R respectively. The IBV 3’-UTR (+) probe was transcribed 
from the PCR product amplified from pGEM-IBVE plasmid with the primers 
T7_i27106-27125 and LDX30. The transcription template of HCoV-OC43 5’-UTR 




Table 2.9: List of primers used to amplify PCR fragments used as templates for 
transcription of biotin-labeled probes. 

















































The truncated probes of IBV 5’-UTR (+), 5’UTRΔ1, 5’UTRΔ2, 5’UTRΔ3 and 
5’UTRΔ4 were transcribed from PCR fragments amplified from pKT-IBVA using the 
primer pairs T7_i1-27/pT_i140-121, T7_i1-27/pT_i99-80, T7_i30-51/pT_i140-121 
and T7_i141-162-pT_i507-528R respectively. The template for probe 5’UTRΔ2M1 
was amplified from pKT-IBVASL1dsmut with the primers T7_i1-27SL1dsmut and 
pT_i99-80 while the template for probe 5’UTRΔ2M2 was amplified from pKT-
IBVASL1rsmut with the primers T7_i1-36SL1rsmut and pT_i99-80. 
 
2.10 In-vitro transcription 
2.10.1 Template preparation 
PCR templates were produced with a forward primer containing a T7 promoter 
sequence and a reverse primer containing 18 to 21 thymidine residues at their 
respective 5’ ends. Plasmid DNA templates with a T7 promoter sequence were 
linearized by an enzyme cutting at the 3’ end of the template strand. All nucleic acids 
were kit purified and eluted in DEPC-treated water. 
2.10.2 Transcription 
1 mg of linearized plasmid DNA or 200 ng of PCR fragment was incubated with 10 U 
T7 RNA polymerase, 10 U Protector RNase Inhibitor and NTPs (1 mM each of ATP, 
CTP, GTP, UTP) in 1X Transcription Buffer (provided with polymerase), at 37°C for 
2 hours. The transcription mix was incubated with 5 U of DNase I at 37°C for 15 
minutes to remove template DNA. For labeling of RNA products, NTPs were 
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replaced with either DIG RNA Labeling Mix (1 mM each of ATP, CTP, GTP, 0.65 
mM UTP, 0.35 mM DIG-11-UTP) or Biotin RNA Labeling Mix (1 mM each of ATP, 
CTP, GTP, 0.65 mM UTP, 0.35 mM biotin-16-UTP). Transcripts were purified with 
UltraPureTM Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) and stored at -80°C. 
 
2.11 Mammalian Gene Over-Expression and Gene Silencing 
2.11.1 Transient protein over-expression for biochemical assays 
H1299 cells were grown to a confluency of 100% and infected with Vaccinia/T7 
recombinant virus for 1 hour at 37°C, 5% CO2. Plasmid DNA was delivered into the 
infected cells with Effectene® Transfection Reagent, purchased from Qiagen (Hilden, 
Germany). The cells were incubated with the transfection mix for 20 hours in the 
37°C incubator before they were lysed with Lysis buffer. 
2.11.2 Transient protein over-expression and BrUTP labeling for immunofluorescence 
detection 
Vero cells grown to 50% confluency in 4-chamber glass slides were transfected with 
either pXJ40Flag vector or pXJ40Flag-Madp1 using Effectene® Transfection Reagent 
for 16 h. Transfected cells were infected with wild-type IBV or mock-infected with 
Vero cell lysate for 1 hour and replaced with fresh serum-free medium. The infection 
was allowed to progress for another 2 hours and the cells were treated with 
actinomycin D at a concentration of 15µg/ml for 4 hours. 1mM of BrUTP (Sigma 
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Aldrich) was delivered into the cells with SuperFECT® purchased from Qiagen 
(Hilden, Germany), and incubated for 3 hours before they were fixed. 
2.11.3 Transient gene silencing with DharmaFECT® 
In each well of a 6-well plate, H1299 cells were grown to a confluency of 30% and 
200 picomoles (pmoles) of homogeneous siRNA or 250 pmoles of prescribed siRNA 
pools (target sequences listed in Table 2.10) was delivered into the cells with 2 µl of 
DharmaFECT® 2 Transfection Reagent purchased from Thermo Scientific 
Dharmacon (Lafayette, CO, USA). The transfection was repeated 24 hours later and 
the cells were incubated with the transfection mix for a further 48 hours before they 
were lysed with Lysis buffer for analysis or infected with IBV. Vero cells were 
transfected using DharmaFECT® 3 Transfection Reagent with the same protocol. 
Table 2.10: Target sequence of siRNAs used for silencing MADP1. 
siRNA Target Sequence 
siMADP1 5'-CAAUGACUUGUACCGGAUA-3' 








2.11.4 Transient gene silencing with Lipofectamine® RNAiMAX 
Transfections were performed on Vero and H1299 cells grown to a confluency of 
40% in 6-well plates. A 5 µM stock of the siRNAs was diluted with DEPC-treated 
water from the 50 µM stock solutions from the supplier. For each well, the siRNA 
was mixed with serum-free medium to a final volume of 250 µl and the 5 µl of 
transfection reagent, Lipofectamine® RNAiMAX purchased from Invitrogen 
(Carlsbad, CA, USA), was mixed with serum-free medium to a final volume of 250 µl 
in a different tube. The two tubes were them combined, mixed by vortexing and left to 
stand at room temperature for 15 minutes. Meanwhile, the cells were washed twice 
with serum-free medium and 2.5 ml of fresh serum-free medium was added to the 
cells. The transfection mixture was then added to the serum-free medium and 
incubated for 6 hours at 37°C, 5% CO2. The medium was then replaced with fresh 
culture medium (with serum). The second transfection was performed 24 hours after 
the first transfection with the same procedure. 
2.11.5 Stable gene silencing of MADP1  
H1299 cells grown to a confluency of 60% on a 100 mm culture dish and 2 µg of the 
plasmid pSilencer-shMadp1 was delivered into the cells using Effectene® 
Transfection Reagent using serum-free medium. The cells were incubated with the 
transfection mixture for 24 hours and the medium was replaced with selection 
medium (RPMI with 500 µg/ml G418). The dosage of G418 was pre-determined to be 
lethal to 100% of non-transfected H1299 cells. The cells were cultured under the same 
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selection condition until most cells were killed and small colonies (diameter 1 to 2 
mm) appeared.  
The medium was removed and the colonies incubated with trypsin-soaked 3mm 
cloning discs purchased from Scienceware® Sigma-Aldrich (St. Louis, MO, USA) for 
5 minutes. The cloning discs were then transferred into 24-plates containing 1 ml of 
selection medium in each well. The colonies that expanded were transferred into 
larger culture vessels and the expression of the hairpin siRNA was indirectly 
determined by the mRNA level of MADP1 (madp1) of each colony via RT-PCR. The 
colony with the highest percentage reduction of madp1 (compared to non-transfected 
H1299 cells) was chosen to be used in subsequent experiments as the cell line H1299-
shMADP1.  
To setup a negative-knockdown control cell line, the plasmid pSilencer-2.1 U6-neo 
negative control (expressed hairpin siRNA that does not target any human gene 
sequence) was also used to create the cell line H1299-shNC screened alongside 
H1299-MADP1. 
 
2.12 Gene over-expression in E. coli by induction 
Inserts cloned into pDEST15, pGEX-5x-1 or pET-16b bacteria expression vectors 
were transformed into BL-21 E. coli. For each plasmid, one colony was picked and 
cultured with 3ml of LB broth containing the necessary antibiotic at 37°C, shaking at 
200 rpm for 16 hours. The overnight culture was used to inoculate the desired volume 
of LB (with antibiotic) at a dilution of 1:100 and incubated at 37°C, shaking at 200 
rpm until OD595 fell between 0.5 and 0.6. Isopropyl-1-thio-β-D-galactopyranoside 
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(IPTG) was added to the culture and incubation continued for another 3 to 4 hours. 
The bacteria was sedimented by centrifugation at 5000 rpm, 4°C for 5 minutes in 50 
ml polypropylene centrifuge tubes and resuspended with PBS (containing 100 µg/ml 
of lysozyme). The suspension was frozen with dry-ice in ethanol for 20 seconds and 
thawed in a 37°C water-bath for 1 minute for 10 cycles. Cell debris (pellet) was 
sedimented at 13200 rpm, 4°C for 1 hour and the lysate (supernatant) was transferred 
to a new tube. 
  
2.13 Immunofluorescence Detection 
Cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature and 
permeabilized with 0.2% Triton-X 100 for 10 minutes. Treated cells were blocked in 
1X PBS with 10% goat serum, stained with primary antibodies mouse monoclonal 
anti-BrdU and rabbit polyclonal anti-Flag then probed with Alexa Fluor® 488 anti-
rabbit and Alexa Fluor® 594 anti-mouse antibodies. The stained cells were embedded 
with fluorescence mounting medium and covered with a glass coverslip. Washings 
were performed with PBS before the addition of secondary antibodies and the 
application of mounting medium. Images were captured with Olympus Fluoview 





2.14 Cell Fractionation 
The extraction of nuclear proteins from mammalian cells was performed using 
reagents from the CelLyticTM NuCLEARTM Extraction Kit purchased from Sigma-
Aldrich (St. Louis, MO, USA). Cells were rinsed with PBS twice, scraped from the 
culture vessel in fresh PBS into a 1.5 ml microcentrifuge tube. The tube was 
centrifuged for 5 minutes at 450 x g, 4°C, the supernatant was removed and the 
packed cell volume (PCV) was estimated.  For every 100 µl PCV, 500 µl of lysis 
buffer was added. Both H1299 and Vero cells were lysed with 1X Lysis Buffer, 
isotonic (10 mM Tris pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 0.5 M sucrose, 0.1 mM 
DTT) with 1X Protease Inhibitor Cocktail. The cell pellet was resuspended in the lysis 
buffer and incubated on ice for 15 minutes until the cells swell (5 µl of the lysate was 
used to check for swelling under the microscope). 
10% IGEPAL CA-630 was added to the swollen cells to a final concentration of 0.6% 
and the mixture was vortexed vigorously. The nuclear fraction was immediately 
sedimented at 10000 x g for 30 seconds at 4°C. The supernatant (cytoplasmic 
fraction) was transferred to a new tube and the pellet (nuclear fraction) was washed 
twice with 200 µl PBS and sedimented at 10000 x g for 30 seconds at 4°C. The pellet 
was boiled with 2X SDS loading dye (same volume as lysis buffer used) for 10 
minutes to lyse the nuclei.  
For analysis of the proteins in the respective fractions, 10% volume of the 
cytoplasmic fraction boiled for 5 minutes in an appropriate volume of 6X SDS 
loading dye (with DTT) and 10% volume of the nuclear fraction were resolved by 
SDS-PAGE and western blot with the required antibodies was performed.  
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2.15 Luciferase Assay 
Firefly luciferase activity was determined with the Luciferase® Assay System 
purchased from Promega (Fitchburg, WI, USA). Cells grown in 6-well plates were 
lysed with either 200 µl of Lysis Buffer or 400 µl of Passive Lysis Buffer (supplied 
with kit). For each sample, 5 µl of lysate was added to 50 µl of Luciferase Assay 
Substrate (supplied with kit) and measured immediately using TD-20/20 single-tube 
luminometer from Turner Biosystems (Sunnyvale, CA, USA). The averaged reading 
of three independent measurements of each sample was recorded. 
Dual-Luciferase® Reporter Assay System was used when both firefly and renilla 
luciferase activities were to be determined in a single sample. For each sample, 5 µl of 
lysate was added to 50 µl of Luciferase Assay Substrate and measured immediately 
using the luminometer to determine its firefly luciferase activity. 50 µl of Stop & 
Glo® Substrate (supplied with kit) was added into the same tube and measured 
immediately to determine its renilla luciferase activity. The averaged reading of three 
independent measurements of both luciferase activities was recorded. 
 
2.16 Detection of IBV and Host mRNAs by RT-PCR 
Total RNAs were prepared from the infected cells at their specified time points using 
Trizol Reagent (Invitrogen) and RT-PCRs were performed with the primers listed in 
Table 2.11. Reverse transcription (RT) was performed with Expand Reverse 
Transcriptase using the sense primer IBV leader for the detection of negative-stranded 
sgRNA and the antisense primer IBV24803-R for the detection of positive-stranded 
sgRNA. Both primers were then used for PCR. If transcription of sgRNAs did occur, 
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a 415-bp PCR product corresponding to the 5’-terminal region of mRNA 5 and a 648-
bp fragment corresponding to the 5’-terminal region of mRNA 4 would be expected. 
Similarly, RT was carried out with the sense primer IBV14931-F for the detection of 
negative-stranded gRNA. Sense primer IBV14931-F and the antisense primer 
IBV15600-R were used for PCR. If replication of viral RNA occurred, a 670-bp PCR 
fragment would be expected. 
Table 2.11: Primers used for amplifying IBV mRNAs, MADP1 mRNA and GAPDH 
mRNA. 
Primer Name Primer Sequence 









For the detection of host mRNAs, oligo-dT primer was used for RT. Primers used to 
amplify MADP1 mRNA were 5’Madp1_Sma1 and 3’Madp1_Sma1. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) mRNA which was used as a housekeeping 
gene control was amplified with the primers GAPDH-F and GAPDH-R.  
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2.17 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
2.17.1 Protein extraction from TRIzol® lysed cells 
The interphase and organic phase from the phase separation step (after removal of the 
aqueous layer for RNA extraction) were used to the preparation of denatured protein 
samples. For every 1 ml of TRIzol® treated cell lysate, 300 µl of ethanol was added 
into and mixed by gentle inversion with the interphase and organic phase. The sample 
was incubated at room temperature for 3 minutes and the DNA was pelleted by 
centrifugation at 4500 rpm, 4°C for 5 minutes. 400 µl of the supernatant was 
transferred to a new 2.0 ml tube containing 1.2 ml of acetone and mixed by inversion. 
The sample was incubated at room temperature for 10 minutes for protein 
precipitation. The precipitate was sedimented at 11000 rpm, 4°C for 10 minutes. The 
pellet was dispersed by mechanical stirring using a pipette in 0.5 ml of guanidine 
hydrochloride/ethanol/glycerol solution (0.3 M guanidine hydrochloride, 95% 
ethanol, 2.5% glycerol). An additional 0.5 of the same solution was added after the 
pellet was completely dispersed and the sample was left to stand at room temperature 
for 10 minutes before it was sedimented at 9000 rpm, 4°C for 5 minutes. This was 
repeated twice with vortexing to disperse the pellet instead then washed with 
ethanol/glycerol solution (97.5% ethanol, 2.5% glycerol). The pellet was air-dried and 




2.17.2 Sample preparation  
Pellets were resuspended in 2X SDS loading dye and liquid samples were mixed with 
6X SDS loading dye. Both types of samples were heated at 100°C for 10 minutes then 
cooled on ice before loading onto the gel. 
2.17.3 Electrophoresis 
Polyacrylamide gels were prepared with 30% acrylamide/bis solution (29:1) in 375 
mM Tris and 0.1% SDS. The electrophoresis was performed using the Bio-Rad Mini-
PROTEAN®II System from Bio-Rad (Hercules, CA, USA), with 1X Tris-Glycine 
running buffer (25 mM Tris, 250 mM glycine, 0.1% SDS) at a current of 20 
milliampere (mA) per gel (1 mm thickness). Resolved proteins were visualized by 
coomassie blue staining or transferred onto a membrane for immune-detection. 
2.17.4 Coomassie blue staining 
Gels were immersed in Staining Solution (0.25% (w/v) Coomassie Brilliant Blue R-
250, 20% methanol, 10% glacial acetic acid) for 30 minutes until they were stained 
completely. The stained gel was rinsed with de-ionized water and immersed in 
Destaining Solution (20% methanol, 10% glacial acetic acid). Destaining Solution 
was changed when it turned blue until the bands become visible. The destained gels 





2.18 Western Blot 
2.18.1 Wet transfer 
Gels were equilibrated in 1X Wet Transfer buffer (48 mM Tris, 39 mM glycine, 20% 
methanol) before they were transferred onto either nitrocellulose or PVDF 
membranes. Transfer was performed with a Mini Trans-Blot Cell purchased from 
Bio-Rad (Hercules, CA, USA) in 1X Wet Transfer buffer at 4°C and 110 volts (V) for 
90 to 120 minutes.  
2.18.2 Semi-dry transfer 
Gels were equilibrated in 1X Semi-Dry Transfer buffer (24 mM Tris, 192 mM 
glycine, 20% methanol) before they were transferred onto nitrocellulose membranes. 
Transfer was performed with a Trans-Blot SD Semi-Dry Transfer Cell from Bio-Rad 
(Hercules, CA, USA) in 1X Semi-Dry Transfer buffer at 20 V for 40 minutes. 
2.18.3 Antibody binding and detection 
Membrane was blocked in Blocking Solution (10% (w/v) non-fat milk, 1X PBS) for 1 
hour at room temperature then incubated with the primary antibody at the appropriate 
concentration in Blocking Solution for 1 hour with constant shaking. The membrane 
was washed with PBS-T (1X PBS, 0.1% Tween®-20) three times then incubated with 
the required secondary antibody at a 1:2000 X dilution factor in Blocking Solution for 
1 hour with constant shaking. The membrane was washed again with PBS-T three 
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times and Western Lightning®-ECL from Perkin Elmer (Waltham, MA, USA) was 
applied onto the membrane. 
 
2.19 Northern Blot 
2.19.1 Probe preparation 
DIG-labeled DNA probes used for the detection of specific nucleic acids were 
generated by PCR using PCR DIG labeling mix (2 mM dATP, 2 mM dCTP, 2 mM 
dGTP, 1.9 mM dTTP, 0.1 mM DIG-11-dUTP).  
2.19.2 Denaturing agarose gel electrophoresis 
Denaturing agarose gel was prepared with UltraPureTM agarose in 1X MOPS (20 mM 
MOPS, 5 mM NaOAc, 1 mM EDTA) with 0.7 M formaldehyde. RNA loading buffer 
(50% formamide (v/v), 17.5% formaldehyde (v/v), 11% glycerol (v/v), 1X MOPS, 
0.025% bromophenol blue and 0.15 mg/ml ethidium bromide) was mixed with 20 µg 
of total RNA or 100 ng of DIG-labeled RNA molecular weight marker at a volume 
ratio of 1:4.5. The mixture was heated at 65°C for 15 minutes and cooled on ice 
before it was loaded. A voltage of 6 V/cm gel length was used to resolve the loaded 
RNA samples in 1X MOPS running buffer.  
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2.19.3 Blot transfer 
The resolved RNA was transferred onto Hybond N+ nylon membrane from 
Amersham (Amersham, United Kingdom) with a capillary transfer setup using 20X 
SSC (3 M NaCl, 0.3 M sodium citrate, pH 7.0)  as the transfer buffer for 24 hours. 
The transferred RNA was cross-linked to the membrane using a UV cross-linker from 
Stratagene (La Jolla, CA, USA). 
2.19.4 Probe hybridization 
The membrane was pre-hybridized in DIG Easy Hyb (without probe) for one hour at 
50°C then hybridized with the probe (denatured at 100°C for 5 minutes then cooled 
on ice) for 16 hours at 50°C in a hybridization oven. The membrane was washed 
twice with 2X SSC, 0.1% SDS at room temperature, then twice with 0.2X SSC, 0.1% 
SDS at 68°C, followed by a single wash with Washing buffer (0.15 M NaCl, 0.1 M 
maleic acid, pH 7.5, 0.3% Tween-20) at room temperature. 
2.19.5 Detection 
For detection of DIG, the membrane was blocked in Blocking buffer (1% w/v 
Blocking Reagent, 0.15 M NaCl, 0.1 M maleic acid, pH 7.5) for 1 hour with shaking 
then incubated with anti-DIG-AP (1:10000X in Blocking buffer) for 30 minutes. 
Following which, the membrane was washed twice with Washing buffer and 
equilibrated in Detection buffer for 5 minutes. 1ml of CDP-Star substrate solution 




2.20 North-Western Blot 
2.20.1 Probe and blot preparation 
Digoxigenin (DIG)-labeled RNA probes for both coronaviruses were produced by in 
vitro transcription. N-terminal Flag-epitope tagged MADP1 was over-expressed in 
Vaccinia-T7 infected H1299 cells on a 60 mm TC-treated culture dish (Corning, 
USA). The cells were lysed with 150 µl of Lysis Buffer (140 mM NaCl, 10 mM Tris 
(pH 8.0), 1% Nonidet P-40) containing protease inhibitors. 40 µl of total cell lysate 
was mixed with 8 µl of 6X SDS loading dye and incubated 100°C for 5 minutes and 
cooled at room temperature before it was loaded onto a 15% SDS-PAGE gel. The 
resolved proteins were transferred onto a Hybond C-Extra nitrocellulose membrane 
purchased from Amersham (Amersham, Great Britain) using a semi-dry transfer 
setup.  
2.20.2 Probe binding 
Fresh probe buffer (10 mM Tris-HCl, 50 mM NaCl, 1mM EDTA, 1x Denhardt’s 
Reagent) was prepared from stock buffers 1 M Tris (pH 7.5), 5 M NaCl, 100 mM 
EDTA pH (8.0) and 50X Denhardt’s Reagent (1% polyvinylpyrrolidone, 1% Ficoll 
400, 1% BSA) in nuclease-free water. The membrane was equilibrated in probe buffer 
at room temperature for 10 minutes with shaking and blocked in 10 ml of fresh probe 
buffer containing 250 µg yeast tRNA (Ambion, USA) for 1 hour at room temperature 
with shaking. The blocking buffer was then discarded and membrane was incubated 
with fresh probe buffer containing 10 ug of DIG-labeled probe for 1 hour at room 
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temperature with shaking. The membrane was then washed 3 times, for 10 minutes 
each with shaking in probe buffer and procedures for DIG detection were performed 
(Section 2.10.5).  
 
2.21 Biotin Pull-down Assay 
2.21.1 Probe and lysate preparation 
Biotin-labeled RNAs for this assay were produced by in vitro transcription. All 
proteins used in this assay were whole cell lysates of Vaccinia-T7 recombinant virus 
infected H1299 cells over-expressing N-terminal Flag-epitope tagged proteins. 
Enhanced green fluorescent protein (EGFP) over-expressed with the same method 
was used as a negative control.  
2.21.2 Binding and Immunoprecipitation 
In a 200 µl binding reaction, 0.1 µM of biotin-labeled RNA was mixed with 150 µl of 
total cell lysate in the presence of 10 mM DTT, 20 µg of yeast tRNA, 200 U of 
Protector RNase inhibitor and nuclease-free water in a 1.5 ml eppendorf tube. The 
tube was incubated at room temperature with gentle rotation for 30 minutes. 40 µl of 
streptavidin agarose beads (Sigma-Aldrich, USA) was added directly into the tube and 
the mixture was incubated at room temperature with gentle rotation for 30 minutes. 
The tube was centrifuged at 1000 rpm for 5 minutes with a microcentrifuge and 
placed upright on a tube rack for 1 minute to pack the beads before the supernatant 
was removed carefully using a micro-pipette. 500 µl of RNase P (RP) buffer (50mM 
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KCl, 1mM MgCl2, 10mM Hepes) was used to wash the beads trice with gentle 
inversion and the beads were collected by centrifugation. The buffer was removed 
thoroughly by gently aspiration with a gel-loading pipette after the last wash. 25 µl of 
2X SDS loading dye with DTT was mixed with the beads and the mixture incubated 
at 100°C for 10 minutes, cooled at room temperature before loading onto a PAGE gel 










Chapter 3 Characterization of interaction between host protein 




The ability of the coronavirus in carrying out replication and transcription of its 
genome is crucial to the establishment of an infection and its successful propagation. 
This is an important part of the coronavirus life cycle which is made possible by the 
virus-encoded replicase gene. Coronavirus RNA synthesis takes place in the host 
cytosol, on DMVs which are modified host membrane structures, possibly originating 
from the ER or, specifically EDEMosomes.  Regulatory sequences are scattered 
throughout the coronavirus genome in the form of TRS-Bs at the 5’-end of each 
designated mRNA, the 5’-UTR (including TRS-L) and the 3’-UTR. As such, the role 
of RNA-binding proteins in viral RNA synthesis is of particular significance as a 
bridge between these regulatory signals on the viral RNAs and replicase proteins 
which possess the enzymatic activities required for synthesis. 
The critical enzymatic activities associated with the various steps involved in the 
synthesis of positive-sense mRNAs from the positive-sense genome have been 
assigned to the various replicase gene products. However, set in a myriad of host 
proteins, host protein involvement in viral RNA synthesis is almost inevitable and 
could not be dismissed. This has been supported by several reports of host proteins 
participating in coronavirus RNA synthesis, in particular, the involvement of hnRNP 
A1 in MHV RNA synthesis through its interactions with multiple transcription 
regulatory sequences. Although several other host proteins were subsequently 
reported to be required for efficient coronavirus RNA synthesis, information 
pertaining to the involvement of host proteins in coronavirus RNA synthesis is still 
limited and not fully understood. Furthermore, prior studies were mostly conducted in 
alpha- and betacoronaviruses TGEV and MHV, no such information was available for 
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SARS-CoV, a betacoronavirus of certain medical significance, and the 
gammacoronavirus IBV, a pathogen of great veterinary significance. 
Therefore, it was of great importance to study how host proteins may be involved in 
viral RNA synthesis in these two coronaviruses. However, due to the lack of a facility 
suitable for handling SARS-CoV, a strategy was devised to first screen for human 
proteins which could interact with regulatory signals of SARS-CoV (strain Sin2774, 
accession AY283798), confirm the interaction using biochemical methods in both 
SARS-CoV and IBV (strain Beaudette isolate IBV-p65, accession DQ001339), then 
validating the significance of interactions in IBV infections. As most of the regulatory 
signals were clustered on the 5’- and 3’-UTRs, it was decidedly the most appropriate 
to look for proteins that could participate in coronavirus replication/transcription by 
screening for human proteins that could interact with the 5’- and 3’-UTRs. Also, 
during replication and transcription, coronaviruses generate both positive and negative 
sense RNAs, so each orientation of the UTRs could interact with different proteins. 
Hence, a screen for human proteins which could interact with both sense and 
antisense SARS-CoV 5’- and 3’-UTRs was finalized as the approach to study the 




3.1 Human MADP1 Interacts with SARS-CoV 5’-UTR 
3.1.1 Yeast three-hybrid screen for human proteins that could potentially interact with 
SARS-CoV transcription regulatory regions. 
Using the yeast three-hybrid system that was obtained from Marvin Wickens of the 
University of Wisconsin, the corresponding author of the original publication by 
SenGupta et. al. (332), the human cDNA library was screened for RNA-binding 
proteins that could interact with both sense and antisense SARS-CoV 5’-and 3’-UTR. 
However, a clone for the sense 3’-UTR could not be obtained after screening 50 
colonies, it was dropped off the screen and only the antisense 3’-UTR, as well as the 
5’-UTR in both orientations were screened instead. 
3.1.2 Candidates identified from yeast three-hybrid screen using 5’-UTR (+) as bait 
Three groups of positive candidates of initial screen (SD/-his) were classified by 
second tier screen into three groups: Group I (strong positives), Group II (weak 
positives) and Group III (false positives). Colonies classified under Group I, A81, 
A83, A127 A250, B169 and B225 were subjected to colony PCR (Figure 3.1) with an 
annealing temperature of 58°C. The PCR fragments from clones A81 and B225 were 
gel purified and sequenced.  
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The identity of the cDNA insert fragment was subsequently determined by 
performing a BLAST search on NCBI. Clone A81 was found to contain the N-
terminal 408 nt of the zinc finger CCHC-type and RNA binding motif 1 protein 
(ZCRB1), also known as morphine (acute) dependence-related protein 1 (MADP1) 
(accession NM_033114). Clone B225 was found to have the cDNA fragment inserted 
in the wrong orientation on the library vector and was therefore invalid. Clones A83 
and A127 were not sequenced as the PCR fragments were decided to be too short for 
consideration. As the primers used for the colony PCR bound roughly 200 to 300 nt 
apart on the vector (without insert), it was highly likely the two fragments were 
derived from the vector sequence. This was supported by the observation that both 
fragments were of an almost equal size.  
The colony PCR was repeated at a different annealing temperature (61°C) (Figure 
3.3) and an additional clone, B169, was gel purified and sequenced. The cDNA 
fragment in clone B169 was also found to be inserted in the reversed orientation and 
was invalid. No PCR fragment could be amplified from clone A250 so the clone was 






 100bp ladder 
A81     A83    A127   A250   B169   B225 
Figure 3.1: Colony PCR of colonies isolated from three-hybrid screen with SARS-
CoV 5'-UTR (+). PCR products were resolved on a 1% agarose gel, stained by 
ethidium bromide. Clones A81 and B225 were gel-purified and sent for sequencing. 
A representative result of two experiments was shown. 
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3.1.3 Candidates identified from yeast three-hybrid screen using 5’-UTR (-) as bait 
Group I (strong positives) colonies isolated from the screen using SARS-CoV 5’-UTR 
(-) as the bait were C12, C35, C88, C129, C130, C140, C224 and C225. The colonies 
were subjected to colony PCR at 58°C (Figure 3.2) and the PCR fragments from 
clones C35 and C88 were gel-purified and sent for sequencing. The cDNA fragment 
for clone C35 was found to be inserted with a cDNA fragment in the reverse 






 100bp ladder 
A81      A127      A250    B169     B225 
Figure 3.3: Repeat of colony PCR using a different annealing temperature with clones 
A83, A127, A250, B169, B225, isolated from three-hybrid screen with SARS-CoV 5'-
UTR (+). PCR products were resolved on a 1% agarose gel, stained by ethidium 
bromide. Clone B169 produced a strong band and was subsequently gel purified then 








C12 C35 C88 C129 C130 C140 C224 C225 D26 D27  D33  D40 D100 D202   
Figure 3.2: Colony PCR of colonies isolated from three-hybrid screen using SARS-
CoV 5'-UTR (-) and 3'-UTR (-). PCR products were resolved on 1% agarose gel 
stained with ethidium bromide. Clones C35, C88, D27, D33, D100 and D202 were 




Clone C88 was found to match nt 466 to 808 of hematopoietic cell-specific Lyn 
substrate 1 (HCLS1)-associated protein X-1 (HAX1) variant 2 mRNA (accession 
NM_001018837), within the coding sequence of the protein HAX1 isoform b.  
3.1.4 Candidates identified from yeast three-hybrid screen using 3’-UTR (-) as bait. 
Colonies classified under Group I (strong positives) isolated from the screen using 
SARS-CoV 3’-UTR (-) as the bait were D26, D27, D33, D40, D100 and D202. 
Colony PCR was performed for the 6 clones (Figure 3.2) and the PCR products from 
clones D27, D33, D100 and D202 were gel-purified and sequenced. Both clones D27 
and D33 were found to contain similarity to only 33 nt of the X chromosome genome 
contig (accession NM_001842393) without similarity to any annotated protein coding 
sequence. For clone D100, it was found that the cDNA fragment was inserted in the 
reverse orientation so the clone was invalid. For clone D202 however, the sequence of 
the amplified PCR product matched that of ribosomal protein L27a (RPL27A) 
(accession NM_000990) with an identity of 98% spanning across 317 nt. 
3.1.5 Consolidation of candidates from the screens 
In total, only one protein was determined to be a valid candidate for interaction with 
each of the screened UTRs, that being MADP1, HAX1 (isoform b) and RPL27A for 
sense 5’-UTR, antisense 5’-UTR and antisense 3’-UTR respectively. HAX1 is a 
mitochondrial protein which functions as an anti-apoptotic protein (333-335) in the 
cell. The protein has been reported to interact with classical swine fever virus N-
terminal protease (336), however, the absence of prior reports of an associated RNA-
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binding activity and predicted RNA-binding domains deemed it less likely to be 
interacting with SARS-CoV 5’-UTR (-) specifically.  
RPL27A being a component of the eukaryotic 60S ribosome, a ribonucleoprotein 
complex, is likely to possess RNA-binding activity. Although it was interesting to 
find RPL27A interacting with SARS-CoV 3’-UTR (-), which would not be required 
for viral protein translation, the ribosomal protein did not prove to be an attractive 
candidate as functional analysis could prove to be problematic. This problem would 
arise due to the fact that the virus relies heavily on the host translational machinery, 
which includes the host ribosomes, for the translation of viral proteins necessary for it 
to propagate.  
MADP1 is a nuclear protein reported to be a member of the 18S U11/12 small nuclear 
ribonucleoprotein (snRNP), part of the minor spliceosome (337), and has been linked 
to morphine dependence, heat shock and hepatocarcinoma (338). It was also predicted 
to contain two conserved nucleic acid binding domains, the RNA recognition motif 
(RRM) and the provisional universal minicircle sequence binding protein domain, 
which is a zinc finger, CCHC-type. Although splicing had been ruled out as the 
mechanism by which discontinuous transcription could be achieved in coronaviruses, 
the RNA-binding domains on MADP1 which would likely interact with small nuclear 
RNAs (snRNAs) in the spliceosome complex, could also play a role in other 
processes. Hence, it was decided that the interaction between MADP1 and SARS-





3.2 MADP1 Interacts with IBV 5’-UTR 
In order to validate the interaction between human MADP1 and SARS-CoV 5’-UTR 
as well as to verify if it could interact with the IBV counterpart as well, the 
interactions were assessed with a different method. The first method chosen for this 
purpose was North-Western Blotting using DIG-labeled RNA to probe for bacteria 
expressed human MADP1 immobilized on a membrane.  
3.2.1 Bacteria expression of MADP1 N-terminally tagged with HIS(X6) or GST 
The bacteria expression system was chosen for its potential benefits of high protein 
yield and low cost. Also, a recombinant protein expressed with a small tag like 
HIS(X6) would not incur the additional step of tag removal as MADP1 was not a 










NI      P      S     NI     P      S 
clone 1              clone 2 
Figure 3.4: No expression of HIS-
MADP1 was detected after induction 
at 1 mM IPTG for 3 hours at 37°C. 
BL-21 E. coli was transformed with 2 
clones of plasmid pET-MADP1 and 
induced. Samples were resolved by a 
12% SDS-PAGE gel. Non-induced 
samples (NI) were prepared from 
bacteria sedimented from 1 ml of each 
culture just before induction. Pellet 
(P) and supernatant (S) fractions were 
prepared from freeze/thaw lysed 
bacteria after induction. Unit for 
molecular weight reference is 
kilodaltons (kDa). A representative 
result of three independent 
experiments was shown. 
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MADP1 was cloned into the vector pET-16b to express N-terminally HIS-tagged 
MADP1 (HIS-MADP1). The expression of HIS-MADP1 was induced by 1 mM IPTG 
at 37°C and its expression level was assessed coomassie blue staining as shown in 
Figure 3.4.  
The expected band of HIS-MADP1 was not detected. However, it was noticed in the 
supernatant fraction of the lysed bacteria, that a strong band of an undetermined size, 
smaller than 14.8 kDa was present in both clones tested. This implied that the 
recombinant protein could have been unstable and the induction condition needed to 
be optimized. Hence, BL-21 transformed with clone 2 of pET-MADP1 was induced at 
a lowered temperature of 30°C, for a longer duration of 4 hours with either 0.8 mM or 
1 mM of IPTG. The samples obtained were resolved and analyzed by western blot 









NI  P   S   P   S    NI   P    S    P    S 
IPTG (mM)        0.8       1.0             0.8        1.0  
WB                    staining 
Figure 3.5: Expression of HIS-MADP1 was too low to be detected by coomassie blue 
staining. Optimization of HIS-MADP1 expression. E. coli transformed with clone 2 
of pET-MADP1 plasmid was induced at 30°C for 4 hours with either 0.8 or 1.0 mM 
of IPTG. Samples were resolved by a 15% SDS-PAGE gel. WB: western blot was 
performed with anti-HIS antibody and total protein was visualized by coomassie blue 




A dense band was observed in the stained gel with a molecular mass close to HIS-
MADP1, but it did not belong to the protein as it was present in the non-induced 
sample as well. In addition, detection of the recombinant protein, HIS-MADP1, by 
anti-HIS antibody indicated that its expression was impossible to be visualized by 
coomassie blue staining. As the amount of protein was considered low even for 
western blot detection, it was decided that the fusion tag be changed to GST even 
though it could imply an additional tag-removal step if the protein could be 
successfully expressed. Hence, MADP1 was first cloned into Gateway® pDEST15 
vector to express N-terminally GST-tagged MADP1 (GST-MADP1) of an estimated 
relative molecular mass of 57 kDa. However the expression level of the recombinant 
protein from the chosen clone (Figure 3.6, panel A) after 3 hours of induction with 1 
















NI     P      S                        NI     P      S     NI      P      S 
clone 1                                clone 2             clone 3 A                            B 
Figure 3.6: Expression of GST-MADP1 was too low for detection by coomassie blue 
staining. GST-MADP1 recombinant protein was expressed from from BL-21 E. coli 
transformed with three different clones of expression plasmid pDEST15-MADP1 
induced by 1 mM IPTG for 3 hours at 37°C. (A) Samples from clone 1 resolved by a 
12% SDS-PAGE gel. (B) Samples from clones 2 and 3 resolved by a 10% SDS-
PAGE gel. A representative result of two independent experiments was shown. 
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Two more clones (clones 2 and 3) were assessed for their recombinant protein 
expression levels under the same induction condition, (Figure 3.6, panel B) but the 
result was still unsatisfactory although the total bacteria protein expression profiles 
differed from clone 1. The condition for induction was changed to 0.8 mM of IPTG 
for 4 hours at 37°C and the supernatant fraction (S) was concentrated by resuspending 
the sedimented bacteria in half the volume of PBS (with 100 µg/ml lysozyme). 
However, as shown in Figure 3.7, a clear induction of the recombinant protein 
expression was not detected as a band of the expected size, 57 kDa, remained 
conspicuously absent in all three clones tested.  
Due to the lack of recombinant protein expression, the expression of GST with 
pDEST15 vector was assessed to rule out the possibility that the vector sequence was 
erroneous as this was the first time the vector was used in the laboratory. It was found 
that the expression of the GST tag, with an estimated relative molecular mass of 26 
kDa, from pDEST15 plasmid following an induction with 1 mM IPTG for 3 hours at 









P       S      P       S       P       S 
clone 1       clone 2       clone 3 Figure 3.7: GST-MADP1 
expression still could not be 
detected after reducing the 
concentration of IPTG to 0.8 
mM. GST-MADP1 recombinant 
protein was expressed from BL-
21 E. coli transformed with 
three different clones of 
expression plasmid pDEST15-
MADP1 induced by 0.8 mM 
IPTG for 4 hours at 37°C. 
Samples were resolved by a 
10% SDS-PAGE gel. A 
representative result of two  




blue staining (Figure 3.8) which was much poorer than what could be achieved with 
the vector pGEX-5x-1, which was normally used in the laboratory for GST-
recombinant protein expression in E. coli. Hence, MADP1 was cloned into the 
expression vector pGEX-5x-1.  
Expression of GST from vector pGEX-5x-1 and recombinant GST-MADP1 from two 
clones of plasmid pGEX-MADP1 following induction with 1 mM of IPTG for 3 
hours at 37°C was assessed by SDS-PAGE followed by coomassie blue staining as 
shown in Figure 3.9. The expression of GST from vector pGEX-5x-1 transformed E. 
coli appeared normal. A band corresponding to the estimated molecular mass of GST-
MADP1 was not detected in both clones transformed with the plasmid pGEX-











NI      P       S 
GST 
Figure 3.8: Expression of GST was 
confined to the insoluble fraction. 
Expression of GST protein from BL-
21 E. coli transformed with vector 
pDEST15 induced by 1 mM IPTG for 
3 hours at 37°C. Samples were 
resolved by a 12% SDS-PAGE gel. A 
representative result of three 
independent experiments was shown.  
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This observation implied the possibility that translation of the recombinant protein 
was pre-maturely terminated just after the GST-tag was translated. This was not likely 
caused by the presence of a stop codon between the GST and MADP1 nucleotide 
sequences as reflected by the results from sequencing the plasmids used. Hence, the 
induction conditions were to be optimized.  
The induction duration was maintained at 3 hours, temperature was lowered to 30°C 
and IPTG concentrations 0.6 mM and 1 mM were used to induce GST-MADP1 
expression from E. coli transformed with clone 2 of pGEX-MADP1 plasmid (Figure 
3.10, panel A). The expression level of the recombinant protein was observed to be 
higher when 0.6 mM of IPTG was used for induction compared to 1 mM. A second 
experiment was performed to compare the expression level of GST-MADP1 at 0.6 
mM and 0.8 mM IPTG (Figure 3.10, panel B). The result was almost the same, with 








NI     P     S     NI    P     S     NI    P     S 
clone 1            clone 2 
pGEX-5x-1              pGEX-MADP1 
GST 
Figure 3.9: Expression profile of GST-MADP1 appeared to be similar to that of 
GST-tag only. Expression of GST and GST-MADP1 from BL-21 E. coli transformed 
with plasmid pGEX-5x-1 or pGEX-MADP1 induced by 1 mM IPTG for 3 hours at 
37°C. Samples were resolved by a 10% SDS-PAGE gel. A representative result of 
two independent experiments was shown. 
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experiments, the recombinant protein could only be detected in the insoluble fraction 
(P) by coomassie blue staining although the soluble fraction (S) was observed by 
probing with anti-GST, to contain a similar amount of GST-MADP1. However, even 
if the same amount of protein was present in the soluble fraction, the amount was not 
enough to undergo purification and tag cleavage.  
In the third and last experiment, the induction temperature was lowered to 27°C, 
duration increased to 4 hours and 0.6 mM of IPTG was used to induce recombinant 
protein expression (Figure 3.11). No improvement to the expression level of GST-









NI P  S   P  S   NI  P   S   P   S                NI  P  S   P   S    NI  P   S   P   S 
 
IPTG 
(mM) 0.6     1.0          0.6     1.0                          0.6     0.8            0.6     0.8 









A           B  
Figure 3.10: Lowering of IPTG concentration to 0.6 and 0.8 mM increased the 
expression of GST-MADP1 but is still not detectable by coomassie blue staining. 
Optimization of induction conditions I. E. coli transformed with clone 2 of pGEX-
MADP1 was induced to express recombinant GST-MADP1 at 30°C for 3 hours with 
different contrations of IPTG. The samples were resolved on a 12% SDS-PAGE gel 
and protein expression profile of each induction was analyzed by total protein 
staining with coomassie brilliant blue or western blot with anti-GST antibody. (A) 
Expression profile of induction with 0.6 mM and 1.0 mM IPTG. (B) Expression 
profile of induction with 0.6 mM and 0.8 mM IPTG. WB: western blot, staining: 
coomassie brilliant blue staining. This experiment was performed once. 
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In view of the poor result obtained from the expression of either GST-MADP1 or 
HIS-MADP1 recombinant protein in the bacteria system, it was abandoned in favour 
of mammalian expression system which was more likely to produce stable 








P  S       P   S 
WB    staining 
Figure 3.11: Lowering of induction temperature to 
27°C did not further increase the expression of GST-
MADP1. Optimization of induction conditions II. E. 
coli transformed with clone 2 of pGEX-MADP1 was 
induced to express recombinant GST-MADP1 at 
27°C for 4 hours with 0.6 mM IPTG. Samples were 
resolved using a 10% SDS-PAGE gel and the 
protein expression profile was analyzed by total 
protein staining with coomassie brilliant blue or 
western blot with anti-GST antibody. This 
experiment was performed once. 
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3.2.2 Mammalian Expression Of MADP1 N-Terminally Tagged With FLAG 
To select a cell line for expressing the recombinant protein FLAG-MADP1, a trial 
experiment using three cell lines commonly used in the laboratory was performed. 
FLAG (from vector pXJ40Flag) or FLAG-MADP1 (from plasmid pXJ40Flag-Madp1) 
proteins were over-expressed in Vero, H1299 and HuH-7 cells grown in 6-well plates 
without Vaccinia/T7 virus for 24 hours. The cells were lysed and the lysate was 
resolved by SDS-PAGE and western blot was performed with anti-FLAG-HRP 











F     FM      F     FM     F     FM 
Vero         H1299        HuH-7 
FLAG-MADP1 
Figure 3.12: FLAG-MADP1 expression was higher in Vero and H1299 cells 
compared to HuH-7 cells. Trial over-expression of FLAG-MADP1 in Vero, H1299 
and HuH-7 cells. Cells grown in 6-well plates were infected with Vaccinia/T7 virus 
and transfected with 0.4 µg of plasmid DNA pXJ40Flag or pXJ40Flag-Madp1 using 
Effectene® for 24 hours. Cells were lysed with 200 µl of lysis buffer, 20 µl of each 
lysate was resolved on a 12% gel and transferred onto a nitrocellulose membrane. 
Recombinant protein FLAG-MADP1 (indicated by an arrow) was detected after 
probing with anti-FLAG-HRP. Samples were labeled by the identity of over-
expressed protein, F: FLAG tag and FM: FLAG-MADP1. A representative result of 
two independent experiments was shown. 
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The expression level of recombinant FLAG-MADP1 protein was found to be 
comparable in Vero and H1299 cells but much lesser in HuH-7 cells, so the latter was 
not used for the subsequent experiments. It was surprising that the expression level of 
FLAG-MADP1 in Vero was as high as H1299 as the former cell line was usually 
associated with low over-expression levels. Hence, it was decided that H1299 would 
be used for subsequent experiments as the expression level achieved by Vero could be 
non-reproducible.  
3.2.3 North-western blot of FLAG-MADP1 and the 5’-UTRs of SARS-CoV and IBV. 
FLAG tag (negative control) and FLAG-MADP1 were over-expressed in H1299 cells 
grown in a 6-well plate in the presence of Vaccinia/T7 virus for 24 hours to increase 
the protein yield. The cells were harvested and lysates were purified using anti-
FLAG® M2 affinity gel and eluted with 3X FLAG® peptide. The eluted samples were 
resolved using SDS-PAGE and north-western blot was performed using either DIG-
labeled SARS-CoV or IBV full-length 5’-UTR (+) probes. The expression of the 
recombinant protein was assessed by western blot with anti-FLAG-HRP as shown in 
Figure 3.13, panel B contained multiple bands (smaller mass), which were pre-mature 
termination products common to over-expression system using Vaccinia/T7 virus. 
The north-western blot did not show a clear band corresponding to the estimated size 
of FLAG-MADP1 when probed with both 5’-UTRs, as was obtained from the western 
blot (top band) of the same samples. Although there appeared to be a dense band in 
the north-western blot for IBV 5’-UTR (+) (Figure 3.13, panel A) which might 
correspond to the second band seen on the western blot (Figure 3.13, panel B), the 
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band appeared in the negative control sample, F, as well. The identities of the multiple 
bands seen on the north-western blot for both probes (lanes marked FM) were 
unknown but could be associated with MADP1 (as co-purified bands) as they were 
not found in the lanes that were loaded with negative control purified lysate (lanes 
marked F). In conclusion, north-western blot was not sensitive enough to detect the 
low amounts of FLAG-MADP1 over-expressed even with Vaccinia/T7 virus. 
3.2.4 MADP1 interacts with SARS-CoV 5’-UTR (+) and IBV 5’-UTR (+) 
A different method based on the ability of interacting proteins to co-purify with 
biotin-labeled RNA probes using streptavidin beads was used to assess the interaction 
between FLAG-MADP1 recombinant protein and the 5’-UTR (+) from SARS-CoV 
and IBV. The full-length 5’-UTR (+) probes synthesized as biotin-labeled RNA by in 









F     FM           FM    F                                      F     FM 
IBV             SARS-CoV                                     WB    
Figure 3.13: FLAG-MADP1 could not be detected by north-western blotting using 
both IBV and SARS-CoV 5’-UTR (+) probes. (A) North-western blot of affinity 
purified FLAG-MADP1 probed with 5'-UTR (+) of IBV or SARS-CoV. The bands 
corresponding to full-length FLAG-MADP1 on both blots were indicated by the 
double headed arrow. (B) Western blot (WB) of affinity purified FLAG-MADP1 
used in north-western blot detected by anti-FLAG-HRP antibody. A representative 
result of three independent experiments was shown. 
A              B 
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of Vaccinia/T7 virus were used for the assay. As this was the first time this method 
was used in the laboratory, all fractions were analyzed to ensure that the conditions 
were optimized. The samples were resolved by SDS-PAGE and western blot was used 
for the detection of FLAG-MADP1 (Figure 3.14).  
The strength of interaction between MADP1 and the RNA probe was assessed by a 
comparison of the relative band intensity corresponding to full-length FLAG-MADP1 
for the cell lysate loaded and the eluted proteins. The SARS-CoV 5’-UTR (+) 
appeared to interact weakly with MADP1 (Figure 3.14, right panel). Although the 
interaction observed for SARS-CoV 5’-UTR (+) was weak, it indicated that the 












































IBV 5’-UTR (+)    SARS-CoV 5’-UTR (+) 
Figure 3.14: MADP1 interacts with the 5'-UTR (+) of IBV and SARS-CoV. Lysate of 
H1299 cells over-expressing FLAG-MADP1 was mixed with biotin-labeled RNA 
probes and the mixture was affinity purified by streptavidin beads. The beads were 
washed thrice and co-purified proteins eluted with 2X SDS loading dye. All eluted 
proteins, 10 µl of cell lysate and 20 µl of all other fractions were resolved with a 12% 
SDS-PAGE gel and western blot was performed with anti-FLAG-HRP antibody. A 
representative result of two independent experiments was shown. 
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negligible compared to the amount detected in the eluted sample. IBV 5’-UTR (+) on 
the otherhand, was exhibiting an unquestionably stronger interaction with MADP1 
compared to its SARS-CoV counterpart. 
As the interaction observed for SARS-CoV 5’-UTR with MADP1 was much weaker 
than expected, it could complicate further analyses of the interaction when mutations 
targeted at obliterating the interaction were performed. Hence, the subsequent 
mapping of interaction domains were based on the interaction between IBV 5’-UTR 
(+) and MADP1. 
 
3.3 MADP1 Translocated to the Cytoplasm during IBV Infection 
Although the interaction between MADP1 and both SARS-CoV and IBV 5’-UTR (+) 
appeared to be true, the possibility of a nuclear protein participating in coronavirus 
RNA synthesis which occurs in the cytoplasm in virus-induced DMVs needed 
verification. As a previous report on MADP1 only noted its nuclear (excluding 
nucleolus) localization, there was no indication that the protein could be transported 
out of the nucleus. Hence, to confirm if the interaction between the IBV 5’-UTR (+) 
and MADP1 was possible in infected cells, a cell fractionation experiment was 
performed to assess the cellular distribution of MADP1 during an IBV infection. 
3.3.1 MADP1 was present in the cytosol during IBV infection 
For this purpose, 2 cell lines, H1299 and Vero cells, were selected as H1299 cells 
would be used for most transfection-related experiments and Vero was the cell line 
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the strain of IBV used had been adapted to. The cells grown in a 6-well plate were 
either infected with IBV virus stock at a multiplicity of infection (MOI) of 
approximately 1 or with the same volume of mock virus stock for 10 hours. The cells 
were fractionated using CelLyticTM NuCLEARTM Extraction Kit and both nuclear and 
cytoplasmic fractions were resolved by SDS-PAGE. Nuclear marker Histone H1 and 
cytoplasmic marker β–tubulin were probed with the appropriate antibodies. A made-
to-order serum antibody produced in rabbit was used to detect endogenous MADP1.  
In H1299 cells (Figure 3.15, left panel), MADP1 localized predominantly in the 
nuclear fraction but was present in the cytoplasm as well, with or without IBV 
infection. Although the amount of MADP1 present in the cytosol appeared lower in 
the presence of IBV infection than without, densitometric analysis revealed that the 
C/N ratios were consistent at 25% and 29% respectively. The lower amount of 




C      N      C      N            C          N           C          N 
+ IBV + IBV 
H1299    Vero 
Figure 3.15: MADP1 localized predominantly in the nucleus but was detectable in the 
cytoplasm. H1299 and Vero cells were infected with IBV virus stock at MOI ≈ 1 
(+IBV) or with an equal volume of mock virus stock for 10 hours then cell 
fractionation was performed for each sample. 10% of the respective fractions were 
resolved by a 12% SDS-PAGE gel and western blot was performed with antibodies to 
histone H1, β-tubulin and MADP1. C: cytoplasmic fraction, N: nuclear fraction. A 
representative result of three independent experiments was shown. 
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post infection as the mock virus infected cells could continue replication while the 
IBV infected cells experienced cell cycle arrest, which resulted in their inability to 
replicate. 
In Vero cells (Figure 3.15, right panel), MADP1 did not appear to be present in the 
cytoplasmic fraction for the mock virus infected. However, a minute amount of 
MADP1 was detected in the cytosol for the IBV infected sample (indicated by an 
asterisk). Densitometric analysis of the detected bands has revealed an increase of the 
C/N ratio from 3.6% to 18.7% after IBV infection. This increased presence of 
MADP1 resulting from IBV infection was significant considering the lack of histone 
H1 contamination in the cytoplasmic fractions. 
3.3.2 MADP1 translocates to the cytoplasm during IBV infection 
Although the cell fractionation study indicated the presence of MADP1 in the cytosol 
at least during IBV infection, it was unable to prove that the host protein was present 
at regions with active viral RNA synthesis, the viral replicase/transcriptase complex 
(RTC). To determine if MADP1 was able to co-localize with the viral RTCs, indirect 
immunofluorescence confocal microscopy was performed. The serum antibody for 
MADP1 was not suitable for immunofluorescence detection of the endogenous 
protein, so MADP1 was over-expressed as recombinant protein FLAG-MADP1, its 
detection made by polyclonal rabbit anti-FLAGTM antibody. The active RTCs were 
labeled with bromouridine triphosphate (BrUTP) and detection was made by a 




Cells infected with IBV were treated with actinomycin D at 3 hours post infection 
(h.p.i.) for 4 hours to inhibit host transcription and BrUTP was introduced by 
transfection to label newly synthesized RNAs for 3 hours before the cells were fixed. 
Immunofluorescence detection was performed by probing with both primary 
antibodies then Alexa Fluor® 488 conjugated anti-rabbit and Alexa Fluor® 594 
conjugated anti-mouse secondary antibodies.  
Two negative Controls (Figure 3.16) were included in the experiment. The first was 
IBV infected FLAG expressing Vero cells (upper panel) which displayed only 
positive staining for BrUTP (red) in the cytoplasm as punctate structures. The second 









   
   








Figure 3.16: Negative controls for indirect immuno-fluorescent detection of BrUTP 
and FLAG-MADP1. Top panel: Vero cells over-expressing FLAG which were 
infected with IBV were stained with anti-BrdU only. Bottom panel: Vero cells over-
expressing FLAG-MADP1 which were mock virus infected were stained with anti-
FLAG only. A representative set of images from three independent experiments was 
shown (between three to six images were taken for each experiment). 
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was mock virus infected FLAG-MADP1 expressing Vero cells (lower panel) which 
displayed only positive staining for FLAG-MADP1 in the cell nuclei (green). Taken 
together, the two negative controls indicated that detection by both anti-BrdU and 









             
 
 set 2 
Figure 3.17: FLAG-MADP1 was present in the cytoplasm of Vero cells during IBV 
infection. Indirect immunofluorescence visualization of FLAG-MADP1 and BrUTP 
labeled RNA in IBV-infected Vero cells. FLAG-MADP1 was stained by Alexa Fluor 
488 (green), BrUTP was stained by Alexa Fluor 594 (red) and overlapping staining 
(yellow) in the overlapped images indicated points of overlapping signals. Two sets 
of representative images were selected to show the extent of colocalization. Cells 
were visualized at 400X magnification and selected fields were magnified at 1000X. 
Two representative sets of images from three independent experiments was shown 




Two sets of representative images of IBV-infected FLAG-MADP1 expressing Vero 
cells were shown in Figure 3.17 (set 1 and set 2) at 400X and 1000X magnification. In 
both sets of images, FLAG-MADP1 (green) displayed a pre-dominantly nuclear 
staining with some cytoplasmic staining as punctate structures that appeared to be 
slightly more concentrated in the perinuclear region. BrUTP (red) staining was 
observed as punctate structures in the cytoplasm which exhibited stronger signals in 
the perinuclear region. The overlap images (left column) showed some yellow regions 
(green + red), indicating the presence of both stains at the same positions. This 
implied that FLAG-MADP1 could be located in close proximity to de novo 
synthesized RNA labeled by BrUTP. Although the overlap was far from complete, 
and a co-localization in the perinuclear region could not be confirmed, the cellular 
distribution of FLAG-MADP1 was clearly affected by IBV infection. 
overlap         α-BrdU        α-FLAG 
Figure 3.18: FLAG-MADP1 was present in the cytoplasm of H1299 cells during IBV 
infection. Indirect immunofluorescence visualization of FLAG-MADP1 and BrUTP 
labeled RNA in IBV-infected H1299 cells. FLAG-MADP1 was stained by Alexa 
Fluor 488 (green), BrUTP was stained by Alexa Fluor 594 (red) and overlapping 
staining (yellow) in the overlapped images indicated points of overlapping signals. 
Cells were visualized at 400X magnification. A representative set of images from 
three independent experiments was shown (between two to four images were taken 




The same observation could be made in H1299 cells as shown in Figure 3.18 (left 
image). However, as the infection proceeded much faster in H1299 cells, fusion cells 
were formed so no single infected cells were observed. BrUTP staining (middle 
image) and regions stained for both BrUTP and FLAG-MADP1 (yellow) appeared to 
be concentrated near one particular nucleus, which likely belonged to the original 
infected cell before the syncytium was formed. It was also noted that in H1299 cells, 
FLAG-MADP1 appeared to be almost absent from most nuclei in the syncytium (right 
image) during IBV infection. 
Although the immunofluorescence data were insufficient to show that MADP1 could 
colocalize with de novo synthesized viral RNA (in the presence of actinomycin D) in 
the cytosol, there was a distinct change in the staining pattern for MADP1 after the 
cells were infected with IBV. This was in addition to the results from cell 
fractionation experiment that MADP1 was present in the cytosol in low amounts at 
least during IBV infection in both Vero and H1299 cells. As the labeling of RNA 
lasted only three hours just before the cells were fixed, the stained punctate structures 
would likely indicate the positions of active RTCs since the retired RTCs which 
stopped RNA synthesis would not have been labeled. The close proximity of FLAG-
MADP1 with active RTCs may indicate the significance in its interaction with viral 
RNA in the virus infected cells, although further analysis would be required to 
confirm if close proximity of MADP1 to the newly synthesized RNA indicates its 






3.4 MADP1 Interacts Specifically with IBV 5’-UTR (+) 
Although MADP1 was able to copurify with biotin-labeled IBV 5’-UTR (+) in the 
biotin-pull-down assay, it was not known if the interaction was specific or if MADP1 
could be a non-specific RNA binding protein. To investigate the specificity of the 
RNA-binding activity of MADP1, a binding competition assay, based on the biotin 
pull-down assay, was performed. Unlabeled IBV 5’-UTR (+) (IBV genome nt 1 to 
528) RNA and negative-sense EGFP coding sequence nt 1 to 528 (EGFP (-)) were 
synthesized by in vitro transcription to be used as specific and non-specific RNA 
competitors respectively. As a control, the binding of IBV N protein, a non-specific 
RNA-binding protein, to one of its biological targets, the IBV 3’-UTR (+) was 
examined. Unlabeled IBV 3’-UTR (+) (IBV genome nt 27106 to 27611) was 
synthesized by in vitro transcription to be used as the specific RNA competitor while 
unlabeled EGFP (-) RNA was used as the non-specific RNA competitor. 
For both specific and non-specific competition assays, different amounts of unlabeled 
probes (0 µM, 0.5 µM, 1.0 µM, 1.5 µM and 2.0 µM final) were mixed with a fixed 
amount (0.1 µM final) of biotin-labeled probes (5’-UTR (+) and 3’-UTR (+)) prior to 
the addition of cell lysate from FLAG-MADP1 or FLAG-IBV N over-expressing 
H1299 cells respectively. Each mixture was incubated 30 minutes at room 
temperature before streptavidin beads were added. The proteins that co-purified with 
biotin-labeled RNA were resolved by SDS-PAGE and probed for FLAG-MADP1 
using anti-FLAG-HRP antibody.  
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The binding of MADP1 to biotinylated 5’-UTR (+) decreased in the presence of an 
increasing concentration of specific RNA competitor, unlabeled 5’-UTR (+) (Figure 
3.19, top panel). The binding was reduced to about 50% when the concentration of the 
specific competitor equaled that of the biotinylated 5’-UTR (+) (0.1 µM). When twice 
the amount (0.2 µM) of unlabeled probe was present, the binding of MADP1 to 
biotinylated 5’-UTR (+) suffered at least a 10-fold reduction. Conversely, the 
presence of non-specific RNA competitor, EGFP (-) did not affect the binding of 
MADP1 to biotinylated IBV 5’-UTR at the maximum concentration used (0.2 µM) 
(Figure 3.19, top panel). 
FLAG-MADP1 
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Figure 3.19: MADP1 interacts specifically with IBV 5’-UTR (+). Increasing 
concentrations of unlabeled specific RNA competitor (IBV 5’-UTR (+)) decreased the 
binding of MADP1 to biotinylated IBV 5’-UTR. Increasing concentrations of 
unlabeled non-specific RNA competitor (EGFP (-) did not affect the interaction. The 
binding of non-specific RNA-binding protein, IBV N, to its biotinylated biological 
target,  IBV 3’-UTR (+) was affected by increasing concentrations of both its specific 
RNA competitor (IBV 3’-UTR (+)) and non-specific RNA competitor (EGFP (-)). A 




For the control experiment, both unlabeled IBV 3’-UTR (+) (specific competitor) and 
EGFP (-) (non-specific competitor) probes decreased the binding of IBV N to its 
biotinylated biological target, IBV 3’-UTR (+) RNA. This was vastly different from 
the observation made from the interaction between MADP1 and biotinylated IBV 5’-
UTR (+), which could only be affected by the presence of unlabeled specific RNA. 
Hence, it could be concluded that the interaction between MADP1 and IBV 5’-UTR 
was of a specific nature and not a result of non-specific RNA-binding activity 
exhibited by MADP1.  
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3.5 Stem Loop I of IBV 5’-UTR (+) is required to interact with MADP1 
To map the binding site of MADP1 on the IBV 5’-UTR (+), biotinylated RNA 
spanning different regions of the sequence were synthesized by in vitro transcription 
for use in biotin-pull down assays using FLAG-MADP1 over-expressing H1299 cell 
lysate. The probes which were created for the mapping of the MADP1 binding site 



















Figure 3.20: Schematic diagram of biotinylated probes synthesized used to map the 
MADP1 binding site on IBV 5'-UTR (+). All probes were produced by in vitro 
transcription with PCR templates spanning the indicated regions. 5’-UTR spanned the 
entire 5’-UTR. 5’-UTRΔ1, 5’-UTRΔ2 and 5’-UTRΔ3 spanned nucleotides 1-140, 1-
99 and 30-140 respectively while 5’-UTRΔ4 spanned nucleotides 141-528. Predicted 
secondary structures for the first 140 nucleotides were indicated. 
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3.5.1 The first 140 nucleotide residues of IBV 5’-UTR (+) is required to interact with 
MADP1 
Two biotinylated probes, 5’-UTRΔ1 and 5’-UTRΔ4 (Figure 3.21) were assessed for 
their binding to MADP1 first to determine if the binding site for MADP1 was located 
in the 5’ one-third or the 3’ two-thirds of the IBV 5’-UTR (+). Comparing the relative 
binding efficiency of the three probes, 5’-UTR, 5’-UTRΔ1 and 5’-UTRΔ4, it was 
observed that 5’-UTRΔ1 while 5’-UTRΔ4 did not retain much interaction with 
MADP1, 5’-UTRΔ1 was able to maintain its interaction, although it appeared to be 
less efficient compared to that observed for full length 5’-UTR (probe 5’-UTR). This 

















Figure 3.21: The binding site for 
MADP1 lies in the first 140 nucleotides 
of the IBV 5’-UTR (+). Biotin pull-down 
assay performed with probes 5’-UTR 
(full length IBV 5’-UTR, nucleotides 1-
528), 5’-UTRΔ 1 (nucleotides 1-140) 
and 5’-UTRΔ4 (nucleotides 141-528). A 
representative result of three independent 

























Figure 3.22: Stem-loop I was required to retain the interaction between biotinylated 
RNA and MADP1. Biotin pull-down assay was performed with the probes 5’-UTR, 
5’-UTRΔ1 to 4. The probes 5’-UTRΔ3 (nucleotides 30-140) and 5’-UTRΔ4 
(nucleotides 141-528) were unable to interact with MADP1. A representative result of 




3.5.2 Stem-loop I of the IBV 5’-UTR is required to interact with MADP1 
The first 140 nt of the IBV 5’-UTR contains four predicted stem loop structures, stem 
loops I to IV, indicated in Figure 3.20 (5’-UTR) which are well conserved across the 
three genera of coronaviruses. In an attempt to pin-point the secondary structure(s) 
responsible for the interaction between IBV 5’-UTR (+) and MADP1, two additional 
probes, 5’-UTRΔ2 and 5’-UTRΔ3 were assessed for their interaction with MADP1 
together with probes 5’-UTR, 5’-UTRΔ1 and 5’-UTRΔ4 (Figure 3.22).  
As shown earlier in Figure 3.21, 5’-UTRΔ4 which was unable to interact with 
MADP1 was included in this assay to serve as a control for negative binding. It was 
observed that probes 5’-UTR (full length), 5’-UTRΔ1 (nt 1-140) and 5’-UTRΔ2 (nt 1-
99) were able to bind MADP1 efficiently while 5’-UTRΔ3 (nt 30-140) and 5’-UTRΔ4 
(nt 141-528) did not bind MADP1. While probes 5’-UTR and 5’-UTRΔ4 served as 
controls for positive and negative interaction with MADP1, probes 5’-UTRΔ1, 5’-
UTRΔ2 and 5’-UTRΔ3 contained a different set of secondary structures each. 5’-
UTRΔ1 contained stem loops I to IV, 5’-UTRΔ2 contained stem loops I to III and 5’-
UTRΔ3 contained stem loops II to IV.  
Since probes 5’-UTRΔ1 and 5’-UTRΔ2 could both bind to MADP1, stem loop IV 
would likely not be required for the interaction. In addition, the observation that 5’-
UTRΔ3 could not bind to MADP1 indicated that a critical secondary structure 
required for the interaction was not present on the probe but present on probes 5’-
UTRΔ1 and 5’-UTRΔ2. These observations had narrowed down the secondary 
structure responsible for the interaction to stem loop I. 
130 
 
3.5.3 The integrity of stem-loop I structure is essential to maintain its interaction with 
MADP1 
As stem loop I of the IBV 5’-UTR (+) was determined to be the binding site for 
MADP1, and that 5’-UTRΔ2 (nt 1-99) was the shortest tested probe which could bind 
MADP1 at high efficiency, a mutant probe 5’-UTRΔ2M1, was synthesized based on 
the probe 5’-UTRΔ2. The two-residue mutation changed nt 11 and 12 from “GA” to 
“CU” and was predicted to destabilize the structure of stem loop I by creating 
unpaired bases in the mid-stem region (Figure 3.23).  
A second mutant probe 5’-UTRΔ2M2, which contained an additional two-residue 
mutation in mutant probe 5’-UTRΔ2M1 changing nt 25 and 25 from “UC” to “AG”. 
This change was predicted to reinstate the stem loop I structure through the 
restoration of base pairing in the mid-stem region, residue 11 with residue 26 and 
residue 12 with residue 25. Both mutants were assessed for their binding efficiency to 
Figure 3.23: Two mutations introduced to probe 5'-UTRΔ2 to create mutant probes 
5'-UTRΔ2M1 and 5'-UTRΔ2M2. 5’-UTR Δ2M1 contains a two-residue mutation 
which was predicted to destabilized stem loop I while 5’-UTRΔ2M2 contains an 




MADP1 with the biotin pull-down assay using FLAG-MADP1 over-expressing 
H1299 cell lysate or negative control EGFP over-expressing H1299 cell lysate. 
As shown in Figure 3.24, the interaction between MADP1 and IBV 5’-UTR (nt 1-99) 
was obliterated when the probe contained a destabilized stem loop I, 5’-UTRΔ2M1. 
On the otherhand, the interaction was restored, albeit partially, when the mutant probe 
which contained an additional mutation to restore the stem loop I structure, 5’-
UTRΔ2M2, was used. The inability of 5’-UTRΔ2M2 in fully restoring the interaction 
between MADP1 and IBV 5’-UTR (nt 1-99), despite having restored the secondary 
structure, could indicate an importance of the primary nucleic acid sequence of stem 
loop I as a critical determinant for the interaction.  
For non-RNA binding protein, EGFP, the band observed in the lane loaded with 
sample from the pull-down assay with probe 5’-UTRΔ2 was likely due to a leakage 





















Figure 3.24: The secondary structure of stem loop I was essential to bind MADP1. 
Biotin pull-down assay with probes 5’-UTRΔ2, 5’-UTRΔ2M1 and 5’-UTRΔ2M2. 
Mutant probe 5’-UTRΔ2M1 did not interact with MADP1 but 5’-UTRΔ2M2 could 
bind MADP1. MADP1 interacted with 5’-UTRΔ2M2 at a lower efficiency compared 
to 5’-UTRΔ2 (positive control). EGFP (negative control) did not interact efficiently 




of EGFP in the cell lysate and EGFP had not been observed to interact with any RNA 
probes in the earlier assays. 
With these results, we could confirm that stem loop I of the IBV 5’-UTR (+) is the 
binding site for MADP1. 
 
3.6 The RNA Recognition Motif Domain of MADP1 is required to interact with 
IBV 5’-UTR (+) 
MADP1 protein was predicted to contain two nucleic acid binding domains, the RNA 
recognition motif (RRM) domain (residues 11 to 84) and a provisional universal 






















Figure 3.25: Schematic diagram of MADP1 truncation mutants used in the 
determination of domain responsible for interacting with IBV 5'-UTR (+). Wild-type 
full length MADP1 (MADP1) contains two conserved domains, the RNA recognition 
motif (RRM) and the universal minicircle sequence binding protein (UMSBP) 
domains. All proteins were N-terminally tagged with FLAG-epitope and amino acid 




to determine the domain responsible for interacting with IBV 5’-UTR, a series of 
truncation mutants of MADP1, shown as a schematic diagram in Figure 3.25, were 
created to assess each of their RNA-binding activity with full length 5’-UTR (+) as 
the binding partner. EGFP protein was used as the negative control.  
3.6.1 The IBV 5’-UTR (+) binding activity was mapped to the RRM domain of 
MADP1 
The first three truncated mutants, MADP1n, MADP1m and MADP1c which spanned 
the RRM domain (N-terminus), UMSBP domain (middle) and the C-terminus which 
contained mostly phosphorylation sites were assessed for their RNA-binding to IBV 
5’-UTR (+), using biotin pull-down assay, to determine the domain responsible for 
interaction. As shown in Figure 3.26, it appeared the UMSBP domain (MADP1m) 
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EGFP       MADP1    MADP1n       MADP1m         MADP1c 
Figure 3.26: The RRM domain interacted weakly with IBV 5’-UTR (+). Biotin pull-
down assay of three MADP1 truncation mutants, MADP1n (RRM domain) MADP1m 
(UMSBP domain) and MADP1c (C-terminus) performed with biotinylated probe 5’-
UTR. MADP1m and MADP1c did not interact with the biotinylated probe and the 
interaction of MADP1n with the biotinylated was much weaker compared to full-length 
MADP1 (MADP1). EGFP (negative control) did not bind to the biotinylated probe. C: 
cell lysate, E: eluted proteins bound to streptavidin beads. A representative result of 
four independent experiments was shown. 
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RRM domain (MADP1n) was able to interact with IBV 5’-UTR (+), the interaction 
was much weaker compared to that with the full-length MADP1 protein. This 
observation indicated the importance of the peptide sequence beyond the RRM 
domain in achieving its full RNA-binding capacity.  
Therefore, three additional mutants based on MADP1n (Figure 3.25), were created 
and assessed for their RNA-binding activity with the biotin pull-down assay using 
biotinylated 5’-UTR as the RNA probe. The mutants MADP1x and MADP1z were 
extensions of MADP1n by 14 and 31 amino acid residues respectively while 
MADP1y was a variation of MADP1x with a 40 amino acid residue deletion at its N-
terminal. Both MADP1x and MADP1z exhibited efficient binding to the biotinylated 
IBV 5’-UTR (+) while MADP1y bound weakly (Figure 3.27).  
This observation showed that the peptide sequence beyond the RRM is critical for its 
function in RNA-binding and that the minimum number of additional amino acid 
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EGFP        MADP1    MADP1n      MADP1x     MADP1y      MADP1z 
Figure 3.27: Extension by a minimum of 14 amino acid residues of RRM domain or 
MADP1n (amino acid residues 1 to 86), was required to achieve a RNA-binding 
activity comparable to that of full-length MADP1. MADP1x (amino acid residues 1 
to 100) and MADP1z (amino acid residues 1 to 117) both bound efficiently to 
biotinylated IBV 5’-UTR (+). N-terminally truncated MADP1y (amino acid residues 
41-100) did not bind to the biotinylated probe efficiently. C: cell lysate, E: eluted 
proteins bound to streptavidin beads. A representative result of four independent 
experiments was shown. 
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required to ensure correct protein folding which would have been crucial to the 
domain function. Also, the 40 residue N-terminal truncation proved detrimental to the 
RNA-binding function of the RRM as represented by the poor RNA-binding 
efficiency exhibited by MADP1y. This observation confirmed that the RRM interacts 
with IBV 5’-UTR (+) as the truncation at the N-terminus would have disrupted the 
structure of the domain and affected its function in RNA-binding.  
3.6.2 The active site of MADP1 RRM domain is required to interact with IBV 5’-
UTR (+) 
To confirm if the RRM domain is required for the IBV 5’-UTR (+) to bind MADP1, 
mutations to disrupt the active site of the domain would be required. The RRM 
domain active site of MADP1 was predicted to be made up of three residues, tyrosine 
13, valine 53 and phenylalanine 55. Valine and phenylalanine would have been 
required to interact with the bases via hydrophobic interactions or base stacking 
respectively while positively charged tyrosine would likely act as an anchor for the 
negatively charged phosphate backbone. Hence, three mutants of MADP1 which had 
one, two or all three active site residues replaced by a neutral charged alanine residue 
were created. The tyrosine 13 residue was substituted in the Y mutant (Y13→A), 
valine 53 and phenylalanine 55 residues were substituted in VF mutant (V53→A, 
F55→A), while the YVF mutant had all three active site residues substituted replaced 
(Y13→A, V53→A, F55→A). The mutants which were over-expressed as FLAG-
tagged proteins were assessed for their interaction with IBV 5’-UTR (+) using biotin 
pull-down assay alongside wild-type FLAG-tagged MADP1.  
136 
 
All three mutants were found to exhibit lower RNA-binding to the biotinylated 5’-
UTR probe compared to wild-type MADP1 (Figure 3.28). Single and double residue 
mutants, Y and VF were co-purified with the biotinylated probe with similar 
efficiencies while the triple residue mutant YVF was co-purified at a much lower 
efficiency. These observations have demonstrated that the domain which served as the 
interacting partner to IBV 5’-UTR (+) was the RRM, not the UMSBP domain nor the 
C-terminus as the preservation of its active site residues was critical to the ability of 
full-length MADP1 protein to bind its target. Also, the interaction was the result of all 
three active site residues interacting with the RNA. 
In conclusion, the experimental results have affirmed that the RRM domain of 
MADP1 interacts with IBV 5’-UTR (+) and that a minimum of 16 additional amino 
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Figure 3.28: The MADP1 RRM domain active site residues are essential for its ability 
to bind to IBV 5’-UTR (+). Single (Y), double (VF) or triple (YVF) residue 
substitution mutants of MADP1 were used in a biotin pull-down assay with 
biotinylated 5’-UTR probe. Both Y and VF mutants showed a decreased binding to 
the biotinylated probe and YVF mutant showed a drastic decrease in its ability to bind 
to the probe. C: cell lysate, E: eluted proteins bound to streptavidin beads. A 
representative result of three independent experiments was shown. 
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3.7 Transient Gene Silencing of MADP1 Reduced Viral Replication and 
Transcription 
Although the interaction between MADP1 and IBV 5’-UTR (+) was determined to be 
specific and had been validated to have a possibility in occurring during virus 
infection, the significance of MADP1 in viral RNA synthesis had yet to be 
determined. The first strategy employed to demonstrate the significance of MADP1 
was to determine the effect of gene silencing on IBV infection in cultured cells. 
3.7.1 Optimization of MADP1 gene silencing 
Gene silencing was first attempted using transfection reagent Lipofectamine® 
RNAiMAX on both Vero and H1299 cells. A trial knockdown experiment was 
performed on both cell lines with a range of concentrations of siRNA to MADP1 
(siMADP1): 0 nM, 1 nM, 5 nM, 15 nM, 30 nM and 50 nM. The cells were transfected 
twice, 24 hours apart and RNA was extracted from the cells 48 hours after the first 
transfection. RT was performed with an oligo-dT primer and PCR performed with the 
primers 5’MADP1_SmaI and 3’MADP1_SmaI. 





Figure 3.29: Silencing of MADP1 with Lipofectamine® RNAiMAX in H1299 and 
Vero cells. Different concentrations of siMADP1 were transfected into the cells. 2 µg 
of total RNA was used for RT and 2 µl of RT product used for PCR. All samples 
were resolved by agarose gel electrophoresis on a 1% gel and stained with ethidium 
bromide. A representative result of two independent experiments was shown. 
138 
 
It was observed that although about 50% reduction in mRNA level of MADP1 was 
achieved in Vero cells at 5 nM siRNA concentration, the silencing efficiency was not 
high enough to see a visible effect on IBV infection (Figure 3.29). Silencing using 
Lipofectamine® RNAiMAX reagent was poor in H1299 cells. Hence, a second 
transfection reagent, DharmaFECT® was assessed for its silencing efficiency in the 
two cell lines. The reagent had been tested in a wide range cell lines by the 
manufacturer, it was indicated that DharmaFECT® 2 and DharmaFECT® 3 were 
prescribed for H1299 and Vero cells respectively. A single siRNA concentration was 
used for the trial silencing experiment, 100 mM of siMADP1 or siRNA to EGFP gene 
(siEGFP) was transfected into the cells twice, 24 hours apart and RNA was extracted 
at 48 hours after the first transfection. RT-PCR was performed with the same primers 
as with the trial for Lipofectamine® RNAiMAX.  
As shown in Figure 3.30, a high silencing efficiency was achieved in H1299 cells but 
that for Vero cells was still not high enough. Since a high gene silencing efficiency 
could only be achieved in H1299, it was chosen as the cell line with which subsequent 
functional studies were conducted.  
H1299 
Vero 
-         + 
Figure 3.30: MADP1 was efficiently silenced in 
H1299 cells but less efficiently in Vero cells using 
DharmaFECT® Transfection Reagents. Silencing of 
MADP1 with DharmaFECT® 2 and 3 Transfection 
Reagents in H1299 and Vero cells respectively. 2 µg 
of total RNA was used for RT and 1 µl of RT product 
used for PCR. All samples were resolved by agarose 
gel electrophoresis on a 1% gel and stained with 
ethidium bromide. (-) indicates samples transfected 
with siEGFP and (+) indicates samples transfected 
with siMADP1. A representative result of two 
independent experiments was shown. 
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3.7.2 MADP1 silencing in H1299 cells reduced luciferase gene expression of IBV-
Luc virus 
To determine the impact of MADP1 silencing in H1299 cells on IBV infection, a time 
course experiment was conducted. A recombinant IBV virus which had its accessory 
gene 3 (encoding 3a and 3b proteins) replaced by the firefly luciferase gene (339), 
IBV-Luc, was used to provide a quantitative measure of the efficiency of IBV 
infection. H1299 cells grown to a confluency of 30% in 6-well plates were transfected 
twice with 100 nM of siMADP1 or siEGFP using DharmaFECT® 2, 24 hours apart. 
The cells were then infected with recombinant IBV-Luc at MOI ≈ 1 in serum-free 
medium 72 hours after the first transfection. The cells were incubated at 37°C, in an 
atmosphere of 5% CO2 for 2 hours before the virus was removed and replaced with 
fresh serum-free medium. Cells continued to be incubated at 37°C, 5% CO2 until they 
were ready to be harvested at 4, 8, 12, 16, 20 or 24 hours post infection (h.p.i.) by 
lysis with 200 µl of Lysis Buffer for luciferase assay.  
Samples representative of the point of infection (0 h.p.i.) were incubated at 37°C, 5% 
CO2 for 5 minutes before they were harvested. Mock infected samples were infected 
with mock virus stock, of the same volume as IBV-Luc used for infected samples, 
incubated at 37°C for 2 hours before it was removed and replaced with fresh serum-
free medium. The mock infected samples were harvested only at 24 h.p.i.. 
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Luciferase activity, expressed as Relative Luminescence Unit per ml (RLU/ml) of the 
infected cell lysates was used as an indication of viral replication as illustrated in 
Figure 3.31. Peak luciferase activity was attained by siEGFP transfected cells was 
2.23 x 104 RLU/ml while that for siMADP1 transfected cells was only 8.00 x 102 
RLU/ml at 20 h.p.i.. These observations have shown that at low levels of MADP1 
expression, expression of virus genes were reduced, and that the spread of the 
infection could have been hampered, therefore resulting in a 20-fold reduction of 


























Figure 3.31: Silencing of MADP1 in H1299 cells reduced firefly luciferase activity 
produced by IBV-Luc infection. H1299 cells transfected with siEGFP (control) or 
siMADP1 were infected with IBV-Luc virus. Luciferase activity of the cells were 
measured with 5 µl of lysate and expressed as Relative Luminescence Units per 
milliliter of lysate (RLU/ml). Samples measured were harvested at 0, 4, 8, 12, 16, 20, 
24 hours post infection (h.p.i.). Error bars with standard deviation between the 
readings were included but too narrow to be seen. Maximum luciferase activity in 
MADP1 silenced cells was less than 5% of what was achieved in control cells 




3.7.3 Low efficiency silencing of MADP1 in Vero cells had little impact on luciferase 
gene expression of IBV-Luc virus 
As the impact of MADP1 gene silencing in H1299 cells evident, Vero cells, in which 
a much lower silencing efficiency could be achieved, was also used in a trial time 
course experiment to assess how much impact would a slight reduction in MADP1 
gene expression have on IBV infection. Vero cells grown to a confluency of 30% 
were transfected with twice with 100 nM of siMADP1 or siEGFP using 
DharmaFECT® 3 and infected with the same protocol as described for H1299 cells in 
section 3.7.2. Cells were incubated at 37°C, 5% CO2 until they were ready to be 
harvested at 4, 8, 12, 16, 20 or 24 hours post infection (h.p.i.) by lysis with 200 µl of 
Lysis Buffer for luciferase assay. Samples representative of the point of infection (0 
h.p.i.) and mock infected samples were prepared as described in section 3.7.2. 
It was observed that only about 30% reduction in peak firefly luciferase activity was 
achieved in cells transfected with siMADP1 compared to negative control, siEGFP 
transfected cells (Figure 3.32). This implied that the low gene silencing efficiency 
achieved in Vero cells resulted in a correspondingly weak impact on IBV infection. 
This was a contrast from the results obtained in H1299 cells which exhibited high 
gene silencing efficiency. In addition, peak luciferase activity was achieved at the 
same time point for both siEGFP and siMADP1 transfected cells, which implied that 
the virus spread was most likely not affected. Since a high silencing efficiency was 
not achievable for Vero cells, further analyses of the impact of MADP1 gene 
silencing in cultured cells on IBV replication were performed with H1299 cells only. 
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3.7.4 The silencing of MADP1 gene correlates to a reduction in virus titre and viral 
protein expression 
To further examine the impact of MADP1 silencing upon IBV replication in H1299 
cells, time course experiments were performed using IBV-Luc virus several times and 
the most representative set of data was chosen to be presented. The impact of MADP1 
gene silencing on IBV replication on general was analyzed by virus titration and viral 
protein production in addition to luciferase gene expression of cells infected with 
IBV-Luc virus. Monolayers of H1299 cells grown in 6-well plates to a confluency of 
30% was transfected with either siEGFP (control) or siMADP1 using DharmaFECT® 


























Figure 3.32: Silencing of MADP1 in Vero cells slightly reduced firefly luciferase 
activity produced by IBV-Luc infection. Vero cells transfected with siEGFP (control) 
or siMADP1 were infected with IBV-Luc virus. Luciferase activity of the cells were 
measured with 5 µl of lysate and expressed as Relative Luminescence Units per 
milliliter of lysate (RLU/ml). Samples measured were harvested at 0, 4, 8, 12, 16, 20, 
24 hours post infection (h.p.i.). Error bars with standard deviation between the 
readings were included but too narrow to be seen. Maximum luciferase activity in 
MADP1 silenced cells was less than 70% of what was achieved in control cells 




medium (with serum) 24 hours after the second transfection. The cells were infected 
72 hours after the first transfection and the virus was replaced with fresh serum-free 
medium 2 hours after infection.  
Viability of the transfected cells just before infection was determined to be 
approximately 92%, as assessed by cell counting coupled with trypan blue staining 
using Countess® Automated Cell Counter from Invitrogen (Carlsbad, CA, USA), for 
both types of transfected cells. Samples were harvested at 4, 8, 12, 16, 20 and 24 
hours post-infection with the appropriate method. For virus titration, the cells with its 
medium were subjected to three freeze/thaw cycles and 0 h.p.i. samples were 
harvested after 5 minutes of incubation with the virus at 37°C. Mock-infected samples 
were not collected for virus titration assay. For luciferase assay and viral protein 



























Figure 3.33: Replacement of culture medium after transfection increased luciferase 
activities of cells infected with IBV-Luc virus. Luciferase activity of the cells were 
measured with 5 µl of lysate and expressed as RLU/ml. Samples measured were 
harvested at 0, 4, 8, 12, 16, 20, 24 h.p.i.. Error bars with standard deviation between 
the readings were included but too narrow to be seen Maximum luciferase activity in 
MADP1 silenced cells was less than 6% of what was achieved in control cells 




As the experiment protocol was changed slightly, with the inclusion of an additional 
medium change 24 hours after the second siRNA transfection, 24 hours before the 
virus infection, the luciferase gene expression was assessed by luciferase assay using 
the cell lysate samples as shown in Figure 3.33. It was found to show a similar trend 
as reported in section 3.7.2 earlier.  
From the luciferase assay results, it appeared that the additional medium change 
included in the experiment increased the luciferase activities attained by the assayed 
samples and shifted the peak luciferase activity recorded for siEGFP transfected cells, 
from 20 h.p.i. to 16 h.p.i.. These observations could be an indication of an 
improvement in the general condition of the cells which resulted in greater infectivity 
of the virus in the transfected cells. In addition, there was a drastic drop in luciferase 
activity from 16 h.p.i. to 20 h.p.i. for siEGFP transfected cells which was due to the 
widespread detachment of infected cells as a result of cell death. This could also be 
attributed to the greater infectivity of the virus, resulting in a faster progression of 
infection compared to what was presented in Figure 3.31, which no such drastic 
change in luciferase activity was recorded.  
Virus titration was performed using an end-point dilution assay and calculating the 
50% tissue culture infectious dose (TCID50), or the dilution of virus at which 50% of 
cultured cells would be infected. Log10 TCID50 values calculated for samples 
harvested at each time point were plotted on a graph as shown in Figure 3.34.  
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The amount of virus present in the medium during infection (0 h.p.i.) was similar for 
both kinds of transfected cells and both of them experienced a drop in virus titre at 4 
h.p.i. to a similar level. The drop in virus titre was most likely due to the removal of 
virus at 2 h.p.i. compounded by degradation of input virus particles before progeny 
virus was produced. It was observed at the end of the infection (24 h.p.i.), siMADP1 
transfected cells produced a virus titre what was more than 10-fold lower compared to 
siEGFP transfected cells. The averaged peak virus titre produced by siMADP1 
transfected cells was also more than 10-fold below that of siEGFP transfected cells 
although both occurred at the same time point, 12 h.p.i.. These observations 
demonstrated that despite having a similar amount of input virus (0 and 4 h.p.i.), 
H1299 cells with less MADP1 protein expression produced virus titres that were 
consistently lower than cells which had normal MADP1 protein expression (from 8 




















Figure 3.34: The silencing of MADP1 gene expression reduced the production of 
infectious particles. Virus titres at each specified time point for both siEGFP and 
siMADP1 transfected cells were represented as log10 TCID50 values. Graph was 
plotted with the average values obtained from three titration assays and the error bars 
with standard deviation between the results were included. A representative result of 
four independent experiments was shown. 
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Western blot analysis on the viral structural proteins, 20 µl (10%) of lysate for each 
sample was resolved by SDS-PAGE using either an 8% or a 12% gel. For an 
assessment of viral protein production, the detection of IBV S and N proteins were 
performed with polyclonal serum antibodies, α-S and α-N. Polyclonal serum antibody 
to MADP1 (α-MADP1) was used to detect endogeneous MADP1. Actin and β-tubulin 
used as loading controls were detected with commercial antibodies, α-actin and α-β-
tubulin, respectively. Samples for 20 h.p.i. and 24 h.p.i. of siEGFP transfected cells 
(MADP1 (+)) were not included as most of the cells have detached by 20 h.p.i. so the 
total protein loaded would be too different from the rest of the samples. 
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Figure 3.35: The silencing of MADP1 in H1299 cells with siMADP1 reduced the 
expression of viral structural genes S and N drastically. Samples which expressed 
normal level of MADP1 (siEGFP transfected) were indicated with (+) and samples 
which had MADP1 silenced (siMADP1 transfected) were indicated with (-). 20 h.p.i. 
and 24 h.p.i. samples for siEGFP transfected cells were not included as most cells 




As depicted in Figure 3.35, viral structural protein, S, was only detectable in 
siMADP1 transfected cells (MADP1 (-)) from 16 h.p.i. onwards at extremely low 
levels and N protein from 12 h.p.i. onwards, also at a low level. Densitometric 
analyses on the blots indicated a reduction by more than 80% of structural protein 
expression in MADP1 (-) cells compared to siEGFP transfected cells (MADP1 
(+)).The expression of MADP1 was also reduced by about 50 to 80% in MADP1 (-) 
cells.  
These results corresponded well to the results from luciferase assays performed on the 
same samples (Figure 3.33) which indicated an extremely low level of viral protein 
production. Hence, it could be concluded that the silencing of MADP1 in H1299 cells 
on general exerted a great impact on the production of viral proteins and the progeny 
virus particles. 
3.7.5 Silencing of MADP1 with siRNA resulted in the absence of CPE upon IBV 
infection 
 Direct visualization of the infected cells at the stipulated time points was also 
conducted before the samples were harvested for the various analyses. Infected cells 
were observed by phase contrast microscopy at a magnification of 100X and images 
were captured with a digital microscope camera attached to the light microscope. 
Representative images captured four chosen time points, 0 h.p.i., 12 h.p.i., 16 h.p.i. 




H1299 transfected with siEGFP (control) exhibited cytopathic effects (CPE) from 12 
h.p.i. which reached a peak at 16 h.p.i. when all the cells formed syncytia, followed 
by the detachment of dead cells at 20 h.p.i..  The image captured of siEGFP 
transfected cells at 20 h.p.i. in particular supported the conclusion that the drastic drop 
of luciferase activity recorded for siEGFP transfected cells at 20 h.p.i. in section 3.7.4 
was due to the detachment of dead cells. Also, the peak luciferase activity recorded 
coincided with the attainment of 100% CPE in siEGFP transfected cells.  
CPE was conspicuously absent in cells transfected with siMADP1 at every time point 
observed which was a stark contrast to what was observed for the control experiment. 
This was true even at 20 h.p.i., when the peak luciferase activity was recorded in 
section 3.7.4 for the siMADP1 transfected cells. This observation indicated that the 
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Figure 3.36: Silencing of MADP1 using siRNA resulted in the absence of cytopathic 
effects (CPE) after infection with IBV-Luc virus. H1299 cells transfected with 
siEGFP exhibited regular CPE while none appeared in cells transfected with 




3.7.6 IBV RNA replication and transcription were reduced in MADP1-silenced cells. 
Samples for RNA analyses were also harvested using Trizol® from the same time 
course experiment described in section 3.7.4. RT-PCR was performed to amplify both 
positive and negative sense sgRNAs (mRNA 4 and 5) as well as negative sense gRNA 
(mRNA 1) as described in section 2.14. RT-PCR was not performed on 20 h.p.i. and 
24 h.p.i. siEGFP transfected samples (MADP1 (+)) as the infected most cells have 
already detached and no RNA could be extracted. The amplified PCR products were 
resolved by agarose gel electrophoresis using a 1% gel and stained by ethidium 
bromide as shown in Figure 3.37.  
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Figure 3.37: MADP1 silencing with siMADP1 reduced the amount of viral gRNA 
and sgRNAs produced. H1299 cells were transfected twice with siEGFP (MADP1 
(+)) or siMADP1 (MADP1 (-)) and infected with IBV-Luc virus. Samples were 
harvested at 4 h-intervals, and mock-infected cells were used as negative control. A 




The silencing of MADP1 expression using siMADP1 clearly diminished the amount 
of viral mRNAs produced during the infection by IBV-Luc virus. Densitometric 
analyses identified a reduction between 40-80% of MADP1 mRNA achieved by 
siMADP1 which varied between the time points assessed. The lower levels of 
MADP1 mRNA in siMADP1 transfected cells (MADP1 (-) samples) correlated with a 
reduction of between 70-90% of negative stranded viral gRNA (gRNA (-)), 40-80% 
of negative stranded sgRNA (sgRNA (-)) and 50-90% of positive stranded sgRNA 
(sgRNA (+)) compared to siEGFP transfected cells (MADP1 (+) samples). These 
observations point out the significance of MADP1 in viral RNA synthesis at an early 
stage, negative strand sgRNA synthesis. 
 
3.8 The Impact of MADP1 Silencing on IBV Infection using siRNA was not an 
Off-Target Effect 
The experiments conducted to assess the impact of MADP1 silencing on IBV 
infection were performed with a high concentration of siRNA with a single target 
sequence, siMADP1, which had not been tested for additional effects other than a 
reduction in MADP1 protein expression. Hence, an additional experiment was 
performed to rule out the possibility that the compromised infectivity phenotype seen 
in siMADP1 cells was not due to an off-target effect of the siRNA used.  
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3.8.1 MADP1 silencing using siRNA pools reduced luciferase gene expression in 
IBV-Luc infected H1299 cells 
Table 3.1: Volumes (in microlitres) of each 50 µM siRNA used in the different 
siRNA pool combinations. 
Combi/siRNA siMADP1 si1 si2 si3 si4 
siCombi1 0.5 0.5 0.5 0.5 0.5 
siCombi2 0.5 1 1 - - 
siCombi3 - 0.5 1 1 - 
siCombi4 - - 0.5 1 1 
siCombi5 1 - - 0.5 1 
siCombi6 1 1 - - 0.5 
 
Evaluation of the effect of MADP1 silencing on IBV-Luc virus infection was 
performed with siRNA pools composed of four commercial siRNAs and siMADP1, 
each targeting a different region of the MADP1 mRNA in different combinations. 
H1299 cells grown to a confluency of 30% were transfected twice with 250 pmoles of 
siEGFP, siMADP1 or one of the six siRNA pools (siCombi1 to 6), 24 hours apart. 
The composition of each siRNA pool is listed in Table 3.1. 
The medium containing the transfection mix was changed to fresh culture medium 
(containing serum) 24 hours after the second transfection and the cells were infected 
with IBV-Luc virus at MOI ≈ 1. Infected cells were harvested with 200 µl of Lysis 
Buffer at 20 h.p.i. and luciferase assay was performed to determine the firefly 
luciferase activity in each sample. 
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As shown in Figure 3.38, all siRNA pools used, which contained three out of a total 
of five siRNA duplexes, were able to reduce luciferase activity by more than 65% 
compared to siEGFP transfected cells. Marked reductions of luciferase activity by 
more than 90% was seen in four of the siRNA pools used (siCombi1, siCombi2, 
siCombi5 and siCombi6), which were comparable to what was achieved by 
homogeneous siMADP1. Although it was noted that combinations which did not 
contain siMADP1 (siCombi 3 and siCombi4) exhibited higher levels of luciferase 
activity (about 30% of siEGFP), the effect seen was still significant.  
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Figure 3.38: Silencing of MADP1 using different combinations of siRNA pools 
reduced luciferase expression from IBV-Luc recombinant virus. 250 pmol of either 
siRNA to EGFP or siRNA pools against Madp1 were transfected into H1299 cells 
twice and infected with IBV-Luc recombinant virus at 72 h after the first transfection. 
The averaged luciferase activity of siRNA pool or siMADP1 transfected cells were 
expressed as a percentage of what was obtained by siEGFP transfected cells and 
standard deviation of three separate measurements of each sample were included as 
error bars. A representative result of two independent experiments was shown. 
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3.9 Expression of a Silencing-Resistant mutant MADP1 in a stable MADP1 
Knock-Down Cell Clone Enhances IBV Replication 
A stable cell clone expressing short hairpin RNA to MADP1 (shMadp1), which had 
the same target sequence as siMADP1, was selected from H1299 cells. A stable cell 
clone expressing short hairpin RNA which does not target any human gene (shNC) 
was also selected from H1299 cells using the same conditions. The mRNA levels of 
MADP1 (madp1) and housekeeping gene GAPDH (gapdh) were confirmed using 
northern blot in Figure 3.39 which showed that madp1 was much lower in shMADP1 
cells compared to shNC cells.  
3.9.1 IBV RNA synthesis was reduced in stable MADP1 knock-down cells 
To ensure that the stable cell clone exhibits a similar phenotype to transiently silenced 
cells, the effect of MADP1 knock-down on IBV infection was established by 
comparing the amount of viral RNA synthesized during an infection in shMADP1 
cells with that of shNC cells. Both shMADP1 and shNC cells grown to confluency 
were infected with wild-type IBV virus and the virus-containing medium was 








 Figure 3.39: The mRNA level of MADP1 
in shMADP1 cells were much lower 
compared to shNC cells. Northern blotting 
of total RNA extracted from shNC and 
shMADP1 cells detected using DIG-labeled 
double-stranded DNA probes. A 
representative result of two independent 
experiments was shown. 
154 
 
20 h.p.i. and total RNA was extracted from each of them. 0 h.p.i. samples were 
harvested after 5 minutes of incubation with the virus-containing medium. Northern 
blot was performed using DIG-labeled double-stranded DNA probe which hybridizes 
to both positive and negative sense IBV 3’-UTR, present in all viral mRNAs. 
Housekeeping gene GAPDH mRNA (gapdh) was also detected to serve as a loading 
control. 
As presented in Figure 3.40, the results reflected that on general, silencing of MADP1 
with shMADP1 reduced the total viral mRNA production up to 16 h.p.i.. All species 
of sgRNA (mRNA 2 to mRNA 6) were equally affected. The amount of gRNA (mRNA 
1) was extremely low and the bands were too weak to be visualized, hence it was not 
indicated on the blot. The total amount of virus mRNA was higher in shMADP1 cells 
compared to shNC cells at 20 h.p.i. due to the greater efficiency of the virus infection 
in shNC cells which resulted in most cells having experienced cell death and have 
detached while the infection continued in shMADP1 cells which were still surviving. 
  
mRNA 2 
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Figure 3.40: The production of virus-specific mRNAs was reduced in shMADP1 cells 
compared to shNC cells. Northern blot of IBV infected shNC and shMADP1 cells 
showing viral mRNAs 2 to 6 and GAPDH mRNA (gapdh). A representative result of 
two independent experiments was shown. 
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3.9.2 Over-expression of silencing-resistant MADP1 in shMADP1 cells enhanced 
IBV replication  
The shMadp1 cells were transfected with constructs expressing FLAG-tagged wild 
type MADP1 (FM), triple residue mutant (FM(YVF)), two mRNA mutants resistant 
to silencing by shMADP1 based on wild type MADP1 (FMmut) and the triple residue 
mutant (FMmut(YVF)), negative vector controls expressing FLAG (F) and EGFP (E). 
The two silencing-resistant mutants were constructed by mutating the siRNA-
targeting sequence with degenerate codons at several positions, so that the protein 
sequence of MADP1 was maintained while rendering the mRNA resistant to the 
effect of the shRNA. The transfected cells were subsequently infected with IBV-Luc 
recombinant virus and harvested at 19 h.p.i. with 200 µl of Lysis Buffer.  
Western blot was performed and over-expressed MADP1 was detected with 
commercial α-FLAG-HRP antibody, IBV N protein was detected with a polyclonal 
serum antibody, α-N and loading control actin was detected with a commercial α-













Figure 3.41: Over-expression of shRNA-resistant MADP1 in stable MADP1 knock-
down cells (shMADP1) enhanced viral protein production. IBV N protein was used 
as an indicator of viral protein production and actin as a loading control. Over-
expressed MADP1 proteins were detected with an antibody to the FLAG-epitope tag. 
A representative result of five independent experiments was shown. 
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actin antibody. The results showed an obvious increase in the amount of IBV N 
expression in shMADP1 cells over-expressing silencing-resistant wild-type MADP1 
(FMmut) as well as a slight increase in cells over-expressing both normal triple 
residue mutant (FM(YVF)) and silencing-resistant triple residue mutant 
(FMmut(YVF)) (Figure 3.41).  
An assessment of the luciferase activity of total cell lysates presented in Figure 3.42 
showed that the over-expression of triple residue mutants FM(YVF) and 
FMmut(YVF) resulted in a slight increase of the luciferase activity in shMADP1 cells 
by about 15%. Over-expression of silencing-resistant wild-type MADP1 (FMmut) on 
the otherhand resulted in a more drastic increase of the luciferase activity, by about 
40% compared to control cells over-expressing FLAG (F) only. As expected, the 
over-expression of wild-type MADP1 (FM) did not result in a deviation from the 
luciferase activity recorded for cells over-expressing FLAG (F). It was however noted 
that the over-expression of EGFP resulted in a decrease of luciferase activity 
compared to FLAG expressing cells (F). This phenotype could have arisen from the 
cellular toxicity of the protein when expressed at high levels. 
The observations made in this section as well as section 3.8 provide evidence that the 
phenotype observed from the silencing of MADP1 in H1299 cells using siMADP1 
(sections 3.7.4, 3.7.5 and 3.7.6) on IBV infection was not the result of an off-target 
effect from the siRNA used. These findings affirmed the impact of MADP1 on 
coronavirus RNA synthesis through its interaction with the positive sense 5’UTR of 


































Figure 3.42: Over-expression of shRNA resistant MADP1 enhanced viral infectivity 
as indicated by the increase in luciferase activity. Averaged luciferase activity 
recorded for each cell lysate showed a marked increase in luciferase activity when 
silencing-resistant MADP1 was over-expressed in shMADP1 cells. Luciferase 
activity of FLAG over-expressing cells (F) was used as a benchmark for 100% 
activity. Luciferase activity recorded for cells expressing MADP1 proteins and 
EGFP were expressed as percentages of what was achieved for F. Standard deviation 
of three separate recordings was included. A representative result of five 
independent experiments was shown. 
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3.10 MADP1 Interacts Weakly with Human Coronavirus OC43 (HCoV-OC43) 
5’-UTR (+) 
The screen in which MADP1 was identified as a candidate that could interact with the 
coronavirus untranslated region was performed with the SARS-CoV 5’-UTR (+). It 
was later observed that although MADP1 interacted with both SARS-CoV and IBV 
5’-UTR using the biotin pull-down assay described in section 3.2.4, the interaction 
was rather weak for the former. A comparison of predicted stem loop I structures 
from both coronaviruses indicated a marked difference in both their primary sequence 
and secondary structure as illustrated in Figure 3.43. Hence, a third coronavirus, 
HCoV-OC43 (accession AY391777), whose stem loop I structure and sequence 
deviated further from IBV than SARS-CoV, was also assessed for its binding to 
MADP1.  
A biotin pull-down assay was performed using FLAG-MADP1 or EGFP over-
expressing H1299 cell lysates with biotinylated IBV, SARS-CoV or HCoV-OC43 
full-length 5’-UTR (+) probes. As shown in Figure 3.44, it was found that the binding 
of MADP1 to the 5’ UTR of HCoV-OC43 was as weak, if not weaker than SARS-
Figure 3.43: Predicted stem loop I structures from IBV, SARS-CoV and HCoV-
OC43. 




CoV. All three probes did not bind to negative control EGFP. A comparison of the 
predicted stem loop I structures revealed that the stem loop I of HCoV-OC43 
contained a bulge which encompassed a larger area of the stem compared to SARS-
CoV while bulges caused by unpaired bases in the stem region were conspicuously 
absent from the IBV stem loop I. In addition to the lack of structural similarity 
between the stem loop I of the three coronaviruses, there was a lack of sequence 






















































Figure 3.44: MADP1 binds weakly to both SARS-CoV and HCoV-OC43 5'-UTR (+) 
in a biotin pull-down assay. Biotin pull-down assay was performed using over-
expressed FLAG-MADP1 or EGFP (negative control) with biotinylated 5’-UTR (+) 
probes of the three coronaviruses. IBV 5’-UTR bound strongly to MADP1 while the 
other two probes only interacted weakly. Bound proteins were resolved by SDS-
PAGE with a 12% gel and western blot detection was performed with α-FLAG-HRP 
(FLAG-MADP1) or α-EGFP. A representative result of three independent 
experiments was shown. 
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3.11 MADP1 Interacts with IBV 3’-UTR (+) 
The interaction between MADP1 and the IBV 5’-UTR (+) had been studied in-depth 
in the earlier sections of this chapter but it was not known if MADP1 could interact 
with other untranslated regions of the IBV genome. HnRNP A1 as mentioned in 
section 1.3.5, was reported to be required for viral RNA transcription and could 
interact with multiple untranslated regions of the MHV genome in both polarity. 
Hence, it was of interest to investigate if MADP1 too, could interact with more than 
one untranslated region of the IBV genome. A biotin pull-down assay was performed 
with FLAG-MADP1 or EGFP (non-binding control) over-expressing H1299 cell 
lysate and biotinylated full-length IBV 5’-UTR (+), 5’-UTR (-) and 3’-UTR (+) 
probes. The proteins bound by the streptavidin beads were resolved by SDS-PAGE. 
Western blot was performed and FLAG-MADP1 was detected with α-FLAG-HRP, 

























Figure 3.45: MADP1 interacted 
strongly with both 5’-UTR (+) and 
3’-UTR (+) but weakly with 5’-UTR 
(-). MADP1 was co-purified with 
IBV 5’-UTR (-) at low efficiency 
and 3’-UTR (+) at high efficiency in 
a biotin pull-down assay. EGFP did 
not co-purify with any of the probes 
used. Biotin pull-down assay was 
performed with biotinylated RNA of 
the IBV 5’-UTR (+), 5’-UTR (-) and 
3’-UTR (+). Bound proteins were 
resolved using a 12% gel by SDS-
PAGE and detected using the 
appropriate antibodies by western 
blot. A representative result of three 





As illustrated in Figure 3.45, MADP1 bound to most efficiently to 5’-UTR (+) 
followed by 3’-UTR (+) with which it also exhibited strong binding, then 5’-UTR (-) 
which it bound relatively weakly. No binding was observed for EGFP to all 
biotinylated probes used in the assay. This piece of information emphasized the 





3.12 A Correlation of MADP1 Expression Level to IBV Infectivity could not be 
Established 
Gene expression profiles vary between different cell lines and the infectivity of 
viruses of each cells differs as well. It would certainly institute MADP1 as a critical 
genetic marker for infection susceptibility if a correlation could be established 
between its expression levels to the infectivity of the cell line by IBV. This prompted 
a trial experiment to assess expression level of MADP1 in several human cell lines 
(mostly of carcinoma origin) and to check if the cell lines could be infected by IBV 
virus. Adherent cells grown to between 90% and 100% confluency in 60 mm dishes 
were lysed with 200 µl of 2X SDS loading dye. Suspension cells were grown to 
confluency when clumping was observed, sedimented by centrifugation at 1000 rpm 
for 3 minutes then lysed. The cell lysates were resolved by SDS-PAGE and detection 
of MADP1 and loading control actin was performed using polyclonal serum antibody 
α-MADP1 and commercial α-actin antibodies.  
As shown in Figure 3.46, an interesting observation was made in the detection of 
higher molecular weight bands in the cell lines HuH-4 (hepato-cellularcarcinoma), 
MRC-5 (lung fibroblast) and Sk-Hep1 (hepato-adenocarcinoma) which was also 
present in H1299 (lung cancer). The molecular weight of the band suggested that it 
could be a dimer of MADP1 which could not be dissociated by the reducing agent 
DTT which was present in the loading dye. This was interesting as MADP1 did 
contain a RRM dimerization site at amino acid residues 83 and 84. Bands of 
molecular weights corresponding to neither the monomeric or dimeric mass of 
MADP1 were detected for the cell lines HCT116 (colorectal carcinoma), U937 
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(histiocytic lymphoma) and Y79 (retinoblastoma). As the identities of such higher 
molecular weight bands were unknown, it could only be speculated that they 
correspond to post-translationally modified MADP1. 
Table 3.2: Band densities of MADP1 (normalized with band densities of actin for 
each cell line) in 16 cell lines classified by tissue of origin. 
Tissue Cell Line (Band Density) Tissue Cell Line (Band Density) 
Liver 
Hep3B (0.13), HuH-4 (1.05), 
Sk-Hep1 (0.01), SNU475 
(0.01) 
Cervix HeLa (0.08) 
Lung A549 (1.5), H1299 (1.73), MRC-5 (0.02) CNS SH-SY5Y (0.10) 
Colon DLD-1 (7.83), HCT116 (2.01) Bone U2OS (0.08) 
Kidney 293T (2.42) Monocyte U937 (0.03) 
Breast MCF-7 (0.72) Retina Y79 (0.36) 
For densitometric analysis, only the band of the molecular mass 31 kDa was 

































































































Figure 3.46: Western blot showing the amount of MADP1 and actin in 16 different 
cell lines. Over-expressed (O/E) MADP1 was included as a control for MADP1 
detection by the antibody. Samples were resolved on two separate gels of the same 
percentage but antibody incubations and detection were performed together. A 
representative result of three independent experiments was shown. 
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the amount of actin detected for each cell line and the cell lines were classified by 
their tissue of origin in Table 3.2. 
CPE was observed in all cell lines except SNU475 (hepato-cellular carcinoma), U937 
and Y79. Cell death was observed in SH-SY5Y but it could not be determined if it 
was due to CPE or that the cells did not survive due to the removal of serum during 
infection. Extensive CPE was observed for 293T, H1299, HeLa, Hep3B, MRC-5, Sk-
Hep1 and U2OS. Moderate CPE was observed for DLD-1, HCT116 and HuH-4 and 
limited CPE was observed for A549. It appeared that tissues which do not form part 
of the normal tissue tropism of IBV could also be infected and that no clear 
relationship could be established between the infectivity of IBV and MADP1 
expression or the type of tissue the cells originated from. This could be partly due to 
the fact that almost all of the cells were derived from cancerous tissues, with the 
exception of MRC-5, which expressed an altered proteome that could include the 
differential expression of MADP1. Hence, the results derived from this trial 
experiment were inconclusive and a correlation between the expression of MADP1 
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Figure 3.47: All cell lines exhibited CPE upon IBV infection except SNU475, U937 
and Y79. Images captured of 16 different cell lines infected with IBV at 0 h.p.i. (top 
image) or 24 h.p.i. (bottom image). Extensive CPE was observed for 293T, H1299, 
HeLa, Hep3B, MRC-5, Sk-Hep1 and U2OS. Moderate CPE was observed for DLD-1, 
HCT116 and HuH-4. Low CPE was observed for A549 and no discernable difference 
was observed for SNU475, U937 and Y79. Cell death was observed for SH-SY5Y 
but it could not be determined if it was caused by CPE or the lack of serum. A 




Previous studies on the involvement of host proteins in viral RNA synthesis have 
revealed a number of proteins which are able to interact with the untranslated regions 
of viral genomes (299,307-309,314,340). Some of these proteins may also interact 
with other viral proteins as well (303,304).  
In this study, the interaction between human MADP1 and the SARS-CoV and IBV 5’-
UTR was initially identified in the yeast (S. cerevisiae) system and subsequently 
confirmed using an in vitro RNA pull-down assay with IBV 5’-UTR. MADP1 
(Genbank, BAB56132), a member of the U11/12 alternative snRNP of the minor 
spliceosome, was shown to be localized to the nucleoplasm but excluded from the 
nucleolus, but its role in RNA splicing remains to be determined (337). The GenBank 
entry of MADP1 stated that it contains two conserved RNA-binding domains, the 
RNA recognition motif (RRM) and universal minicircle sequence binding protein 
(UMSBP) domains (a zinc finger CCHC-type) (338). In addition, the GenBank entry 
for MADP1 also stated that the MADP1 RRM conserved domain interacts with 
nucleic acid residues via aromatic and hydrophobic side chains at its active site, which 
in the case supplied by phenylalanine 55 and valine 53, respectively. Tyrosine 13 may 
have acted as an anchor for the phosphate backbone via electrostatic interactions.  
A deeper look at the details of this interaction revealed that the RNA recognition 
motif, but not the zinc finger motif, of MADP1, is responsible for the interaction 
(Figure 3.26 and Figure 3.27). Using a competitive RNA binding assay based on the 
RNA pull-down assay, it was found that the interaction between MADP1 and IBV 5’-
UTR (+) was specific (Figure 3.19). This conclusion was derived from the 
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observation of a non-specific unlabeled RNA probe, EGFP (-), being unable to 
compete for binding to MADP1 with the biotinylated IBV 5’-UTR (+) probe. The 
three active-site residues predicted for MADP1 were also subsequently shown to be 
vital for MADP1 to bind IBV 5’-UTR (+) (Figure 3.28). These findings collectively 
asserted the interaction between MADP1 and the IBV 5’-UTR (+). In addition, the 
binding site for MADP1 on the IBV 5’-UTR had been determined in this study to be 
its stem loop I (Figure 3.22) and that the integrity of the stem loop structure is vital for 
the interaction to occur (Figure 3.24). 
Although MADP1 was reported to be a nuclear protein (338), it could be detected in 
the cytoplasm of IBV-infected cells by both indirect immunofluorescence and western 
blot. The staining pattern for MADP1 coincidentally, appeared to partially overlap 
with that of de novo synthesized viral RNA, which marks the location of the viral 
RTCs in infected cells, in the presence of actinomycin D. Although a colocalization of 
MADP1 and viral RTCs could not be established, it was clear that MADP1 
translocated to the cytoplasm during IBV infection.  
Functional studies were conducted and it was found that the silencing of MADP1 
resulted in a marked reduction in syncytium formation upon IBV infection (Figure 
3.36). A closer examination revealed that the synthesis of both gRNA and sgRNAs 
was compromised (Figure 3.37), resulting in a drastic reduction of viral structural 
protein expression and release of progeny virus particles, hence the overall reduction 
of viral infectivity in the cells. Hence, it could be concluded that MADP1 is required 
for viral RNA synthesis, including negative-strand synthesis, which occurs via 
discontinuous transcription.  
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As the functional studies were conducted using an untested, homogeneous siRNA, it 
was not known if the phenotype observed from the silencing was due to an off-target 
effect of the siRNA sequence used. A validation experiment using siRNA pools 
targeting different regions of MADP1, which was meant to minimize off-target effects 
(Figure 3.38). The results showed that the phenotype of reduced viral infectivity was 
reproducible with different siRNAs targeting the same gene.  
Across different coronaviruses, the leader sequence situated in the extreme 5’ end of 
the genome, is composed of stem loops I and II. Mutations introduced into either stem 
loop I or II resulted in non-viable viruses, impaired (sense and anti-sense) sgRNA 
synthesis, but not the full-length gRNA synthesis (74,75). It was, however, observed 
in this study that silencing of MADP1 did render an impact on gRNA synthesis, 
although to a lesser extent compared to sgRNA synthesis. This might have been a 
secondary effect of decreased sgRNA synthesis, as proteins encoded by sgRNAs may 
enhance viral RNA replication (135), or gRNA synthesis.  
The leader sequence of coronaviruses spans the first two stem loops of the 5’-UTR, 
nucleotide residues 1 to 64 in IBV. The predicted structure of stem loop II indicated a 
strong secondary interaction, which is highly conserved across different groups of 
coronaviruses. The predicted stem loop I structure, on the other hand, appears to fold 
into a hairpin of low thermodynamic stability, shows a wider sequence variation and 
is characterized by the presence of bulges, non-canonical base pairing as well as a 
prevalence of A-U base pairing (341). It has been shown in MHV that the structural 




Comparing the predicted stem loop I structures of IBV to SARS-CoV and HCoV-
OC43 (Figure 3.43), it was noted that there exists a difference in the loop sequence. In 
addition, IBV stem-loop I has a shorter stem and bulges are conspicuously absent, 
although the structure may be as unstable thermodynamically as that of SARS-CoV 
and HCoV-OC43, due to the extremely high prevalence of weak base pairing between 
A and U as well as the presence of a non-canonical base pair at the base of the stem 
(341). A trial experiment revealed that betacoronaviruses HCoV-OC43, SARS-CoV 
and gammacoronavirus IBV 5’-UTR (+) all bound to MADP1, albeit with different 
affinities (Figure 3.44). Hence, sequence and structural differences may be one of the 
possible explanations for the observation of a weaker binding between MADP1 and 
SARS-CoV or HCoV-OC43 5’-UTR than with IBV 5’-UTR. In fact, the relatively 
weaker binding of MADP1 to the stem loop I restoring mutant (5’-UTRΔ2M2) 
demonstrated in this study (Figure 3.24) supports that primary sequences in the 5’-
UTR may play a certain role in this interaction.  
While it seems that the strength of interaction between MADP1 and the coronavirus 
5’-UTR is likely dependent upon both primary sequence and secondary structure of 
the RNA, the functional implication of the relatively weaker interaction between 
SARS-CoV 5’-UTR and MADP1 remains to be determined. This was not completed 
due to the lack of a higher containment facility required for the handling of live 
SARS-CoV. It is, therefore, yet to be demonstrated if this weaker binding dictates less 
dependency on MADP1 in SARS-CoV RNA replication and infectivity.  
It was shown in section 3.11, in a trial experiment that MADP1 not only interacts with 
IBV 5’-UTR (+), it could also interact with other untranslated regions of the IBV 
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genome, strongly with the 3’-UTR (+) and weakly with 5’-UTR (-) (Figure 3.45). 
This new finding seemed to support the proposed function of MADP1 in viral 
negative-strand synthesis as hnRNP A1, a very well documented host protein for its 
function in MHV RNA synthesis, also interacted with coronavirus MHV genome at 
multiple regulatory regions (299). This common trait of multiple-site interactions 
between the hnRNP A1 and MADP1 with coronavirus MHV and IBV genomes 
respectively, could possibly facilitate the occurrence of template-switching during 
discontinuous transcription. The interaction of MADP1 with the other untranslated 
regions of IBV, especially the 3’-UTR (+), would need to be further characterized to 
confirm this finding before any conclusions could be drawn. 
Current evidence indicates that MADP1 is compartmentalized in the nuclei of 
cultured cells (338), markedly differing from the cytoplasmic, perinuclear localization 
of the coronavirus RTCs (342-344). As there was no report on the possibility of 
MADP1 shuttling between the nucleus and cytoplasm, our observation using indirect 
immunofluorescence that over-expressed MADP1 upon IBV infection became 
partially localized in the cytoplasm may represent a first report that MADP1 could be 
localized outside the nucleus (Figure 3.15 and Figure 3.17). This could have been 
achieved with either an existing shuttling mechanism used by a nuclear protein or the 
assistance of viral factors. For example, IBV N protein is known to enter the nucleus 
while maintaining a predominantly cytoplasmic localization (232,345). Alternatively, 
binding of viral RNA may partially retain the newly synthesized MADP1 in the 
cytoplasm, as observed in this study.  
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It was observed that the over-expression of Flag-tagged MADP1 was unable to fully 
restore IBV infection in MADP1-knockdown cells, even though the expression level 
of the introduced MADP1 construct far surpassed the endogenous level, as observed 
by Western blot analysis. Considering the fact that only 30% of cells were transfected 
and over-expressed MADP1 protein despite the presence of a higher level of the 
protein in the transfected cells, it is understandable that the expression of viral 
proteins could not be restored after combining both transfected and untransfected 
cells. Interestingly, over-expression of silencing-sensitive MADP1 (FM) was unable 
to cause an increase in virus infection, comparing to what was observed for silencing-
resistant MADP1 (FMmut) in shMadp1 cells, even though their expression levels 
were comparable. This lends further support to the conclusion that MADP1 is actively 
involved in the replication and infectivity of IBV. 
It was found that the expression level of MADP1 could not be correlated to 
originating tissues of different cell lines. A correlation of MADP1 expression levels to 
the infectivity of IBV in the different cell lines was also unable to be established. Cell 
lines which originated from tissues not part of the regular tissue tropism of IBV could 
be infected as well. Hence, no clear relationship could be established between the 
infectivity of IBV and MADP1 expression or the type of tissue the cells originated 
from. This was most probably due to the fact that almost all of the cells were derived 
from cancerous tissues, with the exception of MRC-5. Such cell lines would express 
an altered proteome that could also include the differential expression of MADP1.  
In a prior report, it was shown that MADP1 could be selectively upregulated in the 
hepatocarcinoma cell line, HepG2, compared to normal liver cells (338). Hence, the 
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results derived from this trial experiment were inconclusive and a correlation between 











Chapter 4 Interaction Between Non-Structural Proteins With Viral 




As mentioned earlier in Chapter 3, efficient replication and transcription of the viral 
genome is required for infection to progress. The key player in this part of the 
coronavirus life cycle is the virus-encoded replicase gene. Replicase gene, the 5’-most 
ORF of the coronavirus genome is translated into the polyproteins pp1a and pp1ab 
which are auto-proteolytically processed into 15 (IBV) or 16 non-structural proteins 
in other coronaviruses, the replicase gene products. Among these non-structural 
proteins are the key enzymes critical to the virus’ ability to replicate its genome and 
propagate in the host cell, including the RNA-dependent RNA polymerase (RdRP) or 
nsp12, which is presumably central to the ability of the coronavirus to synthesize viral 
mRNAs. 
Enzymatic activities required for most of the key processes in coronavirus RNA 
synthesis have been mapped to the some of the non-structural proteins. However, 
information on their specific interactions with the viral genome or other non-structural 
proteins is limited. In addition, it is not known if the non-structural proteins which 
were not yet assigned with key functions in coronavirus RNA synthesis could be 
participating in viral RNA replication or transcription. 
Hence, a two-pronged approach was adopted to study viral proteins and protein-RNA 
interactions in coronavirus RNA synthesis. To elucidate RNA-protein interactions, an 
attempt was made to detect the presence of RNA-binding activity in any of the non-
structural proteins of IBV, which had not been reported to possess such an activity. 
This was done using available constructs over-expressing individual non-structural 
proteins in a biotin pull-down assay with biotinylated probes. The second method 
175 
 
used was to conduct a screen for protein-protein interactions between non-structural 
proteins and the viral polymerase, nsp12. 
 
4.1 Biotin pull-down screen for RNA-binding activity of non-structural proteins 
Plasmids based on the vector pXJ40-FLAG inserted with nucleotide sequences of the 
non-structural proteins either in tandem (nsp7/8 fusion and nsp8/9 fusion) or 
individually were used to over-express the proteins in H1299 cells coupled with 
Vaccinia/T7 virus infection. The cell lysates were used in biotin pull-down assays 
with biotinylated 5’-UTR (+), 5’-UTR (-) or 3’-UTR (+) RNA probes. As the focus of 
the study was on negative strand RNA synthesis, only the positive sense UTRs and 
the 5’-UTR (-), which contains the anti-leader TRS important for strand-transfer 
during discontinuous transcription of negative strands, were included in the screen. 
The proteins bound to the streptavidin beads were resolved by SDS-PAGE and 
detected by western blot using α-FLAG-HRP antibody. Negative control, non-binding 
protein, EGFP was also included in each screen. 
4.1.1 Non-structural proteins nsp2, nsp5 and nsp10 may interact with IBV 5’-UTR (+) 
For the screen conducted using biotinylated, IBV 5’-UTR (+), individual non-
structural proteins, two fusion proteins, nsp7/8 and nsp8/9, and EGFP were over-
expressed in Vaccinia/T7 recombinant virus infected H1299 cells on 60 mm dishes. 
Cells were lysed with 250 µl Lysis Buffer and used immediately. Biotin pull-down 
assay was performed with 0.1 µM (final concentration) biotinylated IBV 5’-UTR (+) 
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probe with 150 µl cell lysate. Streptavidin beads were used to purify the biotinylated 
RNA from the mixture and additional proteins bound to the beads through interactions 
with the bound RNA were eluted with 2X SDS loading dye. For western blot analysis, 
10 µl of cell lysate and all of the eluted proteins were denatured and resolved by SDS-
PAGE. Detection of the FLAG-tagged non-structural proteins and EGFP were 
performed with α-FLAG-HRP antibody and α-EGFP antibody respectively. 
As shown in Figure 4.1, the non-structural proteins that were able to co-purify with 
the biotinylated probe in the assay were nsp2, nsp10 and to a lesser extent, nsp5. The 
clones for nsp8 and nsp9 were not available at the time of this assay so only the fusion 
proteins nsp7/8 and nsp8/9 were used. Non-structural proteins that were not shown 
were either not detectable in the cell lysate, in the case of nsp6 and nsp13, or not 










C    E     C    E   C  E   C    E      C   E    C    E  C   E  C   E   C  E    C   E   C   E 
EGFP     nsp2   nsp5     nsp7     nsp7/8 nsp8/9 nsp10 nsp12 nsp14  nsp15 nsp16 
Figure 4.1: IBV nsp2, nsp5 and nsp10 showed binding activity to its 5’-UTR (+). 
Biotin pull-down assay of non-structural proteins with IBV 5’-UTR (+). Cell lysates 
of H1299 cells ver-expressing different non-structural proteins were incubated with 
biotinylated 5’-UTR (+) probes and purified using streptavidin beads. Bound proteins 
were resolved by SDS-PAGE and western blot was performed. Proteins which did 
not express were not presented. C: cell lysate, E: elution. A representative result of 
two independent experiments was shown. 
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4.1.2 Non-structural proteins nsp5 and nsp10 may interact with IBV 5’-UTR (-) 
All non-structural proteins except nsp3, nsp4, nsp6, nsp13 and EGFP were over-
expressed in Vaccinia/T7 recombinant virus infected H1299 cells grown on 60 mm 
dishes. The cell lysates were used in biotin pull-down assays with biotinylated 5’-
UTR (-) probe to screen for interacting proteins. Proteins which co-purified with the 
biotinylated RNA probe were eluted from the beads with 2X SDS loading dye and 
resolved by SDS-PAGE. Detection was performed as described in section 4.1.1 and 
the result for this set of biotin pull-down assays is presented in Figure 4.2. 
For this screen, the expression of nsp12 although detectable, was extremely weak, 
hence it could not be determined if it co-purified with IBV 5’-UTR (-). As the 
expression level of nsp2 was too low to be detected for this particular screen, it was 
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EGFP    nsp5      nsp7      nsp8      nsp9    nsp10   nsp12   nsp14   nsp15   nsp16 
Figure 4.2: IBV nsp5 and nsp10 showed binding activity to its 5’-UTR (-). Biotin 
pull-down assay of non-structural proteins with IBV 5’-UTR (-). Cell lysates of 
H1299 cells ver-expressing different non-structural proteins were incubated with 
biotinylated 5’-UTR (-) probes and purified using streptavidin beads. Bound proteins 
were resolved by SDS-PAGE and western blot was performed. The expression of 
nsp2 was not detectable for this assay and was excluded. C: cell lysate, E: elution. A 
representative result of two independent experiments was shown. 
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non-structural proteins nsp5 and nsp10 were found to be interacting with IBV 5’-UTR 
(-). 
4.1.3 Non-structural proteins nsp5, nsp8 and nsp9 may interact with IBV 3’-UTR (+) 
For the last screen for non-structural proteins interacting with IBV 3’-UTR (+), all 
non-structural proteins except nsp3, nsp4, nsp6, nsp13 and EGFP were over-
expressed in Vaccinia/T7 recombinant virus infected H1299 cells grown on 60 mm 
dishes. The cell lysates were used in biotin pull-down assays with biotinylated 3’-
UTR (-) probe and proteins which copurified with the biotinylated RNA probe were 
eluted from the beads with 2X SDS loading dye, resolved by SDS-PAGE and 








 C   E   C   E   C   E    C    E   C   E   C   E    C   E    C   E   C   E  C   E   C  E 
EGFP   nsp2    nsp5    nsp7    nsp8    nsp9   nsp10   nsp12 nsp14 nsp15 nsp16 
Figure 4.3: IBV nsp5, nsp8 and nsp9 showed binding activity to IBV 3’-UTR (+). 
Biotin pull-down assay of non-structural proteins with IBV 3’-UTR (+). Cell lysates 
of H1299 cells ver-expressing different non-structural proteins were incubated with 
biotinylated 3’-UTR (+) probes and purified using streptavidin beads. Bound proteins 
were resolved by SDS-PAGE and western blot was performed. C: cell lysate, E: 
elution. A representative result of two independent experiments was shown. 
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As presented in Figure 4.3, nsp5 showed strong interaction , nsp8 and nsp9 showed a 
moderate level of interaction with IBV 3’-UTR. The expression levels of nsp2, nsp12 
and nsp14 for this assay were too low for any RNA-binding to be observed and it 
could not be concluded if they interacted with the biotinylated probe. 
4.1.4 Candidates identified from the screen which could interact with IBV 5’-UTR 
(+), 5’-UTR (-) or 3’-UTR (+) 
In summary, out of the 11 non-structural proteins tested, only nsp2, nsp5, nsp8, nsp9 
and nsp10 were able to interact with one or more of the untranslated regions of IBV. 
Out of these five replicase gene products, only nsp2 and nsp5 have not been reported 
to possess RNA-binding activity. Existing literature reported that the coronavirus 
nsp8 possessed non-specific RNA-dependent RNA polymerase activity and was 
proposed to function as a primase, synthesizing short ribonucleotide chains, or 
primers, which are required for transcription initiation by the coronavirus RNA-
dependent RNA polymerase nsp12 (103). This implied that nsp8 could bind to RNA 
in a non-specific manner. Although it was not surprising to find nsp8 interacting with 
IBV 3’-UTR (+), it was noted that the interaction observed was very weak and was 
not detected for all three RNA probes tested. This could have resulted from 
experimental variance if nsp8 could weakly bind RNA non-specifically as the three 
screens were not conducted at the same time. 
The coronavirus nsp9 was shown to be a weak, non-specific single-stranded nucleic 
acid binding protein (ssDNA and ssRNA) (106,108). Hence, it was interesting that 
nsp9 was found to interact weakly only with IBV 3’-UTR (+) and not at all with the 
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5’-UTR in both polarity. As nsp9 had not been proven not to bind specifically with 
particular regions of the coronavirus genome, there is still a possibility of it being able 
to bind RNA in a specific manner and that the 3’-UTR (+) could have been its specific 
interaction partner. Conversely, the low affinity binding could imply that the weak 
affinity binding to the biotinylated probe was of a non-specific nature. Further studies 
would be required to verify the specificity of the interaction. 
The crystal structure of nsp10 showed that it contains two zinc-finger motifs (109), 
forms a dodecameric complex (110) and functions as a stimulatory factor to nsp16, 
the 2’-O-methyltransferase which catalyzes the conversion of the cap-0 structure on 
m7GpppA-RNA to a cap-1 structure (121). It was also shown to exhibit low-affinity 
binding to single stranded RNA (ssRNA), double stranded RNA and DNA (dsRNA 
and dsDNA) in the absence of other viral proteins (109). Hence, in a case similar to 
nsp9, the binding of nsp10 to IBV 5’-UTR (-) could also be of low-specificity. 
Nsp2 was found to interact with IBV 5’-UTR (+) and it could not be concluded if it 
bound to IBV 5’-UTR (-) and 3’-UTR (+). Although nsp2 was not reported to be a 
RNA-binding protein, it had been demonstrated as a weak antagonist of PKR 
antagonist (219), a dsRNA-activated kinase. The mechanism of this antagonism has 
yet to be determined hence nsp2 acting as a competitive dsRNA-binding protein to 
prevent PKR activation by dsRNA synthesized by the virus during replication and 
transcription is not beyond the bounds of possibility.  
It was intriguing to find nsp5 interacting with all three probes tested, of which its 
interactions with the 5’-UTR (-) and 3’-UTR (+) were rather strong. Nsp5 is a 3C-like 
protease, one of the proteases involved in the proteolytic processing of the replicase 
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gene products. Having no prior reports of it possessing RNA-binding activity, this 
represents a novel piece of information with regards to the function of nsp5 in 
addition to its role as a protease if the interactions could be validated. Hence, nsp5 
along with nsp2 were chosen to have their RNA-binding activity assessed again to 
confirm the interactions. 
4.1.5 Interactions of nsp5 with viral RNA could not be confirmed and nsp2 exhibited 
weak binding for viral RNA 
Biotin pull-down assays were performed for nsp2 and nsp5 with biotinylated RNA 
probes of IBV 5’-UTR (+), 5’-UTR (-) and 3’-UTR (+) to confirm if the interactions 


























































) A         B 
Figure 4.4: IBV nsp2 was confirmed to interact weakly with the single stranded viral 
UTRs. Selected results of repeated biotin pull-down assays performed for nsp2. The 
efficiency of RNA-binding for nsp2 was generally low. Binding to IBV 3’-UTR (+) 
could only be detected when a higher amount of nsp2  was present in the lysate. Panel 
A: High nsp2 expression. Panel B: Low nsp2 expression. Two representative results 
of four independent experiments were shown. 
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were performed several times for both proteins and it was found that the expression 
level of nsp2 differs between different experiments. This could have been due to the 
pronounced effect of different transfection efficiencies more visible when the 
expression was generally low.  Figure 4.4 shows two sets of results of the biotin pull-
down assays performed for nsp2.  
On the otherhand, the expression level of nsp5 in the cell lysate was generally high 
enough for detection by western blot. However, as shown in Figure 4.5, the RNA-
binding efficiency of nsp5 appeared to be much weaker (Panel A) at best or even 
nullified (Panel B). 
The results from these confirmatory interaction pull-down assays indicated that nsp2 
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Figure 4.5: IBV nsp5 was not confirmed to interact with the single-stranded viral 
UTRs. Selected results of repeated biotin pull-down assays performed for nsp5. Panel 
A: low efficiency RNA-binding was observed for nsp5.  Panel B: no RNA-binding 
was detected for nsp5 in this experiment. Two representative results of five 
independent experiments were shown. 
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to be verified. As it could interact weakly with both strands of the IBV 5’-UTR, there 
lies a possibility that it may bind to a double-stranded 5’-UTR. These would need 
further confirmation with other assays using dsRNA probes instead. However, the 
proposed function of a dsRNA-binding nsp2 would most likely be linked to PKR 
antagonism, which was not the aim of the study, no follow up was planned. 
Additional assays performed for nsp5 painted a completely different picture for the 
RNA-binding activity of the protein. Most of the repeated assays performed for nsp5 
showed no RNA-binding for any biotinylated probe tested and it was likely that nsp5 
did not bind RNA and the bands observed during the screen could be an experimental 
artifact. 
 
4.2 Screen for non-structural proteins interacting with nsp12 
An IBV recombinant virus which expressed N-terminally HA-epitope tagged nsp12 
(HA-RdRP recombinant virus) was created by another lab member using reverse 
genetics. This virus was used to infect confluent Vero and H1299 cells to prepare the 
infected cell lysates for the screen. The expression level of nsp12 in Vero cells 
infected with wild-type IBV or HA-RdRP recombinant IBV as well as its IP 
efficiency with α-HA coated beads (HA-beads) was determined by western blot using 
a polyclonal serum antibody to nsp12 (α-RdRP) before the screen. This was done to 
ensure that the protocol was able to precipitate the HA-tagged protein efficiently 
enough for detection of other coprecipitated proteins.  
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As shown in Figure 4.6, the expression of nsp12 and HA-nsp12 in wild-type virus and 
HA-RdRP virus infected cells were comparable and only HA-nsp12 was precipitated 
by HA-beads. 
4.2.1 Nsp8 coprecipitated with nsp12 
Confluent Vero and H1299 cells grown in 80 cm2 flasks were infected with either 
wild-type IBV or HA-RdRP recombinant IBV. The cells were harvested at 9 h.p.i. 
and 16 h.p.i. for Vero, at 9 h.p.i. for H1299 by lysis with 800 µl of Lysis Buffer for 
each flask. HA-beads (20 µl of 50% slurry) were added to 500 µl of each lysate to 
precipitate HA-nsp12 and any other interacting proteins from the lysates. The bound 
proteins were eluted with 55 µl of 2X SDS loading dye and resolved by SDS-PAGE 
using an 8% or 15% gel (20 µl per lane) together with 20 µl of each cell lysate. 
Detection of coprecipitated proteins was performed by western blot using available 
anti-sera for some non-structural proteins of IBV as well as structural proteins S and 







wt        HA         wt       HA 
lysate                    IP Figure 4.6: Only HA-nsp12 was 
present in the sample after IP with 
HA-beads. Western blot showing 
nsp12 detected by serum antibody, 
α-RdRP in the cell lysates (lysate) 
of wild-type (wt) IBV or HA-
RdRP recombinant (HA) IBV 
infected Vero cells and after 
immuno-precipitation with HA-
beads (IP). A representative result 





The results of the co-IP detection were presented in Figure 4.7 and Figure 4.8 for 
H1299 cells and Vero cells respectively. Many of the anti-sera used were unable to 
detect the correct bands in the cell lysates which could be due to the low expression 
level of the proteins during IBV infection in addition to the low levels of antibody in 
the serum. For the structural proteins, S was not detected in the IP samples and N was 
detected in both wild-type (wt) and HA-RdRP recombinant (HA) IBV infected cells. 
Although it appeared that the amount coprecipitated in HA-RdRP IBV infected 
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samples was higher compared to wild-type IBV infected samples, the amount detected 
in the cell lysates was also higher. So it was unlikely for N to have been specifically 
coprecipitated by an interaction with nsp12.  
Nsp5 was strongly detected in the cell lysates but a band corresponding to its 
molecular mass was not detectable in the IP samples although many other bands were 
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lysate           IP                       lysate          IP 
nsp5                                      nsp8                                     nsp10 
N                                           S 
Figure 4.7: IBV nsp8 co-precipitated with nsp12 in infected H1299 cells. Western 
blot detection of IBV proteins with serum antibodies to the respective proteins in the 
cell lysates (lysate) of wild-type (wt) or HA-RdRP recombinant IBV (HA) infected 
H1299 cells and samples after immunoprecipitation with HA-beads (IP) . Only serum 
antibodies which were able to detect the correct bands in the lysates were presented. 
Positions of the bands were indicated by arrowheads. Anti-sera which were used but 
not presented were for the following proteins: nsp2, nsp3, nsp3/4 , nsp7, nsp13, ORF 




undetermined mass was detected in HA-beads precipitated samples. The identity of 
the band was likely a partially processed product of pp1a or pp1ab, which included 
nsp5 that was detected by the antibody. Nsp8 was detected by the anti-sera to be 
present in only HA-beads precipitated HA-RdRP IBV infected cell lysates and not 
HA-beads precipitated wild-type IBV infected cell lysates. The co-precipitation was 
detected in both H1299 and Vero cells. Hence, nsp8 was the only protein found to be 
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wt HA wt HA      wt HA wt HA 
(h.p.i.)   16        9              16         9                             16        9              16         9  
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nsp5                                                               nsp8 
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IP                                                                    IP 
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N                                                                    S 
IP                                                                  IP 
Figure 4.8: IBV nsp8 co-precipitated with nsp12 in infected Vero cells. Western blot 
detection of IBV proteins with serum antibodies to the respective proteins in the cell 
lysates (lysate) of wild-type (wt) or HA-RdRP recombinant IBV (HA) infected Vero 
cells and samples after immunoprecipitation with HA-beads (HA). Only serum 
antibodies which were able to detect the correct bands in the lysates were presented. 
Positions of the bands were indicated by arrowheads. Anti-sera which were used but 
not presented were the same as that for H1299 infected cells. A representative result 
of two independent experiments was shown. 
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4.2.2 The co-precipitation of nsp8 and nsp12 is confirmed 
To confirm if nsp8 interacts with nsp12, the IP of nsp12 was repeated with HA-beads. 
In addition, a reciprocal precipitation was performed using anti-nsp8 serum antibody. 
The lysates were prepared as described in section 4.2.1 except that the cells were only 
harvested at 9 h.p.i.. The bead-bound proteins were eluted with 55 µl 2X SDS loading 
dye and resolved by SDS-PAGE using an 8% or 15% gel (20 µl per lane) together 
with 20 µl of each cell lysate. Detection of nsp8 was performed for proteins 
precipitated by HA-beads and the detection of nsp12 was performed for proteins 
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Vero                   H1299                                Vero                  H1299 
 
Figure 4.9: IBV nsp8 coprecipitates with HA-nsp12 and vice versa. Immuno-
precipitation of wild-type IBV (wt) or HA-RdRP (HA) recombinant IBV infected 
Vero and H1299 cell lysates. Immuno-precipitation was performed with either α-
nsp8 (rabbit serum) (left panel) or HA-beads (right panel). Detection of nsp8 (right 
panel) and nsp12 (left panel) were performed with α-nsp8 and α-HA-HRP antibodies 
respectively and their positions were indicated by arrowheads. A representative result 
of three independent experiments was shown. 




As observed from the results of the IP in Figure 4.9, in addition to the detection of 
HA-nsp12 in HA-RdRP recombinant IBV infected cell lysate after precipitation with 
α-nsp8, a band corresponding to a similar molecular mass was also detected in wild-
type IBV infected cell lysates after precipitation (very weak for H1299).  
A closer examination revealed that there was an additional band detected in all cell 
lysates of a molecular mass slightly higher than HA-nsp12 (left panel). Hence, to 
confirm that the band predicted to be HA-nsp12 was accurate, and that the higher 
molecular weight band was indeed a non-specific band detected by the antibody, the 
blot for IP using HA-beads was checked for the presence of HA-nsp12 using α-HA-
HRP antibody. The blot depicted in Figure 4.10 detected the same band in all lanes 
which were loaded with IP samples. Hence, the band was confirmed to be a non-
specific band detected by the antibody used for western blot. Since the additional 
band was confirmed to be non-specific, the observation that nsp12 was coprecipitated 








wt  HA    wt  HA wt  HA    wt  HA                  
 
lysate           IP: α-HA          lysate 
 
Vero                     H1299   
  
WB: α-HA      
 
Figure 4.10: Higher molecular 
weight band observed from 
the IP was a non-specific 
band. Cell lysates precipitated 
with HA-beads was probed 
with α-HA-HRP antibody. A 
representative result of three 




Although the interaction between nsp8 and nsp12 had been reported before for SARS-
CoV (133), it was not reported in other coronaviruses and the interaction had not been 
subjected to an in-depth study. Hence, the interaction between nsp8 and nsp12 was to 
be further characterized. 
4.2.3 The interaction between nsp8 and nsp12 is not RNA-dependent 
IP was performed using co-expressed nsp8 and nsp12 to confirm their interaction. The 
proteins were co-expressed as a FLAG-tagged protein for nsp8 (FLAG-nsp8) and a 
Myc-tagged protein for nsp12 (Myc-nsp12) in H1299 cells infected with Vaccinia/T7 
virus. As controls, dual vector transfected samples (FLAG + Myc) and single vector 
transfected samples (FLAG-nsp8 + Myc and FLAG + Myc-nsp12) were used. The IP 
was performed with α-Myc coated beads (Myc-beads) and the bound proteins were 
resolved by SDS-PAGE together with 20 µl of the cell lysates. Western blot (WB) 
was performed using α-FLAG-HRP and α-Myc-HRP antibodies to detect the 
precipitated proteins as shown in Figure 4.11. 
FLAG-nsp8 was detected at almost equal amounts whether it was expressed together 
with Myc only (FLAG-nsp8 + Myc) or with Myc-nsp12 (FLAG-nsp8 + Myc-nsp12) 
but was detected in the IP samples only when it was co-expressed with Myc-nsp12 
(Figure 4.11, left panel. The ≈ 50 kDa band detected in all IP samples was likely to be 
the heavy chain eluted from the beads during sample preparation for SDS-PAGE. 
Also, Myc-nsp12 was detected in both the cell lysates and IP samples (Figure 4.11, 
right panel). As the appearance of FLAG-nsp8 in the IP sample occurred only in the 
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presence of Myc-nsp12, it was be concluded that FLAG-nsp8 was coprecipitated with 
Myc-nsp12 by interacting with it. 
Nsp8 was shown to be exhibit RNA-binding activity in section 4.1.3 earlier and was 
also reported by other groups to function as a primase for the viral RdRP, nsp12. 
Since both of them are RNA-synthesizing enzymes and would likely be interacting 
with viral RNA and it was not known if their interaction was direct or RNA-
dependent. Hence, another IP was performed with cell lysates that were either treated 
(+RNase A) or not treated (-RNase A) with 50 µg/ml of RNase A at 37°C for one 
hour before the addition of α-Myc (Myc-beads) or α-FLAG (FLAG-beads) coated 



















































































































































































WB: α-FLAG              WB: α-Myc 
 
Figure 4.11: FLAG-nsp8 was precipitated by Myc-beads only when it was co-
expressed with Myc-nsp12. Western blot detection was performed with α-FLAG (left 
panel) and α-Myc (right panel) antibodies. IP: immuno-precipitated samples, WB: 
western blot. A representative result of two independent experiments was shown. 
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RNase A treatment, nsp8 was still precipitated when RNA had been removed. Hence, 
it was confirmed that nsp8 interacts directly with nsp12 and not indirectly through 





























































































































































































 IP: α-FLAG 
WB: α-FLAG                      WB: α-Myc 
 
Figure 4.12: FLAG-nsp8 and Myc-nsp12 co-precipitates with or without RNase A 
treatment. RNase A treated or untreated cell lysates were subjected to IP with either 
FLAG-beads or Myc-beads and precipitated proteins were detected with the 




4.3 Nsp8 interacts with the N- and C-terminal portions of nsp12 
Since the interaction between nsp8 and nsp12 had been confirmed, the domain 
responsible for the interaction on nsp12 was to be mapped. Three Myc-tagged 
mutants of nsp12 were created as shown in Figure 4.13.  
The three mutants and full length nsp12 (Myc-nsp12) were either co-expressed with a 
vector control expressing FLAG-epitope only or a construct expressing FLAG-nsp8. 
The cell lysates were precipitated with FLAG-beads and the bound proteins were 
resolved by SDS-PAGE and detection was made with α-Myc-HRP antibody. The cell 
lysates were also probed to assess the expression levels of the different nsp12 
mutants. 
It could be observed from the results of the IP that all Myc-tagged truncation mutants 
and full-length nsp12 were coprecipitated by FLAG-beads except for Myc-nsp12m 
(amino acid residues 328 – 729) (Figure 4.14, right panel). The absence of Myc-
tagged protein co-precipitation in samples which were co-expressed with FLAG-
epitope, indicated that the coprecipitation of Myc-nsp12n and Myc-nsp12c were 






1                                                                                                     940 
1                                    400                                  
                                  328                               729                             
                                                               538                                938 
Figure 4.13: Schematic diagram of Myc-tagged nsp12 truncation mutant proteins. 
Numerals indicate amino acid positions. 
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Myc-nsp12. The lysates were examined for the expression levels of the respective 
Myc-tagged proteins as well (Figure 4.14, left panel). 
 
4.4 Discussion 
In summary, IBV nsp2, nsp8, nsp9 and nsp10 have been shown to exhibit RNA-









































































































































































































































Figure 4.14: The N- and C-terminal portions of IBV nsp12 co-precipitated with 
FLAG-nsp8 using FLAG-beads. Full-length and truncated nsp12 proteins or Myc 
(vector control) were co-expressed with FLAG (vector control) or FLAG-nsp8. The 
cell lysates were precipitated with FLAG-beads and bound proteins were analyzed 
with western blotting using α-Myc. Full-length nsp12 and mutants nsp12n (residues 9 
– 400), nsp12c (residues 538 – 938) were co-precipitated by the beads. A 
representative result of three independent experiments was shown. 
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revealed that IBV nsp8 interacts with nsp12 at two points, the N- and C-termini of the 
latter.  
Studying viral RNA-protein interactions using the biotin pull-down assay was 
hampered by the difficulty of cloning certain viral non-structural proteins like nsp3 
and nsp4, as well as the insolubility of nsp6, a protein containing multiple 
transmembrane domains of the replicase gene (126). In addition, the low expression 
levels of nsp12, nsp13 and nsp14 in cultured cell made it difficult to detect any RNA-
protein interactions. One previously undocumented interaction, that between nsp2 and 
viral RNA, was unfounded by the screen. This finding adhered to a previous report of 
nsp2 possibly being an antagonist to PKR (219), which requires double-stranded RNA 
for activation. Since current evidence is not indicative on an active role of nsp2 in 
viral RNA synthesis, the RNA-binding activity of nsp2 was not further studied.  
The screen also showed that previously documented RNA-binding activities of nsp9 
and nsp10 which surprisingly, did not bind to all three probes tested as both were 
determined to be of a non-specific nature (106,108,109). This could however be 
explained by the generally weak interactions between these two proteins and RNA 
that could escape detection in one or more of the screens. The interaction between 
nsp8 and IBV 3’-UTR (+) may have provided another piece of evidence that nsp8 is 
heavily involved in viral RNA synthesis, as a RNA-primer synthesizing enzyme for 
nsp12. Although the interaction was only shown for the protein with IBV 3’-UTR, it 
was notable that the interaction was also weak like that of nsp9 and nsp10. Hence, it 
cannot be concluded that nsp8 only bound to the 3’-UTR. 
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The approach taken to study viral protein-protein interactions was also hampered by 
the availability of sensitive anti-sera to viral proteins, especially that of the less 
immunogenic non-structural proteins and accessory proteins. Compounded by the fact 
that the non-structural proteins were also expressed in much lower amounts compared 
to structural proteins like S and N which were easily detected, their detection in cell 
lysates proved to be much more difficult. Out of the five proteins which could be 
detected by the available anti-sera, only nsp8 was identified as a binding partner to 
nsp12. This interaction had been reported in an ORFeome screen for SARS-CoV 
(133). Since it has not been proven to exist in other coronaviruses, reporting the same 
interaction in IBV suggested that it is highly probable that the interaction holds true 
across the three genera.  
The nsp8 binding activity of nsp12 appeared to be present in both truncation mutants 
Myc-nsp12n and Myc-nsp12c (Figure 4.14), its N- and C-terminal. Coincidentally, it 
had been reported for SARS-CoV that both a p12 fragment in its N-terminal and a 
p64 fragment in its C-terminal were required for the exhibition of RdRP activity by 
nsp12 (346). The p12 and p64 fragments were shown to form a stable complex in the 
same report and the p12 fragment had been suggested by the authors to play a role in 
primer-binding while the p64 fragment contains the polymerase activity. Therefore, 
the ability of nsp8 to interact with truncation mutant Myc-nsp12n (residues 9 to 400) 
seemed to act a piece of supporting evidence for the role of the p12 fragment in 
primer-binding. This offers an interesting perspective on the coordination between 















The main focus of this thesis is the investigation of the interaction of host protein, 
MADP1, with the coronavirus genome, the significance of its interaction with IBV 5’-
UTR (+) as well as that of viral proteins in coronavirus RNA synthesis. This chapter 
is dedicated to the summarization of findings described in Chapters 3 and 4, 
discussion of the significance of these findings and suggestions for future work to be 
done. Since coronavirus RNA synthesis occurs early in the replication cycle, the 
information presented by these studies could reveal new strategies to drug design 
targeted to coronaviruses.  
In the case of MADP1, a drug designed to inhibit its binding to the coronavirus 5’-
UTR could possibly arrest the infection at an early stage, thus reducing the extent of 
virus-associated morbidity.  Viral non-structural proteins are believed to be an integral 
part of the viral replicase complex. In-depth knowledge of their functions and 
interactions with other viral components could facilitate the development of critical 
processes into effective therapeutic targets. For the interaction between nsp8 and 
nsp12, an inhibition of their interaction could become a strategy to reduce the 
efficiency of viral RNA synthesis. 
 
5.1 Main Conclusions 
5.1.1 Identification of host proteins interacting with coronavirus by yeast 3-hybrid 
screen 
• MADP1 (alias ZCRB1) was identified to interact with SARS-CoV 5’-UTR (+). 
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• HAX1 was identified to interact with SARS-CoV 5’-UTR (-). 
• RPL27a was identified to interact with SARS-CoV 3’-UTR (+). 
5.1.2 Biochemical characterization of the interaction between MADP1 and the IBV 
5’-UTR 
• Using a RNA pull-down assay based on the interaction between biotinylated RNA 
and streptavidin beads, MADP1 was shown to exhibit a strong interaction with 
IBV 5’-UTR (+). The interaction was shown to be sequence-specific and the 
secondary structure, stem loop I, served as the MADP1 binding site.  
• The RNA recognition domain (RRM) of MADP1 was shown to be the domain 
responsible for interacting with IBV genome and that the active site residues were 
vital to its RNA-binding activity. 
5.1.3 MADP1 in IBV RNA synthesis 
• Using both cell fractionation and indirect immunofluorescence detection, it was 
demonstrated that MADP1 was either translocated from the nucleus to the 
cytoplasm or selectively retained in the cytoplasm during IBV infection. 
• Silencing of MADP1 with siRNA resulted in a decimated infection by IBV 
exemplified by the reduction of luciferase gene expression by recombinant IBV-
Luc virus, viral structural protein expression, synthesis of both genomic (- gRNA) 
and subgenomic (+ sgRNA and – sgRNA) mRNA, and the absence of syncytium 
formation. This phenotype was subsequently shown to be valid and not an off-
target effect of the siRNA. 
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• The over-expression of a silencing-resistant MADP1 enhanced IBV infection in 
stable MADP1 knockdown cells. 
5.1.4 Interaction of coronavirus nsps with the 5’- and 3’-UTRs 
• During the screen, IBV nsp2, nsp5 and nsp10 were found to interact with the 5’-
UTR (+).  
• IBV nsp5 and nsp10 were found to interact with the 5’-UTR (-). 
• IBV nsp5, nsp8 and nsp9 were found to interact with the 3’-UTR (+). 
• Nsp2 was confirmed to interact weakly with the 5’-UTR (+) and 5’-UTR (-). 
• The RNA-binding activity of nsp5 could not be confirmed 
5.1.5 Interaction of coronavirus nsp12 with other viral proteins 
• Nsp8 was shown to coprecipitate with nsp12 and their interaction occurred 
directly, independent on the presence of RNA. 





5.2 General Discussion  
5.2.1 The yeast three-hybrid screen for human proteins interacting with SARS-CoV 
untranslated regions 
The number of initial hits generated by the yeast three-hybrid screen was relatively 
low, at about four hundred colonies for the 5’-UTR (+) and two hundred and fifty 
colonies for the 5’-UTR (-) and 3’-UTR (-). This was in comparison to the well 
documented yeast two-hybrid system which could generate thousands of initial hits 
for a genome-wide screen of protein-protein interactions. The number of false 
positives for reporter gene activation, HIS3, appeared to be on the high side as strong 
reporter gene activating colonies dwindled to between six and seven (about 2% of 
initial hits) for each bait-RNA sequence after the secondary screen. This led to the 
conclusion that the lower number of initial hits would most likely be a result of poor 
transformation efficiencies or cell densities of the competent cells prepared which 
culminated in a limited representation of the genome being screened.  
After the colony PCRs to identify the fragment contained in library plasmid, only one 
colony for each bait-RNA sequence remained as some appeared to contain fragments 
which were either too short to be translated into a peptide long enough to be 
representative of the protein the sequence was derived from or that the mRNA 
sequence encoded by the plasmid was anti-sense. Although only three proteins, 
MADP1, HAX1 and RPL27a, were identified from the screen, the discovery of 




5.2.2 Over-expression of MADP1 in different systems 
The initial screen which identified MADP1 as a candidate for further characterization 
was performed in yeast, a eukaryotic cell system. Early attempts to express the protein 
using the bacteria expression system were met with problems in obtaining a 
consistent, high expression of the protein in the soluble fraction. The problem could 
not be rectified with a change of the fusion tag as well. Changing the over-expression 
system to a mammalian cell, driven by T7 polymerase, appeared to result in the 
increased stability of the protein. This could imply the presence of post-translational 
modifications in MADP1 which served to enhance its stability. Since there were no 
reports of the post-translational modifications of MADP1, a prediction on Eukaryotic 
Linear Motif server (ELM) based on the amino acid sequence of MADP1 revealed the 
presence of multiple phosphorylation sites as well as a sumoylation site (AKIE) from 
residues 176 to 179. Although it is not known if MADP1 is indeed sumoylated, this 
may be a possible explanation for the perceived instability of MADP1 in E. coli 
which are, by nature, unable to sumoylate proteins. 
5.2.3 The cellular distribution of over-expressed MADP1 during IBV infection 
Both cellular fractionation and indirect immunofluorescence indicated an increased 
presence of MADP1 in the cytoplasm, a deviation from its regular nuclear localization 
(338), during IBV infection. Coimmunofluorescence detection was performed for 
MADP1 with de novo synthesized viral RNA labeled by BrUTP. Although a 
colocalization of the two entities could not be confirmed, they did appear to partially 
overlap in their staining patterns. Regrettably, an antibody for immunofluorescence 
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detection of MADP1 was unavailable; hence, no visual information on the cellular 
distribution of the endogeneous protein could be obtained. This would have amplified 
the significance of the observed change in distribution during infection.  
BrUTP labeling was used as a surrogate marker for the viral RTCs instead of anti-sera 
to viral non-structural proteins which are present in the complex as they were not 
sensitive enough to be used for immunofluorescence assays. Although the problem of 
detection of fully synthesized viral RNA not bound to any RTCs could disrupt the 
staining pattern, the three hour time-frame imposed for the RNA labeling and the 
immediate fixation of cells thereafter minimized any of such effect. Since only RNA 
synthesized during this three hour time frame would be labeled, it was likely that the 
labeled RNA remained associated or in the vicinity of actively synthesizing RTCs. 
5.2.4 MADP1 as an enhancer of IBV RNA synthesis 
The results obtained from the functional studies performed for MADP1 in IBV 
infections supported the conclusion that the interaction with IBV 5’-UTR (+) 
culminated in its involvement in viral RNA synthesis. Although splicing has been 
ruled out as a possible mechanism by which discontinuous transcription in 
coronavirus negative strand synthesis occur, the involvement of a spliceosome-
associated protein in viral RNA synthesis could be beneficial to the virus even as the 
function of MADP1 in the human minor spliceosome remained a mystery.  
It had been demonstrated that MADP1 expression levels in a single cell type 
influenced the efficiency of viral RNA synthesis, including that of negative-sense 
subgenomic mRNAs and the overall progress of the infection. Although the over-
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expression of silencing-resistant MADP1 did not restore IBV infection in stable 
MADP1 knockdown cells to a level comparable to that in normal cells, it did exert a 
certain effect in enhancing IBV infection in the former.  Taking into account that 
normally, only about 30% of the cells were transfected, the seemingly high expression 
level of MADP1 in the knockdown cells is not a true reflection of the entire 
population. Most of the cells did not express MADP1 and therefore negated the 
enhancement of IBV infection by cells expressing silencing-resistant MADP1 to a 
certain extent. In addition, expression of silencing sensitive MADP1 was determined 
to be close to that of silencing-resistant MADP1 in the stable knockdown cells but did 
not result in an enhancement of IBV infection. This observation made it more certain 
that the difference was due to the expression of silencing resistant MADP1 in cells 
infected by IBV. 
5.2.5 Screening for RNA-binding proteins using biotin pull-down assay 
Overall, the results obtained from the screen coincide well with current reports of 
RNA-binding activity in non-structural proteins of other coronaviruses. However, the 
sensitivity of the assay could be an obstacle to the reproducibility of the detection of 
weak and non-specific RNA-protein interactions. That would have been subjected to 
minute differences in variables like washing conditions and amount of beads used for 
each assay. These variations could be easily controlled within the same assay but it 
may prove to be a more difficult task if more samples were involved. Hence, it 
seemed to serve better as an in vitro confirmatory assay, like how it was used for 
confirming the interaction between MADP1 and IBV 5’-UTR, where the number of 
samples involved would be lesser than as part of a screening protocol. 
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5.2.6 Functional conservation of MADP1 in RNA synthesis of different coronaviruses 
in different host species 
Most studies on host involvement in coronavirus RNA synthesis were so far 
performed using MHV (307,308,313,340), a betacoronavirus. Identification of the 
interaction between MADP1 and 5’-UTR as well as its functional involvement in 
coronavirus replication, in this study, therefore may represent the first host protein 
identified to play a role in viral RNA synthesis by interacting with the 5’-UTR of the 
viral RNA in a gammacoronavirus. The functional implication of the interaction 
between MADP1 and IBV 5’-UTR may also be extended to the rest of the members 
of the coronavirus family. In the case of hnRNP A1, it was initially reported to be 
functionally important for viral RNA synthesis for group II virus MHV (299,304). 
Subsequently, its involvement in viral RNA synthesis was also confirmed in TGEV, a 
group I coronavirus (309).  
This discovery that MADP1 could interact with the 3’-UTR (+) as well allowed a 
comparison of MADP1 to hnRNP A1 to be drawn, the latter being the first reported, 
and best characterized host factor in coronavirus MHV discontinuous transcription. 
Although it has been reported that other hnRNPs could replace hnRNP A1 in 
coronavirus RNA synthesis (306), the binding sites of MADP1 and hnRNP A1 only 
partially overlap as the latter was reported to bind negative-sense IG sequences, 5’-
UTR (-) and 3’-UTR (+) (299,300,307). Hence MADP1 may play its role as a 
separate entity, not as an equivalent of hnRNP A1 in gammacoronavirus IBV and 
there is likelihood that MADP1 could play a role in the RNA synthesis of other 
coronaviruses as well. 
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It may seem unconventional that functional studies described in chapter 3 involving 
IBV, a chicken coronavirus, and a human protein, MADP1, were conducted using 
human and African green monkey cells. However, it is noteworthy that MADP1 
(HomoloGene 12095) is conserved in humans (Homo sapiens), chimpanzees (Pan 
troglodytes), wolves (Canis lupus), cattle (Bos Taurus), mice (Mus musculus), rats 
(Rattus norvegicus) and chickens (Gallus gallus). The African green monkey genome 
is not available at NCBI, but an alignment search using basic local alignment search 
tool (BLAST) of the MADP1 amino acid sequence against the closest available non-
human primate, the rhesus macaque (Macaca mulatta) RefSeq Protein library yielded 
a 99% sequence similarity between the two species. The chicken homolog of MADP1 
on the other hand, bears 85% amino acid sequence similarity, but with an almost 
identical match in the N-terminal 120 amino acids, to its human counterpart. As the 
mapped interaction domain lies in the N-terminus, it is highly likely that the homologs 
from other species could replace human MADP1 in the interaction and functional 
studies. Hence, the results obtained for these studies conducted in human and African 
green monkey cells are definitely of relevance to IBV.  
5.2.7 Potential involvement of MADP1 in coronavirus RNA transcription 
An important conclusion from the functional studies of MADP1 in human cells is its 
role in IBV negative-strand subgenomic RNA synthesis. In the discontinuous model 
of transcription for coronaviruses described in Figure 1.7 (93), transcription initiation 
occurs at the 3’-UTR then the replicase complex encounters and transcribes the body 
TRS sequence (TRS-B). Complementary base-pairing between the CS of the nascent 
cTRS-B and the template TRS-L, at the 5’-leader, stalls the complex and allows the 
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nascent strand to either anneal to the TRS-L or to its original template location (88-
91). In the former situation, the template has been switched to the 5’-leader but the 
template remains the same for the latter. Transcription continues until the complex 
reaches the 5’-end of the genome or until the replicase complex encounters another 
TRS-B sequence.  
In principle, the template switching event requires the presence of the 5’-leader 
sequence in the vicinity or in contact with the stalled replicase complex at one of the 
cTRS-B sequences to occur. As the coronavirus genome is extreme long, ranging 
between 27 and 32 kilobases, with the TRS-B sequences occurring within the 3’ one-
third of the genome, it would require assistance for the 5’-UTR to be brought near the 
replicase complex stalled at these points along the transcribed genome instead of 
leaving it to chance. It had been proposed previously that stem loop I of the 
coronavirus 5’-UTR is important in the maintenance of a 5’- UTR to 3’-UTR 
interaction which is critical specifically for discontinuous transcription of negative-
sense sgRNAs to occur (75). Therefore, it seemed befitting that the facilitation of 5’-
UTR to 3’-UTR interaction during discontinuous transcription be the proposed role 
for MADP1 following the discovery that it was able to interact strongly with the stem 
loop I of the IBV 5’-UTR (+) and possibly with the 3’-UTR (+) of the IBV genome as 
well.  
It was indicated in the GenBank entry of MADP1 that it contains a RRM dimerization 
site, composed of two amino acid residues, at the end of the domain. If MADP1 does 
form dimers, and that both monomers could interact with the 5’-UTR (+) and 3’-UTR 
(+), it seemed likely that MADP1 could be the bridge between these two distal RNA 
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sequences. The absence of MADP1 would then result in highly inefficient template 
transfer and disrupt the synthesis of negative-sense sub-genome length mRNAs while 
it may or may not affect the synthesis of negative-sense genome length mRNAs. That 
which has been demonstrated by the silencing of MADP1 in the functional studies 
conducted in IBV infected H1299 cells.  
In addition to the ability of interacting with multiple regions of the MHV genome, 
hnRNP A1 also interacted with the nucleocapsid protein of both SARS-CoV and 
MHV (302,303). That being said, if interactions of MADP1 with viral proteins or 
other host proteins implicated in coronavirus discontinuous transcription could be 
documented, it would bolster the significance of MADP1 in coronavirus 
discontinuous transcription and to paint a better picture of how it functions in the RTC 
as a whole and in particular, the facilitation of template transfer. 
5.2.8 Potential mode of cooperation between nsp8 and nsp12 in RNA synthesis 
Information pertaining to how the coronavirus negative-strand synthesis initiation 
occurs has been limited and only in the recent years has more information been 
available with regards to the source of the primer required for the RdRP (nsp12) to 
function (101). The nsp7-nsp8 hexadecameric complex which has been shown to be 
the second RdRP of the coronavirus that requires no primer to function and 
synthesizes short length RNA non-specifically fulfilled the role as the primase 
synthesizing short RNA primers for nsp12 (103). 
An examination of the interaction between nsp8 and nsp12 has revealed that the 
interaction occurs at two points, the N- and C-terminal of nsp12. Coincidentally, it 
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was reported that a p12 fragment from at the N-terminus and a p64 fragment at the C-
terminus of nsp12 were reported to be required for RdRP activity (346). A likely 
model that would fit the mapped interactions would indicate a direct interaction 
between the N- and C-terminals of nsp12 with the nsp7-nsp8 complex. In this model, 
the nsp7-nsp8 complex would first synthesize a RNA-primer of a sufficient length, 
which would be exposed to and binds to the N-terminus of nsp12, brought in close 
proximity through its interaction with nsp8. The extension of the RNA could then be 
catalyzed by the polymerase domain in the C-terminus of nsp12, which would also be 
oriented in close proximity to the end of the RNA-primer through its interactions at its 
N-terminus with nsp8. This arrangement of the two RdRPs would ensure the high 
efficiency of the replicase complex as the RNA primers synthesized by nsp8 could be 




5.3 Future Directions 
5.3.1 Characterization of interactions involving MADP1 with other viral proteins and 
host proteins known to function in viral RNA synthesis 
The involvement of MADP1 in coronavirus RNA synthesis and its significance have 
been demonstrated in this thesis using the tissue culture system. Further studies with a 
MADP1 knock-out animal system, which is currently not available, would be 
beneficial to affirm the role of MADP1 in coronavirus RNA synthesis. A possible 
function of MADP1 in coronavirus negative-strand synthesis has also been proposed 
with the results obtained thus far.  
Additional work, especially in the characterization of the interaction between MADP1 
and 3’-UTR (+), other viral proteins or even host proteins known to be involved in 
coronavirus transcription, would be required to substantiate the proposed model. 
Characterizing the interaction between MADP1 and the 3’-UTR (+) could be carried 
out in a similar manner as what had been presented in this thesis for the 5’-UTR (+). 
On the otherhand, a screen by co-IP and verification with indirect 
immunofluorescence could be employed to ascertain the identities of viral or host 
proteins interacting with MADP1 during IBV infections. The results from these 




5.3.2 Confirming the colocalization of MADP1 with viral proteins in the RTC 
In addition to the studies suggested above, it would be beneficial to obtain 
colocalization data for MADP1 and the viral RTC. This could possibly be 
accomplished by employing fluorescence resonance energy transfer (FRET) analysis 
to provide quantitative data on the localization of MADP1 and a vital component of 
the viral RTC, for example, nsp8 or nsp12. This would ascertain if MADP1 is indeed 
colocalizing with the viral RTC, thus providing additional evidence that MADP1 is 
indeed required for viral RNA synthesis. 
5.3.3 Functional analysis of MADP1 in other coronavirus infections 
While the role of MADP1 in IBV RNA synthesis is unquestionable, the question if it 
is also required for other coronaviruses remains. The interaction between MADP1 and 
the 5’-UTR (+) of IBV was observed to be exceptionally strong compared to that of 
SARS-CoV or HCoV-OC43. As other host or viral proteins could possibly affect 
binding affinity between MADP1 and the RNA substrate in a cell system, whether the 
weak interaction demonstrated for the two betacoronaviruses amount to a lower 
dependency or independency of MADP1 for RNA synthesis would need to be 
examined with functional studies in virus infected cells.   
5.3.4 Further characterization and structural confirmation of the interaction between 
nsp8 and nsp12 
Some detail on the enzymatic core of the viral RTC, has also been illustrated, 
including a proposed model of the two RdRPs working in tandem, which ensures the 
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efficiency of the replicase complex. However, further characterization of the 
interaction between nsp8 and nsp12 is still required to ascertain if the proposed model 
is valid. Structural information, especially the resolution of the nsp12 structure would 
be of particular importance in confirming if the interactions detected between its N- 
and C-terminals and nsp8 are spatially possible. However, as none of the structures of 
coronavirus nsp12 has been solved till date, only predictions of its structure are 
available. This would be one of the most important studies required for the elucidation 
of cooperation between nsp8 and nsp12. Likewise, the interaction site on nsp8 should 
also be mapped as its interaction with nsp12 would only be meaningful if it is 
confined to the exterior of the hexadecameric complex.  
In addition, functional studies by introducing mutations at the interaction sites could 
be performed to ascertain if the interaction between nsp8 and nsp12 is crucial for the 
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